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General introductionChapter 1
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The position of evidence on outcomes in  
clinical practice
Generally, new drugs are introduced based on evidence from clinical trials to 
ensure that patients have access to safe and efficacious drugs. Clinical trials 
usually use strict in- and exclusion criteria, and as a consequence study popu-
lations are relatively homogeneous and often comprise relatively young and 
healthy patients. As a result, little is known about the effects of the drug in 
clinical practice comprising older patients and patients with comorbidities. 
Besides evidence from clinical trials, some reimbursement authorities 
consider the costs of new drugs in their decision (or advice) to reimburse a 
new drug, in order to ensure short- and long-term financial sustainability of 
the healthcare system. Therefore, they require evidence of cost-effectiveness 
for certain types of drugs (e.g. expensive drugs). Cost-effectiveness analyses 
assess the additional effects of a new treatment against the additional costs. 
The outcomes of such analyses can be used to decide whether the additional 
benefits are worth the additional costs. However, initial estimates of cost-ef-
fectiveness, which are often based on clinical trials, are accompanied by many 
uncertainties. For example, little data are generally available on long-term 
costs and effects. Despite these uncertainties regarding effectiveness and 
cost-effectiveness, reimbursement authorities need to make decisions (or 
give advice) about reimbursement of new drugs.
Regardless of the decision about reimbursement, drugs will not neces-
sarily be used widely in clinical practice. Several barriers, such as limited 
Figure 1.1 Adapted framework from Jönsson et al illustrating the position of evidence on outcomes 
in clinical practice4
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The prognosis of cancer patients has improved dramatically over the past 
years and this is reflected in a significant increase in life expectancy as well 
as important improvements in health-related quality of life. Factors that con-
tributed to these improvements are the introduction of new drugs against 
cancer, but also advances in screening and diagnostic approaches and better 
surgical techniques.1
The costs of factors that contributed to the improvements in health out-
comes are substantial; the economic burden of cancer was more than 126 
billion Euros in the European Union (EU) in 2009, with healthcare costs ac-
counting for 51 billion Euros2 which accounted for 4% of the total healthcare 
expenditures in the EU. Of these, 13.5 billion Euros (27%) were spent on drugs.2 
The enormous pressure of the costs of cancer drugs on healthcare budgets 
creates great tension between financial sustainability of healthcare systems 
and accessibility to (new) treatments. Healthcare authorities need to make 
choices between reimbursement of healthcare procedures, services and pro-
grams,3 but these choices have to be made under considerable uncertainty 
about (long-term) costs and effects. As with other procedures, services and 
programs, the effectiveness and cost-effectiveness of new drugs are uncertain 
at the time they are introduced. As a consequence, conditional funding was 
introduced in the Netherlands in 2006. At that time, conditional funding 
implied the additional funding of innovative drugs (i.e. reimbursing hos-
pitals [most of] the drug costs) for a predetermined period of time on the 
condition that data regarding uptake, use and outcomes of these drugs in 
clinical practice were to be collected. After this time period, these data were 
used to decide whether or not additional funding continued to exist. This 
policy applied to promising but expensive inpatient drugs, including two 
drugs for metastatic renal cell carcinoma (mRCC), that is, bevacizumab and 
temsirolimus, and ensured equal and undelayed access to these drugs. The 
collection and analysis of data about uptake, use, and outcomes of these new 
drugs for mRCC in clinical practice form the focus of the present thesis. This 
thesis also illustrates the possibilities and impossibilities (or limitations) of 
evaluating uptake, use, and outcomes of new drugs in clinical practice, and 
reflects on the difficulties of making decisions about future funding (based 
on evidence from clinical practice).
Before explaining the evolution of funding policies in the Netherlands 
and the introduction of the new drugs for mRCC in this context, the position 
of evidence on outcomes in clinical practice within a drug’s life-cycle will be 
addressed using the framework by Jönsson et al (Figure 1.1).4 
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to avoid unequal access (by removing financial barriers) and guarantee early 
access to expensive drugs through conditional funding. The policy applied to 
drugs with an added therapeutic value and an expected nationwide budget 
impact of at least 0.5% of the total drug costs of hospitals (i.e. an expected 
budget impact of at least 2.5 million Euros per year). For these drugs, hos-
pitals received additional funding (i.e. 80% of the costs), besides their fixed 
budgets. Hospitals needed to pay the remaining 20% in order to discourage 
unnecessary care. In exchange, the collection of data regarding appropriate 
drug use, effectiveness and cost-effectiveness in clinical practice was required. 
These data were intended to complement the findings from clinical trial(s), 
and to evaluate a drug’s real-world value after three years (which became four 
years in 2010) of initial funding. This evaluation was used to decide about 
future funding. One of the criteria for a drug to remain eligible for additional 
funding was that the drug needed to be cost-effective. 
The policy for expensive drugs was abolished on January 1st 2012. Since 
then, expensive drugs are defined as add-ons, i.e. additions to so-called DOT 
(i.e. Diagnosis Treatment Combination – Moving towards Transparency) 
healthcare products. Hospitals no longer receive a fixed percentage of the 
costs of expensive drugs, but instead have to negotiate with individual health 
insurers about prices and volumes. 
Policy for expensive inpatient drugs since 2012
As of January 1st 2012, hospitals have been using a new system to claim their 
costs to health insurers, the so-called DOT system. A DOT healthcare product 
includes all healthcare activities provided as part of a particular treatment. 
For some products maximum prices are determined on a national level by the 
Dutch Healthcare Authority, but for most products hospitals and individual 
health insurers need to negotiate a price. Generally, the costs of inpatient 
drugs (i.e. drugs provided by a hospital pharmacist) are included in these 
DOT healthcare products. 
Besides DOT healthcare products, so-called add-ons were created to pre-
vent disturbances in the homogeneity of DOT healthcare products. Expensive 
drugs, i.e. drugs eligible for additional funding according to the former policy 
for expensive drugs are defined as add-ons.10 Hospitals can claim these add-
ons in addition to a DOT healthcare product, but they do not receive addition-
al funding as with the former policy for expensive inpatient drugs. Instead, 
hospitals and health insurers need to negotiate a price.
New add-on applications are approved if the costs per patient per year are 
higher than 10,000 Euros.11 However, since January 1st, 2015 a threshold no 
longer exists because several issues were observed including issues related 
hospital budgets, could hinder the uptake and use of a new drug in clinical 
practice. As a consequence, its value is not always exploited to its full po-
tential. Furthermore, outcomes (i.e. effectiveness and cost-effectiveness) in 
clinical practice might be less favourable than expected, especially when new 
drugs are prescribed to a wider population than the population eligible to 
participate in the clinical trial.
In the Netherlands, information about uptake and use and evidence on 
outcomes in clinical practice were used to assess the real-world value of ex-
pensive drugs, after four years of conditional funding. After this time period, 
this information was used to decide whether or not additional funding con-
tinued to exist. This procedure has some similarity with the recently revised 
Cancer Drugs Fund in the United Kingdom (UK). New cancer drugs could 
be considered for funding within the new Cancer Drugs Fund for a prede-
termined time period if the drugs’ effectiveness and cost-effectiveness are 
uncertain. During this time period, additional evidence are to be collected, 
which should help to determine whether the treatment should be accepted 
for routine use in the National Health Service (NHS).5 
The evolution of funding policies in the Netherlands
Healthcare costs associated with cancer in the Netherlands doubled from 
2.1 billion Euros in 2003 to 4.3 billion Euros in 2011.6 In the same period, the 
costs of cancer drugs increased from 270 million Euros in 2003 to 670 million 
Euros in 2011.7 From the 670 million Euros spent on drugs, 415 million Euros 
were spent on so-called expensive drugs. These costs further increased to 519 
million Euros in 2013.
To keep a lid on healthcare costs, one of the proposed methods of the 
current Dutch cabinet (i.e. Rutte-Asscher cabinet installed in November 2012) 
was to introduce ‘strict’ package management, meaning the strict application 
of the reimbursement criteria, i.e. necessity, effectiveness, cost-effectiveness 
and feasibility, on both the treatments currently covered through the basic 
health insurance package as well as new treatments.8 As a consequence, var-
ious measures were announced, including a wide implementation of condi-
tional access and funding combined with risk-oriented package management 
(i.e. the option to carry out evaluations on subjects where risks have been 
identified regarding the package’s affordability, accessibility or quality).
Policy for expensive inpatient drugs until 2012
Although conditional access and funding were announced in the coalition 
agreement in 2012, such a policy has existed in the Netherlands since 2006 to 
remove barriers for hospitals to prescribe expensive drugs.9 This policy aimed 
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to grow 2.5 percent in the period 2012–2015 (1 percent in 2016). This measure 
aimed to control costs and further improve the quality of hospital care. 
The introduction of new treatments for metastatic 
renal cell carcinoma
Renal cell carcinoma (RCC) is the most common type of kidney cancer, i.e. RCC 
accounts for about 90% of kidney cancers.17 With RCC, a tumour develops from 
cells from the kidney tubules. These tubules are responsible for reabsorption, 
i.e. the process by which solutes and water are removed from the tubular 
fluid and returned to the bloodstream. Other types of kidney cancer, such as 
transitional cell carcinoma, begin in the renal pelvis (responsible for urine 
collection). Kidney cancer is the seventh most common cancer in men and 
eleventh most common cancer in women.18 In the Netherlands, there were 
about 2,250 new cases with kidney cancer and 930 deaths in 2014.19
Twenty percent to 30% of all RCC patients have metastatic disease at initial 
presentation, and 20% to 40% undergoing nephrectomy (i.e. surgical removal 
of a kidney) for clinically localised RCC will develop metastases.20 Patients 
with metastatic RCC (mRCC) are classified into three risk groups based on the 
International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) 
prognostic model.21 The median overall survival is 43.2 months for patients 
with a favourable risk, 22.5 months for patients with an intermediate risk and 
7.8 months for patients with a poor risk.22 Previously, the Memorial Sloan-
Kettering Cancer Center model was used to classify patients into risk groups.23
Until recently, treatment options for patients with mRCC were limited, 
because of its resistance to radiotherapy and chemotherapy.24 As a conse-
quence, interferon alfa (IFN-α) was the standard approach for many years, 
preceded by cytoreductive nephrectomy in patients with metastatic disease 
at initial presentation. 
However, many new drugs have been introduced since 2006, starting 
with sorafenib and sunitinib (Figure 1.2). The better understanding of the 
molecular pathogenesis of RCC has led to the identification of targets for 
therapeutic interventions; as a result, these new therapies have been called 
targeted therapies.
Evidence of effectiveness from clinical trials
Targeted therapies have been introduced based on evidence from clinical 
trials that showed important improvement in health outcomes. For exam-
ple, in one study, sunitinib increased median progression-free survival (PFS) 
from 5.0 months to 11.0 months compared to IFN-α.25 Similarly, bevacizumab 
combined with IFN-α increased PFS compared to IFN-α monotherapy, and 
to access to the expensive drugs. Since then, representatives of both clini-
cians and health insurers provide advice about whether a drug is eligible to 
become an add-on.12 
Despite these changes in the funding of expensive drugs, the Dutch 
National Health Care Institute can still advice to conditionally fund a new ex-
pensive drug. This means that the drug receives conditional access to the basic 
health insurance package on the condition that the manufacturer encourages 
and supports data collection regarding effectiveness and cost-effectiveness 
in clinical practice.13 Based on these outcomes, the Dutch National Health 
Care Institute can advise to exclude a drug from the basic health insurance 
package.14 
Policy for expensive outpatient drugs
In contrast to expensive inpatient drugs, no additional requirements, such 
as the collection of data regarding appropriate drug use, effectiveness and 
cost-effectiveness in clinical practice were imposed on expensive outpatient 
drugs (i.e. drugs provided by an independent pharmacist or a general prac-
titioner with a dispensary) until 2012. Expensive outpatient drugs were fund-
ed according to the framework of the Medicine Reimbursement System [in 
Dutch: Geneesmiddelenvergoedingssysteem, GVS].15 This framework makes 
different demands on evidence depending on the drug’s therapeutic value; if a 
drug’s therapeutic value is similar to that of medicines that have already been 
added to the Medicine Reimbursement System, applications only require 
pharmacotherapeutic evidence (so-called List 1A). However, if a drug has an 
added therapeutic value, pharmacoeconomic evidence and an estimation 
of the budgetary impact is required, besides pharmacotherapeutic evidence 
(so-called List 1B). Reimbursement limits exist for medicines on List 1A, while 
such limits do not exist for medicines on List 1B. 
Since no additional requirements were imposed on expensive outpatient 
drugs, the system did not guarantee efficient use of these drugs. Additionally, 
the system did not stimulate any price competition. Since 2012, the funding 
of expensive outpatient drugs has been changing; the funding of TNF alpha 
inhibitors, oral oncology drugs and growth hormones was transferred to the 
hospital budgets (although these drugs are used outside a hospital setting). 
Similar to expensive inpatient drugs, add-ons were created for these expensive 
outpatient drugs. 
The costs of expensive in- and outpatient drugs are subject to the maxi-
mum budget growth of hospital care, which is agreed upon by the Ministry 
of Health, healthcare providers and health insurers.16 Hospitals were allowed 
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practice, in line with the policy for expensive drugs (both drugs are currently 
financed based on add-ons).
Also, the outpatient drugs for mRCC were reimbursed in the Netherlands, 
despite the lack of evidence of cost-effectiveness. This can be explained by the 
categories in which these drugs were placed. Some were placed on List 1A of 
the GVS, and therefore evidence of cost-effectiveness was not required. Others 
were placed on List 1B, but were exempted from pharmacoeconomic evidence, 
e.g. no such evidence was needed for everolimus, because everolimus was 
designated as an orphan drug and no alternative treatment was available.33
PERCEPTION registry
As noted above, one of the conditions for the funding of bevacizumab and 
temsirolimus for patients with mRCC was the collection of data regarding 
appropriate drug use, effectiveness and cost-effectiveness in clinical practice. 
Therefore, a population-based registry (i.e. PERCEPTION, PharmacoEconomics 
in Renal CEll carcinoma: a PopulaTION-based registry) was created to evaluate 
the uptake and use of these drugs, as well as treatment outcomes in clinical 
practice (fourth and fifth element of the framework by Jönsson et al4). Since 
the registry was disease-oriented (instead of treatment-oriented), it did not 
only provide data on patients treated with bevacizumab and temsirolimus, 
but also on patients treated with other targeted therapies and on patients 
not treated with targeted therapy. 
The PERCEPTION registry consisted of two parts; a retrospective study and 
a prospective study. Inclusion criteria for the retrospective study comprised 
a diagnosis of mRCC (i.e. metastases at initial presentation) between January 
2008 and December 2010 of any histological subtype. In the prospective study, 
patients with RCC (all stages) of any histological subtype diagnosed from 2011 
until June 30th 2013 were included. 
Data on patient characteristics, treatment schemes and treatment end-
points (e.g. survival) were retrospectively collected from individual patient 
records. Furthermore, patients in the prospective study were asked to fill out 
questionnaires regarding health-related quality of life.
Thesis aims and outline
This thesis is structured as follows. The first part (i.e. chapters 2 to 5) focuses on 
treatment of patients with mRCC. In this part, the uptake and use of targeted 
therapies for mRCC in the Netherlands are evaluated, as well as treatment 
outcomes (i.e. survival, health-related quality of life and cost-effectiveness) 
in clinical practice, based on data from the PERCEPTION registry. This part will 
address the following aims:
pazopanib improved PFS compared to placebo, in patients with a favourable 
or intermediate risk.26-28 For patients with a poor prognosis, temsirolimus 
improved PFS from 1.9 months to 3.8 months compared to IFN-α.29 Besides 
these first-line therapies, several second-line therapies have been introduced 
since 2006. 
The introduction of these drugs resulted in the updating of European 
guidelines for mRCC in 2009, including the recommendation of first-line 
therapy with sunitinib or bevacizumab (combined with IFN-α) for patients 
with a favourable or intermediate prognosis, and the recommendation to use 
temsirolimus for patients with a poor prognosis.30 Second-line therapy with 
sorafenib has been recommended after cytokine therapy has been tried, and 
second-line everolimus has been recommended if patients had progressed 
on tyrosine kinase inhibitors (TKIs). In 2010, first- and second-line (post cy-
tokines) pazopanib was added to the guideline.31 Dutch guidelines were re-
vised in 2010 to bring them in line with European guidelines.32
Evidence of cost-effectiveness
The improved health outcomes of patients with mRCC come at a price. 
Monthly costs of the targeted therapies for mRCC are higher than 3,000 Euros, 
whereas monthly costs of IFN-α amounted to about 800 Euros. 
Little was known about the cost-effectiveness of the new drugs for mRCC 
in the Netherlands at the time they were introduced. Although the man-
ufacturers of bevacizumab and temsirolimus were obliged to provide an 
indication of the cost-effectiveness of their drugs, the Dutch Committee of 
Pharmaceutical Aid [in Dutch, Commissie Farmaceutische Hulp] concluded 
that the cost-effectiveness of these drugs was insufficiently substantiated. 
Nevertheless, the inpatient drugs, bevacizumab and temsirolimus, were con-
ditionally funded in the Netherlands; the condition being to collect data re-
garding appropriate drug use, effectiveness and cost-effectiveness in clinical 
Figure 1.2 The introduction (i.e. EMA approval) of targeted therapies for mRCC
Abbreviations: IFN-α, interferon alfa; EMA, European Medicines Agency.
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1  To evaluate the uptake and use of targeted therapies for mRCC in the 
Netherlands and to study their effectiveness in terms of overall survival 
(Chapter 2). 
2  To examine the factors associated with the prescription of targeted ther-
apies in daily clinical practice (Chapter 2). 
3  To evaluate the effect of cytoreductive nephrectomy on overall survival in 
primary mRCC patients treated with first-line sunitinib (Chapter 3).
4  To provide insight into the most important determinants of health-related 
quality of life (including progression of disease) of patients with mRCC 
(Chapter 4).
5  To estimate the real-world cost-effectiveness of several treatment strate-
gies applied in patients with mRCC comprising one or more sequentially 
administered drugs (Chapter 5).
In the second part, practical recommendations will be provided regarding 
the collection and analyses of data about uptake, use and outcomes in clinical 
practice, in order to conduct outcomes research. This part will address the 
following aims:
6  To provide practical guidance in setting up patient registries for the col-
lection of real-world data (Chapter 6).
7  To provide practical recommendations in constructing a discrete event 
simulation (DES) model to support cost-effectiveness analyses of treat-
ment strategies spanning multiple treatment lines (Chapter 7).
Finally, chapter 8 provides a discussion of the findings and explores the im-
plications and limitations of this thesis. 
Note that chapters 2 to 7 are based on publications in, or intended for, 
international peer reviewed journals and can thus be read independently.
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Variation in use of targeted 
therapies for metastatic renal cell 
carcinoma: Results from a Dutch 
population-based registry
S. de Groot; S. Sleijfer; W.K. Redekop; E. Oosterwijk; J.B.A.G. Haanen; L.A.L.M. Kiemeney; C.A. Uyl-de Groot
BMC Cancer 2016;16:364.
Chapter 2
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Introduction
Kidney cancer accounts for about 3% of all cancers with an estimated inci-
dence of 115,200 in Europe in 2012.18 Renal cell carcinoma (RCC) represents 
90% of all kidney cancers.17 The prognosis is relatively good for patients with 
localised disease, which can be treated with surgery, but the prognosis of 
patients with advanced or metastatic disease (mRCC) is poor.23
Targeted therapies for mRCC have entered the market since 2006, su-
nitinib being the first. Sunitinib increased median progression-free sur-
vival (PFS) from five to 11 months,25 and overall survival (OS) from 22 to 26 
months compared to interferon-alfa (IFN-α) in mRCC patients with a clear-
cell histology.34 Subsequently, it became standard of care for patients with a 
good or intermediate prognosis according to the Memorial Sloan Kettering 
Cancer Center (MSKCC) risk score.30 Recently, the effectiveness of sunitinib 
was demonstrated in a broader ‘real-world’ population.35 Bevacizumab (in 
combination with IFN-α) and pazopanib were added to guidelines as first-
line therapies for patients with a good or intermediate prognosis in 2009 
and 2010, respectively.30,31 For patients with a poor prognosis, temsirolimus 
was recommended30 following the results of a multi-centre, phase III trial 
in mRCC patients without any restrictions in histologic type, showing an 
increase in OS from seven to 11 months compared to IFN-α.29 Furthermore, 
a number of second-line therapies have been added to guidelines, such as 
sorafenib, everolimus and axitinib.30,36
Obviously, full and swift implementation of guidelines into clinical 
practice is essential to maximise the benefits of new therapies. However, the 
adoption of innovations in cancer care is generally quite heterogeneous, and 
differs between countries, and regions within countries.1 A study by Jönsson 
et al showed widespread use of sunitinib in the eight of the countries they 
studied, despite small differences between countries.4 Sorafenib was widely 
prescribed in France, while a very low uptake and use in the United Kingdom 
and the United States were found. Besides between-country variation, Jönsson 
et al found within-country variation in Sweden and suggested that more de-
tailed information is needed on the use of first- and second-line therapies, to 
determine the extent of potential under- and overconsumption in different 
regions and different patient populations.4
The aims of this study were to evaluate the uptake and use of targeted 
therapies for mRCC in the Netherlands, examine factors associated with the 
prescription of targeted therapies in daily clinical practice and study their 
effectiveness in terms of OS.
Abstract
Objective: For patients with metastatic renal cell carcinoma (mRCC), tar-
geted therapies have entered the market since 2006. The aims of this study 
were to evaluate the uptake and use of targeted therapies for mRCC in the 
Netherlands, examine factors associated with the prescription of targeted 
therapies in daily clinical practice and study their effectiveness in terms of 
overall survival (OS).
Methods: Two cohorts from PERCEPTION, a population-based registry of mRCC 
patients, were used: a 2008–2010 Cohort (n  =  645) and a 2011–2013 Cohort 
(n  =  233). Chi-squared tests for trend were used to study time trends in the 
use of targeted therapy. Patients were grouped based on the eligibility criteria 
of the SUTENT trial, the trial that led to sunitinib becoming standard of care, 
to investigate the use of targeted therapies amongst patients fulfilling those 
criteria. Multilevel logistic regression was used to identify patient subgroups 
that are less likely to receive targeted therapies. 
Results: Approximately one-third of patients fulfilling SUTENT trial eligibility 
criteria did not receive any targeted therapy (29% in the 2008–2010 Cohort; 
35% in the 2011–2013 Cohort). Patients aged 65+ years were less likely to receive 
targeted therapy in both cohorts and different risk groups (odds ratios range 
between 0.84–0.92); other factors like number of metastatic sites were of in-
fluence in some subgroups. Amongst treated patients, there was a decreas-
ing trend in sunitinib use over time (p  =  0.006), and an increasing trend in 
pazopanib use (p  =  0.001). 
Conclusions: Targeted therapies have largely replaced interferon-alfa as first-
line standard of care. Nevertheless, many eligible patients in Dutch daily 
practice did not receive targeted therapies despite their ability to improve 
survival. Reasons for their apparent underutilisation should be examined 
more carefully.
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score;23 a time from initial diagnosis to metastatic diagnosis of less than one 
year was used as a risk factor instead of a time from initial diagnosis to ini-
tiation of treatment of less than one year, since many patients in the study 
population did not receive any targeted therapy, thereby making it impos-
sible to calculate the time to treatment. Additionally, the WHO performance 
status was used instead of Karnofsky performance status.
Furthermore, patients were grouped based on the eligibility criteria of 
the SUTENT trial,25 the trial that led to sunitinib becoming standard of care, 
to investigate the use of targeted therapies amongst patients fulfilling those 
criteria. Patients who had a clear-cell subtype, a WHO performance status of 
0 or 1 and no brain metastases were classified as fulfilling the SUTENT trial 
eligibility criteria.
To identify patient subgroups that are less likely to receive targeted thera-
pies in daily clinical practice among patients fulfilling SUTENT trial eligibility 
criteria, multilevel mixed-effects logistic regression was used to account for 
between-hospital variance. At the patient-level, patient and disease charac-
teristics were taken into account including baseline demographics, clinical 
and laboratory factors.37,38 Backward selection was used to select the covar-
iates for the models; any non-significant covariates were excluded from the 
models one at a time.
OS was calculated from the start of therapy until death from any cause 
or the date of last follow-up, whichever came first, using the Kaplan-Meier 
method. For patients not receiving any targeted therapy, OS was calculated 
from the date of diagnosis.
Missing data regarding baseline characteristics were handled using mul-
tiple imputations by chained equations. This method generated imputations 
based on a set of imputation models, one for each variable with missing 
values.39
All analyses were performed separately for the 2008–2010 Cohort and the 
2011–2013 Cohort, because of differences in inclusion criteria, patient selec-
tion and duration of follow-up. The significance level was set at α  =  0.10. Data 
analyses were conducted using STATA statistical analysis software (StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP).
Results
Patient and disease characteristics of the 2008–2010 Cohort
714 patients newly diagnosed with mRCC between 2008 and 2010 were identi-
fied. Of these patients 69 were excluded (Figure S2.1), leaving 645 patients for 
data analysis. These patients were uniformly distributed across the three-year 
Patients and methods
Study population
A population-based registry (entitled PERCEPTION) was created to include pa-
tients with mRCC. The PERCEPTION registry consisted of two parts; a retrospec-
tive study and a prospective study. In the retrospective study, eligible patients 
were selected from the Netherlands Cancer Registry (NCR), which maintains 
a cancer registration database of all cancer patients in the Netherlands. 
Inclusion criteria for the retrospective study comprised a diagnosis of mRCC 
(i.e. metastases at initial presentation) of any histological subtype. Patients 
diagnosed from January 2008 until December 2010 in 42 of 51 hospitals (both 
general and academic) in four regions, covering approximately half of the 
country, were included. All patients were followed for a minimum of three 
years or until death (2008–2010 Cohort).
The prospective study was designed differently in order to measure ad-
ditional aspects of the disease, such as health-related quality of life (not re-
ported in this study). In the prospective study, patients with RCC (all stages) 
of any histological subtype diagnosed from 2011 until June 30th 2013 in 25 of 
32 hospitals (both general and academic) in three regions were included. In 
contrast to the 2008–2010 Cohort, this cohort also comprised patients with 
mRCC who were initially diagnosed with localised disease. Besides the NCR, 
the hospitals’ financing systems were used to select eligible patients at an 
early phase (for quality of life measurements). All patients were followed 
until the end of 2013 or until death (2011–2013 Cohort).
Data collection
Data on baseline demographics, clinical and laboratory factors were retro-
spectively collected from individual patient records by using uniform case 
report forms to ensure consistent data collection. Furthermore, data on 
treatment schemes and treatment endpoints (e.g. survival) were collected. 
Laboratory factors, such as haemoglobin and corrected calcium levels, were 
standardised according to routinely used reference values. Data were collect-
ed by personnel of the NCR and data collection stopped at the end of 2013.
Statistical analyses
To study differences in the proportion of patients receiving targeted therapy 
per half a year chi-squared tests were used. Exact tests were used to study pos-
sible time trends in the use of different therapies amongst treated patients. 
Additionally, chi-squared tests for trend were conducted.
Then, the use of targeted therapies within risk groups was studied. Risk 
groups were created using a slightly modified version of the MSKCC risk 
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Table 2.1 Patient and disease characteristics 2008–2010 Cohort and 2011–2013 Cohort
2008–2010 Cohort:  
mRCC at the initial 
diagnosis (n=621)
2011–2013 Cohort:  
mRCC (n=221)
Sex – n (%)
 Female
 Male
Median age – yr (range)
Histology – n (%)
 Clear cell
 Other *
WHO performance status – n (%)
 0-1
 2-4
Site of metastasis – n (%)
 One
 More than one
Liver metastasis – n (%)
 No
 Yes
Lung metastasis – n (%)
 No
 Yes
Bone metastasis – n (%)
 No
 Yes
Brain metastasis – n (%)
 No
 Yes
Haemoglobin – n (%)
 Normal
 < LLN
Neutrophil count – n (%)
 Normal
 > ULN
Platelet count – n (%)
 Normal
 > ULN
Albumin – n (%)
 Normal
 < LLN
Corrected serum calcium – n (%)
 Normal
 > ULN
Alkaline phosphatase – n (%)
 Normal
 > ULN
Lactate dehydrogenase – n (%)
 Normal
 > 1.5 times ULN
Comorbidities – n (%)
 Zero or one
 More than one
Time since RCC diagnosis
 > One year
 < One year
213 34% 60 27%
408 66% 161 73%
66 23-93 66 27-93
354 57% 152 69%
267 43% 69 31%
430 69% 178 81%
191 31% 42 19%
206 33% 87 39%
415 67% 134 61%
509 82% 175 79%
112 18% 46 21%
173 28% 74 33%
448 72% 147 67%
393 63% 158 71%
228 37% 63 29%
571 92% 200 90%
50 8% 16 7%
205 33% 85 38%
416 67% 136 62%
383 62% 152 69%
238 38% 69 31%
452 73% 159 72%
169 27% 62 28%
391 63% 130 59%
230 37% 91 41%
421 68% 140 63%
200 32% 81 37%
432 70% 152 69%
189 30% 69 31%
372 60% 179 81%
249 40% 42 19%
356 57% 151 68%
265 43% 67 30%
NA NA 16 7%
NA NA 204 92%
Note: 24 patients in the 2008–2010 Cohort and 12 patients in the 2010–2013 Cohort were excluded from this 
table, since these patients received a metastasectomy (combined with a nephrectomy) with a possible 
curative intention, making systemic treatment redundant.
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal; NA, not applicable.
* mRCC was clinically established without histopathological confirmation in 17% of patients and mRCC was 
classified as not otherwise specified without further subtyping in 13% of patients (Cohort 2008–2010). It is 
likely that a substantial proportion of these patients had a clear cell subtype.
period since 213 patients were diagnosed in 2008, 216 in 2009 and 216 in 2010. 
Median follow-up was 3.3 years (95% CI 3.2–3.6).
Table 2.1 shows the patient and disease characteristics for this cohort. 
Median age was 66 years (range 23–93) and the majority of patients was male 
(66%). The distribution of patients according to the MSKCC risk score showed 
a high proportion of patients (58%) with a poor prognosis (versus 42% with an 
intermediate prognosis). Since all patients in the 2008–2010 Cohort presented 
with metastatic disease, none of them had a favourable prognosis (i.e. time 
from initial diagnosis was less than one year). The supplementary material 
(Table S2.1) provides the observed patient and disease characteristics (without 
imputations).
Uptake of targeted therapies and their use in daily clinical practice  
(2008–2010 Cohort)
Table 2.2 shows the first-line therapies used in the 2008–2010 Cohort. 336/645 
patients (52%) received a first-line therapy with the majority (282, 84%) treated 
with sunitinib. The distribution of patients across first-line therapies (per 
half-year period) is presented in Figure 2.1. There is evidence of a difference 
between the half-year periods in the proportion of patients receiving targeted 
therapy (p  =  0.041), but the chi-squared test for trend did not yield a signifi-
cant result. Furthermore, no shift was found in the use of first-line therapies 
amongst treated patients.
Of the 336 patients receiving first-line therapy, 101 patients (30%) also re-
ceived a second-line therapy, with everolimus being the most common (40%), 
followed by sorafenib (28%). There was an increasing trend in everolimus use 
over time (p  <  0.001) and a decreasing trend in sorafenib use (p  <  0.001); from 
2010 onwards, everolimus largely replaced sorafenib.
Use of targeted therapies amongst patients with an intermediate prognosis  
(2008–2010 Cohort)
Forty-two percent (269/645) of the patients in the 2008–2010 Cohort had an 
intermediate prognosis. 105/269 patients (39%) received no targeted therapy. 
Some (n  =  15) of these patients received a metastasectomy (combined with a 
nephrectomy) with a possible curative intention, making systemic therapy 
redundant. 40 of the remaining 90 patients (44%) who were given neither 
targeted therapy nor a metastasectomy (combined with a nephrectomy) ful-
filled the SUTENT trial eligibility criteria, indicating that they might have been 
eligible for treatment with sunitinib or another targeted therapy. 164/269 
patients (61%) received a first-line treatment; the majority was treated with 
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Table 2.2 Treatment patterns 2008–2010 Cohort and 2011–2013 Cohort
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sunitinib (145/ 164; 88%). Of the 145 patients treated with sunitinib, 102 fulfilled 
the SUTENT trial eligibility criteria.
In patients fulfilling SUTENT trial eligibility criteria (including patients 
not receiving any targeted therapy and patients treated with sunitinib), pa-
tients with an abnormal neutrophil count (OR, 0.28; p  =  0.045) were less likely 
to receive sunitinib, whereas patients with more than one metastatic site 
(OR, 3.35; p  =  0.010) were more likely to receive sunitinib after adjustment for 
additional patient and disease characteristics (see frequencies in Table 2.3).
The median OS of eligible patients not receiving any targeted therapy was 
18.6 months (95% CI 8.4–33.7). Table 2.4 presents the median OS in subgroups 
of patients with an intermediate prognosis treated with first-line sunitinib. 
Median OS of eligible patients treated with sunitinib was 14.8 months (95% CI 
10.8–16.1). Note that a different starting point was used for the survival analy-
sis (compared to the survival analysis in patients not receiving any targeted 
therapy). The mean time from diagnosis to start of first-line sunitinib was 4.3 
months (standard deviation [SD] 6.0).
Median OS was 11.9 months (95% CI 6.5–18.3) for ineligible patients treated 
with sunitinib, which was not significantly shorter than the OS of eligible pa-
tients treated with sunitinib. No significant differences were observed within 
the other subgroups.
Figure 2.1 Use of first-line drugs over time per half a year (2008–2010 Cohort)
Note: Patients were classified using the date of diagnosis.
Abbreviations: H1, first half year; H2, second half year.
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Use of targeted therapies amongst patients with a poor prognosis  
(2008–2010 Cohort)
Fifty-eight percent (376/645) of the patients in the 2008–2010 Cohort, had a 
poor prognosis. 204/376 patients (54%) did not receive any targeted therapy. 
Of these patients, 9 patients received a metastasectomy (combined with a 
nephrectomy). 29 of the remaining 195 patients (15%) who were given nei-
ther targeted therapy nor a metastasectomy (combined with a nephrectomy) 
fulfilled the SUTENT trial eligibility criteria. 172/376 (46%) patients received 
a first-line treatment, which was mainly sunitinib (137/376; 80%). Of the 137 
patients treated with sunitinib, 70 fulfilled the SUTENT trial eligibility criteria.
Amongst patients fulfilling SUTENT trial eligibility criteria, older patients 
(OR, 0.90; p  =  0.006) and patients with more than one comorbidity (OR, 0.26; 
p  =  0.090) were less likely to receive sunitinib, whereas patients with more 
than one metastatic site (OR, 5.38; p  =  0.034) were more likely to receive sunitin-
ib (see frequencies in Table 2.3). Furthermore, a significant association was 
found between hospital of diagnosis and prescription of sunitinib (p  =  0.006).
Median OS of eligible patients not receiving any targeted therapy was 6.2 
months (95% CI 1.7–9.9). Table 2.4 shows the median OS in subgroups of pa-
tients with a poor prognosis treated with first-line sunitinib. Median OS of 
eligible patients treated with sunitinib was 6.8 months (95% CI 5.3–10.7). The 
mean time from diagnosis to start of first-line sunitinib was 2.9 months (SD 
5.5).
Median OS was significantly reduced in poor-prognosis patients treat-
ed with sunitinib but not fulfilling the SUTENT trial eligibility criteria (4.7 
months, 95% CI 3.3–6.9). Additionally, OS was significantly reduced in patients 
with brain metastases and patients with a WHO performance status of 2–4.
Patient and disease characteristics of the 2011–2013 Cohort
The second cohort study included 791 patients with (m)RCC diagnosed be-
tween 2011 and 2013. Of these patients, 233 had metastatic disease; 75 in 2011, 
102 in 2012 and 55 in 2013 (one unknown). Median follow-up of the patients 
with mRCC was 1.2 years (95% CI 1.1–1.4).
Table 2.1 shows the patient and disease characteristics of the patients with 
mRCC in this cohort. Median age was 66 years, and 73% (170/233) of the patients 
was men. Metastatic disease was present in 77% (179/233) of patients at the time 
of diagnosis, whereas 23% was initially diagnosed with localised disease. In this 
cohort, 4% of the patients with mRCC had a favourable prognosis, whereas 
54% and 42% had an intermediate or poor prognosis, respectively.
Table 2.3 Patient subgroups that are more or less likely to receive targeted therapy while fulfilling SUTENT 
trial eligibility criteria
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ed patients, there was a decreasing trend in sunitinib use over time (p  =  0.006) 
and an increasing trend in pazopanib use (p  =  0.001).
Thirty-seven patients also received a second-line therapy within the fol-
low-up period. The majority was treated with everolimus (57%), but a decreas-
ing trend in everolimus use over time was observed (p  =  0.002).
Use of targeted therapies amongst patients with a favourable or intermediate 
prognosis (2011–2013 Cohort) 
136/233 patients (58%) had a favourable or intermediate prognosis. 52/136 pa-
tients (38%) did not receive any targeted therapy within the follow-up period. 
However, 12 of these 52 patients received a metastasectomy (combined with 
a nephrectomy). 25 of the remaining 40 patients (63%) who were given nei-
ther targeted therapy nor a metastasectomy (combined with a nephrectomy) 
fulfilled the SUTENT trial eligibility criteria. In addition, 45 of the 66 patients 
treated with sunitinib fulfilled the SUTENT trial eligibility criteria.
Amongst patients fulfilling SUTENT trial eligibility criteria, males (OR, 0.12; 
p  =  0.020) and older patients (OR, 0.92; p  =  0.011) were less likely to receive 
sunitinib after adjustment for additional patient and disease characteristics 
(see frequencies in Table 2.3).
Median OS of eligible patients not receiving any targeted therapy was 20.9 
months (95% CI 7.4-not reached [NR]). Table 2.4 presents the median OS in 
subgroups of patients with a favourable or intermediate prognosis treated 
with first-line sunitinib. Median OS of eligible patients treated with sunitinib 
was 18.0 months (95% CI 10.1-NR). The mean time from diagnosis to start of 
first-line sunitinib was 2.1 months (SD 3.3).
Median OS was 10.9 months (95% CI 2.7-NR) for patients treated with su-
nitinib but not fulfilling SUTENT trial eligibility criteria. No significant differ-
ences were observed within subgroups.
Use of targeted therapies amongst patients with a poor prognosis  
(2011–2013 Cohort)
97/233 patients (42%) had a poor prognosis. Forty-two patients (43%) did not 
receive any targeted therapy; thirteen of these 42 patients (31%) fulfilled the 
SUTENT trial eligibility criteria. Of the 44 patients treated with sunitinib, 26 
fulfilled the SUTENT trial eligibility criteria.
Of patients fulfilling SUTENT trial eligibility criteria, older patients (OR, 
0.84; p  =  0.012) were less likely to receive sunitinib (see frequencies in Table 
2.3). The unadjusted model showed a significant association between hospital 
of diagnosis and the prescription of sunitinib, but this association disap-
peared after adjustment for demographics, clinical and laboratory factors.
Uptake of targeted therapies and their use in daily clinical practice  
(2011–2013 Cohort)
Table 2.2 shows the first-line therapies used in the 2011–2013 Cohort. During 
the follow-up period, 139/233 (60%) patients received a first-line therapy; the 
majority (110, 79%) was treated with sunitinib. The distribution of patients 
across first-line therapies over time (half-year periods) is presented in Figure 
2.2. There were no significant differences between the half-year periods in the 
proportion of patients receiving targeted therapies. However, amongst treat-
Table 2.4 Overall survival in subgroups of patients treated with first-line sunitinib (Cohort 2008–2010 and Cohort 2011–2013)
Abbreviations: OS, overall survival; CI, confidence interval; NR, not reached.
* Since all patients in the 2008–2010 Cohort presented with metastatic disease, none of the patients had a favourable prognosis  
(i.e. time from initial RCC diagnosis was less than one year).
All patients
Fulfilling SUTENT trial 
eligibility criteria
Brain metastases 
WHO performance status 
Histology
Age
Patients with an 
intermediate prognosis  
(or favourable prognosis)*
Fulfilling SUTENT trial 
eligibility criteria
Brain metastases 
WHO performance status 
Histology
Age
Patients with a poor 
prognosis
Fulfilling SUTENT trial 
eligibility criteria
Brain metastases 
WHO performance status 
Histology
Age
n n
Median OS in 
months (95% CI)
Median OS in 
months (95% CI)
2008–2010 Cohort: mRCC  
at the initial diagnosis 2011–2013 Cohort: mRCC
p-value p-value
  282 9.1 (7.2-11.1) – 109 10.1 (7.2-13.8) –
No 110 6.5 (4.9-8.9)  38 6.9 (3.4-10.9) 
Yes 172 11.9 (8.8-14.6) 0.001 71 12.1 (8.9-NR) 0.007
No 261 9.3 (7.6-11.9)  101 10.9 (7.8-18.0) 
Yes 21 4.3 (2.1-11.5) 0.082 8 2.5 (0.8-7.5) 0.013
0-1 248 10.3 (8.4-13.0)  100 11.3 (7.8-18.0) 
2-4 34 3.3 (1.8-6.2) <0.001 9 1.4 (0.6-7.5) <0.001
Clear cell 204 10.0 (7.6-13.3)  81 10.6 (7.2-20.3) 
Non-clear cell 78 6.9 (5.4-11.0) 0.081 28 10.0 (3.5-13.8) 0.333
< 65 years 162 8.9 (6.5-10.8)  64 11.3 (7.2-20.3) 
>= 65 years 120 10.0 (6.5-13.8) 0.837 45 10.0 (5.3-16.6) 0.429
  145 14.6 (11.5-16.0) – 65 16.6 (10.1-NR) –
No 43 11.9 (6.5-18.3)  20 10.9 (2.7-NR) 
Yes 102 14.8 (10.8-16.1) 0.290 45 18.0 (10.1-NR) 0.121
No 136 14.6 (10.7-16.0)  61 16.6 (10.9-NR) 
Yes 9 11.9 (4.3-29.3) 0.807 4 6.9 (2.5-NR) 0.228
0-1 143 14.4 (10.8-16.0)  64 16.6 (10.1-NR) 
2-4 2 - 0.230 1 - 0.247
Clear cell 111 14.8 (11.8-16.2)  49 18.0 (10.0-NR) 
Non-clear cell 34 11.5 (6.3-17.7) 0.195 16 13.8 (2.7-NR) 0.314
< 65 years 87 10.8 (7.2-15.7)  36 12.1 (7.2-NR) 
>= 65 years 58 16.1 (12.4-18.8) 0.261 29 16.6 (8.5-NR) 0.716
  137 6.1 (4.9-7.7) – 44 6.5 (3.4-10.0) –
No 67 4.7 (3.3-6.9)  18 3.5 (1.3-7.8) 
Yes 70 6.8 (5.3-10.7) 0.015 26 6.6 (3.8-NR) 0.072
No 125 6.5 (5.3-8.4)  40 6.5 (3.8-10.1) 
Yes 12 2.1 (0.7-4.2) 0.006 4 1.2 (0.8-NR) 0.013
0-1 105 6.9 (5.3-9.8)  36 6.6 (3.8-10.1) 
2-4 32 3.1 (1.4-5.5) <0.001 8 1.2 (0.6-7.5) 0.009
Clear cell 93 6.1 (4.6-7.8)  32 6.5 (2.7-10.1) 
Non-clear cell 44 5.7 (3.7-10.3) 0.659 12 4.1 (2.6-NR) 0.998
< 65 years 75 6.9 (4.9- 9.8)  28 7.8 (3.8-13.7) 
>= 65 years 62 5.4 (3.8-6.8) 0.404 16 3.2 (1.1-6.6) 0.026
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of second-line therapies, where sorafenib was replaced by everolimus as the 
most frequent choice from 2010 onwards.
The median OS of patients with an intermediate prognosis treated with su-
nitinib in Dutch daily practice and fulfilling the SUTENT trial eligibility criteria 
was shorter than the median OS of patients in the SUTENT trial with an inter-
mediate prognosis, i.e. 14.8 months (95% CI 10.8–16.1) in the 2008–2010 Cohort 
compared to 20.7 months (95% CI 18.2–25.6) in the SUTENT trial.34 However, the 
difference was much smaller for the 2011–2013 Cohort (median OS, 18.0 months 
(95% CI 10.1-NR)) compared to the SUTENT trial patients. Median OS of patients 
with a poor prognosis fulfilling the SUTENT trial eligibility criteria was similar 
to the median OS found in the SUTENT trial, i.e. 6.8 months (95% CI 5.3–10.7) in 
the 2008–2010 Cohort and 6.6 months (95% CI 3.8-NR) in the 2011–2013 Cohort 
compared to 5.3 months (95% CI 4.2–10.0) in the SUTENT trial.34
The median OS of patients with an intermediate prognosis treated with 
sunitinib in Dutch daily practice (regardless of their SUTENT trial eligibility 
status) was shorter than the OS in the expanded-access trial.35 Median OS of 
patients with a poor prognosis was in line with the results of the expanded-ac-
cess trial. The median OS of patients with an intermediate prognosis treated 
with sunitinib in Dutch daily practice was also shorter than the OS in a retro-
spective, non-interventional study in Australia.49 These findings may indicate 
that the patients in the PERCEPTION registry with an intermediate risk had a 
worse prognosis than the patients with an intermediate risk in other studies.
While previous studies suggest that patients fulfilling SUTENT trial eligi-
bility criteria have a survival benefit from first-line sunitinib,34 many eligible 
patients did not receive sunitinib (or any other targeted therapy) in daily 
practice. This was also seen in England where one in three patients with mRCC 
eligible for either sunitinib or pazopanib did not receive the drug.50 Patients 
aged 65+ years were less likely to receive targeted therapy than younger pa-
tients after adjustment for other factors. This age factor was found in patients 
with an intermediate prognosis (2011–2013 Cohort) and in patients with a 
poor prognosis (2008–2010 Cohort and 2011–2013 Cohort). There are several 
explanations for this association, including medical contraindications, other 
grounds for physician reluctance, and patient refusal. Additionally, patients 
with one metastatic site were less likely to receive sunitinib (according to 
the 2008–2010 Cohort results), which might be explained by patients with 
low volume but unresectable metastases whose targeted therapy is delayed. 
Nevertheless, most of these patients died within the follow-up period without 
receiving targeted therapy at any point in time. The reasons for apparent un-
derutilisation of targeted therapies should be examined more carefully. While 
hospital-level factors may also affect utilisation and lead to between-hospital 
Median OS of eligible patients not receiving any targeted therapy was 3.4 
months (95% CI 0.8-NR). Table 2.4 shows the median OS in subgroups of pa-
tients with a poor prognosis treated with first-line sunitinib. Median OS of 
eligible patients treated with sunitinib was 6.6 months (95% CI 3.8-NR). The 
mean time from diagnosis to start of first-line sunitinib was 1.9 months (SD 
1.8).
Median OS was significantly reduced in patients not fulfilling the SUTENT 
trial eligibility criteria (3.5 months, 95% CI 1.3–7.8). Additionally, as in the 
2008–2010 Cohort, median OS was significantly reduced in patients with brain 
metastases and patients with a WHO performance status of 2–4. OS was also 
significantly reduced in older patients.
Discussion
Since 2006, several new targeted therapies for mRCC have entered the market 
and randomised controlled trial (RCTs) have shown that these therapies im-
prove survival.25-29,34,40-48 This study examined the uptake and use of targeted 
therapies in the Netherlands. Not unexpected, targeted therapies, sunitinib 
in particular, have largely replaced IFN-α as first-line standard of care. Few 
patients were treated with bevacizumab (combined with IFN-α) or temsiroli-
mus in the 2008–2013 period, even though these therapies were added to the 
ESMO guidelines in 2009,30 and to Dutch guidelines in 2010.32 Pazopanib has 
only been recommended since 2010,31 which partly explains why an increase 
in its use was only seen from 2012. Furthermore, there was a shift in the use 
Figure 2.2 Use of first-line drugs over time per half a year (2011–2013 Cohort)
Note: Patients were classified using the date of diagnosis. 
Abbreviations: H1, first half year; H2, second half year
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Conclusions
In conclusion, targeted therapies, sunitinib in particular, have largely re-
placed IFN-α as the first-line standard of care in the Netherlands. Nevertheless, 
many patients in Dutch daily practice fulfilling SUTENT trial eligibility crite-
ria did not receive sunitinib (or any other targeted therapy) even though it 
could improve their survival. For example, older patients were less likely to 
receive sunitinib, perhaps because physicians are reluctant to prescribe it. 
The reasons for apparent underutilisation of targeted therapies should be 
examined more carefully.
variation, we found no significant differences in the prescription of targeted 
therapy between hospitals, except for the patients with a poor prognosis in 
the 2008–2010 Cohort. However, the sample size per hospital was small and 
the statistical power to show a difference was therefore limited.
Although this study mainly focussed on patients fulfilling SUTENT trial eli-
gibility criteria, we found that many patients in daily clinical practice are dif-
ferent from patients included in RCTs. In the total study population, only 42% 
and 58% fulfilled the SUTENT trial eligibility criteria in the 2008–2010 Cohort 
and 2011–2013 Cohort, respectively. This was partly caused by the inclusion 
criteria of the PERCEPTION registry, which consisted of a diagnosis of mRCC 
(i.e. metastases at initial presentation in the 2008–2010 Cohort) of any histo-
logical subtype. Since many patients are excluded from clinical trials, such 
as patients with a non clear-cell subtype, patients with a WHO performance 
status of 2 to 4 and patients with brain metastases, one could argue that the 
results of these trials only apply to a subgroup of patients. 
A limitation of this study is the amount of missing data in baseline char-
acteristics, which is inherent to an observational study. To overcome this 
problem, multiple imputations by chained equations were conducted, which 
ensure that all patients are included in the analysis but simultaneously ensure 
that the uncertainties from missing data are retained.39 Additionally, eligibil-
ity criteria, such as the presence of measurable disease and adequate organ 
function were not taken into account when determining whether patients 
fulfilled the SUTENT trial eligibility criteria, since data on these criteria were 
lacking in the PERCEPTION registry. As a consequence, some of the patients 
that we labelled as eligible in this study were not in fact eligible for targeted 
therapy. However, since we used WHO performance status to classify patients, 
and since we expect a relationship between WHO performance status and 
organ function, we believe that this could only have had a limited effect on 
our conclusions about the uptake and use of targeted therapies. Furthermore, 
the follow-up length of the 2011–2013 Cohort was limited. As a consequence, 
patients might have received targeted therapy after the follow-up period, 
leading to an underestimate of actual targeted therapy use. However, this 
limitation is only relevant for patients treated later in the 2011–2013 period 
who did not die. Lastly, OS was calculated from the date of diagnosis (i.e. met-
astatic disease) for patients not receiving any targeted therapy and from the 
start of therapy for patients treated with targeted therapy; as a consequence 
a comparison between the two is impossible. This approach was based on the 
one used in other studies to enable comparisons between the OS of patients 
treated with sunitinib in our study with the OS of patients treated with su-
nitinib in other studies.34,35,49 
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Table S2.1 Patient and disease characteristics (observed and imputed) 2008–2010 Cohort and 2011–2013 Cohort
Sex – n (%)
 Female
 Male
Median age – yr (range)
Histology – n (%)
 Clear cell
 Other
WHO performance status – n (%)
 0-1
 2-4
 Missing
Site of metastasis – n (%)
 One
 More than one
 Missing
Liver metastasis – n (%)
 No
 Yes
 Missing
Lung metastasis – n (%)
 No
 Yes
 Missing
Bone metastasis – n (%)
 No
 Yes
 Missing
Brain metastasis – n (%)
 No
 Yes
 Missing
Haemoglobin – n (%)
 Normal
 < LLN
 Missing
Neutrophil count – n (%)
 Normal
 > ULN
 Missing
Platelet count – n (%)
 Normal
 > ULN
 Missing
Albumin – n (%)
 Normal
 < LLN
 Missing
Corrected serum calcium – n (%)
 Normal
 > ULN
 Missing
Alkaline phosphatase – n (%)
 Normal
 > ULN
 Missing
Lactate dehydrogenase – n (%)
 Normal
 > 1.5 times ULN
 Missing
Comorbidities – n (%)
 Zero or one
 More than one
 Missing
Time since RCC diagnosis – n (%)
 > One year
 < One year
Real-world data 
(n=621)
Real-world data 
(n=221)
2008–2010 Cohort: 
mRCC at the initial diagnosis 2011–2013 Cohort: mRCC
Imputed data 
(n=621)
Imputed data 
(n=221)
213 34% 213 34% 60 27% 60 27%
408 66% 408 66% 61 73% 161 73%
66 23-93 66 23-93 66 27-93 66 27-93
354 57% 354 57% 152 69% 152 69%
267 43% 267 43% 69 31% 69 31%
204 33% 430 69% 94 43% 178 81%
61 10% 191 31% 13 6% 42 19%
356 57%   114 52%  
195 31% 206 33% 85 38% 87 39%
398 64% 415 67% 131 59% 134 61%
28 5%   5 2%  
487 78% 509 82% 171 77% 175 79%
106 17% 112 18% 45 20% 46 21%
28 5%   5 2%  
163 26% 173 28% 72 33% 74 33%
430 69% 448 72% 144 65% 147 67%
28 5%   5 2%  
375 60% 393 63% 154 70% 158 71%
218 35% 228 37% 62 28% 63 29%
28 5%   5 2%  
546 88% 571 92% 200 90% 200 90%
47 8% 50 8% 16 7% 16 7%
28 5%   5 2%  
171 28% 205 33% 76 34% 85 38%
347 56% 416 67% 122 55% 136 62%
103 17%   23 10%  
203 33% 383 62% 82 37% 152 69%
108 17% 238 38% 41 19% 69 31%
310 50%   98 44%  
358 58% 452 73% 127 57% 159 72%
140 23% 169 27% 51 23% 62 28%
123 20%   43 19%  
247 40% 391 63% 86 39% 130 59%
136 22% 230 37% 61 28% 91 41%
238 38%   74 33%  
243 39% 421 68% 88 40% 140 63%
116 19% 200 32% 51 23% 81 37%
262 42%   82 37%  
324 52% 432 70% 112 51% 152 69%
139 22% 189 30% 48 22% 69 31%
158 25%   61 28%  
277 45% 372 60% 130 59% 179 81%
174 28% 249 40% 31 14% 42 19%
170 27%   60 27%  
356 57% 356 57% 151 68% 151 68%
265 43% 265 43% 67 30% 67 30%
0 0%   3 1%  
NA NA NA NA 16 7% 16 7%
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PERCEPTION registry
Figure S2.1 Patient enrolment
Cohort 2008–2010
•	 	mRCC	(i.e.	metastases	 
at initial presentation)
•	 	Diagnosis	2008–2010
Assessed for eligibility (n=714)
Follow-up (n=675)
Analysis (n=645)
Lost to follow-up (n=30)
•	 	Patients	continued	
treatment in a non-
participating hospital
Lost to follow-up (n=16)
•	 	Patients	continued	
(possible) systemic 
treatment in a non-
participating hospital 
Analysis (n=233/791)
(Patients with metastatic disease 
were included in the analysis)
Follow-up (n=807)
Excluded (n=39)
•	 	Not	meeting	inclusion	criteria	(n=26)
	 •	 	No	renal	cell	carcinoma	(n=12)
	 •	 	No	metastases	at	presentation	(n=6)
	 •	 	<	18	years	(n=7)
	 •	 	Other	(n=1)
•	 	Other	reasons	(n=13)
	 •	 	Diagnosed	and/or	treated	in	a	non-participating	hospital,	 
and too little information available on patient and disease 
characteristics (and treatment) (n=12)
	 •	 	Other	(n=1)
Cohort 2011–2013
•	 	(m)RCC
•	 	Diagnosis	2011–2013
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Introduction
In Europe in 2012, an estimated 115,200 patients were diagnosed with kidney 
cancer, and 49,000 patients died from the disease.18 The most common type 
of kidney cancer is renal cell carcinoma. Metastases at the initial presentation 
are present in 25%-30% of the patients.51 
Following a randomised study showing that interferon-alfa (IFN-α) im-
proved overall survival (OS) compared to medroxyprogesterone acetate and 
subsequent randomised studies that concluded that a cytoreductive nephrec-
tomy (CN) further prolongs survival of patients with metastatic renal cell 
carcinoma (mRCC), a tumour nephrectomy followed by IFN-α has been the 
standard approach for many years.52-54 However, treatment has considerably 
changed over the last decade. Targeted therapies for mRCC have entered the 
market since 2006, and sunitinib is nowadays the most frequently used treat-
ment in the Netherlands.
Whether or not CN prolongs the survival of patients treated with targeted 
agents such as sunitinib is unknown given the lack of evidence from ran-
domised controlled trials (RCTs). International guidelines recommend CN 
for patients with a good performance status and large primary tumours with 
limited volumes of metastatic disease, and for patients with a symptomatic 
primary lesion.55,56 Clearly, this is based on a low level of evidence with a high 
risk of bias. As a consequence, clinicians remain uncertain about whether 
or not CN offers any benefit to mRCC patients who are about to start with 
sunitinib and have no complaints arising from their primary tumour.
The effect of CN compared to no surgery in primary mRCC was previously 
investigated in retrospective studies.57-60 However, these studies included 
heterogeneous patient populations that were composed of patients from 
different countries treated with various systemic therapies. In addition, with 
a few exceptions, no attention was given as to when targeted therapy was pro-
vided. This is of importance since the time from diagnosis to targeted therapy 
of <1 year is a validated risk factor in the Memorial Sloan Kettering Cancer 
Center (MSKCC) and International mRCC Database Consortium (IMDC) risk 
scores.21,23 Without correction, indiscriminate inclusion of patients with a 
time to targeted therapy of ≥1 year introduces substantial bias. The aim of this 
paper is to evaluate the effect of CN on OS in primary mRCC patients treated 
with first-line sunitinib. We specifically selected patients within 1 country, 
all treated with the same systemic treatment (i.e. sunitinib) within a limited 
time frame. A subgroup analysis was conducted including patients with a 
time to targeted therapy of <1 year.
Abstract
Objective: To evaluate the effect of cytoreductive nephrectomy (CN) on overall 
survival (OS) in primary metastatic renal cell carcinoma (mRCC) patients 
treated with first-line sunitinib. 
Methods: Patients with primary mRCC treated with first-line sunitinib were 
selected from a Dutch population-based registry. A propensity score was 
calculated reflecting the probability of a patient undergoing CN prior to su-
nitinib using a set of known covariates, such as the Memorial Sloan Kettering 
Cancer Center and International mRCC Database Consortium risk factors. 
After propensity score matching, differences in OS were analysed using the 
Kaplan-Meier method and a multivariable Cox proportional hazards model 
was used to evaluate the effect of CN on OS.
Results: A total of 227 patients met the selection criteria; 74 patients (33%) 
underwent CN prior to sunitinib. In the matched population, the median 
OS of patients who underwent CN was 17.9 months compared to 8.8 months 
for patients treated with sunitinib only. Multivariable analysis showed that 
CN was an independent predictor of OS (hazard ratio 0.61, 95% confidence 
interval 0.41-0.92). A subgroup analysis of patients with a time to targeted 
therapy of <1 year showed a median OS of 12.7 months for patients treated 
with CN compared to 8.0 months for patients treated with sunitinib only. 
The corresponding hazard ratio was 0.67 (95% confidence interval 0.46-0.98).
Conclusions: This study suggests that CN may be effective. However, the ben-
efit was modest when correcting for time from diagnosis to sunitinib. One 
important limitation is the use of a registry (with retrospectively collected 
data), which made it impossible to correct for unmeasured characteristics 
that could be associated with treatment choices or survival.
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In the second approach, we applied 2 different methods to match the treated 
patients (i.e. patients who underwent CN prior to sunitinib) to comparable 
controls (i.e. patients treated with sunitinib only): single nearest-neighbour 
matching (with and without caliper, with replacement) and kernel match-
ing.61 Single nearest-neighbour matching involves matching each treated 
patient to the untreated patient with the closest propensity score. Kernel 
matching involves matching all treated patients with a weighted average 
of all untreated patients.62 In this way, a hypothetical match is constructed 
for each patient who underwent CN prior to sunitinib. Patient characteris-
tics were studied to decide whether single nearest-neighbour matching or 
kernel-matching method achieved the best balance of covariates. Then, a 
multivariable Cox proportional hazards model was estimated in the matched 
population, as recommended by Stuart.61 Covariates considered for inclusion 
were baseline demographics (age at diagnosis and gender), and clinical, bio-
chemical, and hematologic factors (Table 3.1).37,38 Backward selection was used 
to select the covariates for the model; any nonsignificant attributes (α  =  0.05) 
were excluded from the model one at a time. Forward selection was used 
to create an alternative model. The proportionality assumption was tested 
graphically using log–log plots of survival, and formally using Schoenfeld 
residuals.
The analyses were repeated for a subgroup of patients with a time to tar-
geted therapy of <1 year. Again, propensity score matching was applied and 
a multivariable Cox proportional hazards model was estimated to evaluate 
the effect of CN on OS.
Missing data were handled using multiple imputations by chained equa-
tions. This method generated imputations based on a set of imputation 
models, one for each variable with missing values.39 The process of multiple 
imputations produced 10 imputed datasets. The propensity score used in the 
analysis was the mean of 10 propensity scores for each patient.63 
Data analyses were conducted using STATA statistical analysis software 
(StataCorp. 2013, Stata Statistical Software: Release 13. College Station, TX: 
StataCorp LP).
Results
Study population
Out of 714 patients with primary mRCC in the PERCEPTION registry, 282 pa-
tients treated with first-line sunitinib were selected. Finally, 227 patients were 
included in the analysis of whom 74 patients (33%) underwent CN prior to 
sunitinib (reasons for exclusion are presented in Figure S3.1).
Patients and methods
Study population
A population-based registry (PERCEPTION) was initiated to evaluate treatment 
of patients with mRCC in Dutch clinical practice. Eligible patients for this 
registry were selected from the Dutch Cancer Registry, which includes all new 
cancer cases in the Netherlands. Inclusion criteria for the PERCEPTION registry 
comprised a diagnosis of mRCC (i.e. metastases at initial presentation) of any 
histologic subtype. Patients diagnosed between January 2008 and December 
2010 in 42 of 51 hospitals (both general and academic) in 4 regions, covering 
approximately half of the country, were included in the PERCEPTION registry. 
The research protocol was approved by the medical ethical committee of the 
Radboud university medical center in Nijmegen in 2010.
For the present study, we selected patients treated with first-line sunitinib 
to study the effect of CN on OS in a homogeneous patient population. We 
chose to select patients treated with first-line sunitinib because the majority 
of patients treated with a systemic therapy were treated with sunitinib (i.e. 
84% in the PERCEPTION registry).
Variables and definitions
Data on baseline demographics and clinical and laboratory factors were ret-
rospectively collected from individual patient records. Furthermore, data on 
treatment schemes and treatment endpoints (e.g. survival) were collected. 
Laboratory factors were standardised according to routinely used reference 
values.
Statistical analyses
To mimic an RCT on the effect of CN as good as possible, a propensity score 
was calculated reflecting the probability of a patient undergoing CN prior to 
sunitinib, using a set of known covariates and multivariable logistic regres-
sion analysis. The covariates were obtained from the PERCEPTION registry by 
selecting clinical, biochemical, and hematologic factors known to impact 
progression-free survival or OS (Table 3.1).37,38 Also, baseline demographics 
(age at diagnosis and gender) and 3 additional clinical factors (histology, 
clinical tumour stage, and regional lymph node involvement) were incorpo-
rated as covariates, because these factors could have influenced the decision 
to conduct a nephrectomy. OS was calculated from the date of the start of 
treatment (i.e. CN or start of first-line sunitinib) until the date of death from 
any cause or last follow-up using the Kaplan-Meier method. The first approach 
to evaluate the effect of CN was a Cox proportional hazards model using the 
propensity score as a covariate.
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derwent CN was 16.7 months (95% confidence interval [CI] 11.7-20.2) compared 
to a median OS of 6.8 months (95% CI 5.8-8.8) for patients treated with su-
nitinib only (p  <  0.001). The corresponding hazard ratio (HR) was 0.53 (95% 
CI 0.39-0.72).
Matched population
When the propensity score was included as the sole covariate in a Cox propor-
tional hazards model, CN was associated with an HR of 0.56 (95% CI 0.40-0.80) 
(Table 3.3).
Besides estimating a Cox proportional hazards model using the propensi-
ty score as a covariate, single nearest-neighbour matching (with and without 
caliper, with replacement) and kernel matching were applied. Differences in 
patient characteristics were noticeably reduced after single nearest-neigh-
bour matching and kernel matching with kernel matching showing the larg-
est reductions. Patient characteristics of the kernel-matched population are 
presented in Table 3.2. Differences in size or extent of the primary tumour, 
the number of metastatic sites, and the presence of bone metastases were 
noticeably reduced. Also, the percentages of patients with a normal corrected 
serum calcium level became comparable after matching. Figure 3.2 shows the 
Kaplan-Meier curves after matching. The median OS of patients who under-
went a nephrectomy prior to sunitinib was 17.9 months compared to a median 
OS of 8.8 months for patients treated with sunitinib only. After matching, the 
multivariable Cox proportional hazard model showed that CN had an HR of 
0.61 (95% CI 0.41-0.92) (Table 3.3).
A subgroup analysis of patients with a time to targeted therapy of <1 year 
showed a median OS of 12.7 months for patients treated with CN prior to su-
nitinib compared to 8.0 months for patients treated with sunitinib only. The 
corresponding HR associated with CN was 0.67 (95% CI 0.46-0.98) after adjust-
ment for other factors. Figure 3.3 shows the Kaplan-Meier curves of OS after 
matching in this subgroup of patients.
Discussion
Two RCTs have found that CN followed by treatment with IFN-α improves sur-
vival compared to IFN-α alone in patients presenting with mRCC and a per-
formance status of 0 or 1.53,54 In contrast, there is no RCT evidence supporting 
the value of a CN prior to targeted therapies. This has led to a large variation 
in clinical practice, reflected by our data showing that 74 of 227 of the patients 
(33%) presenting with mRCC underwent CN prior to sunitinib.
The median OS of patients who underwent CN prior to sunitinib was 17.9 
months compared to 8.8 months for matched patients treated with sunitinib 
Patient characteristics are shown in Table 3.2. Briefly, the size or extent of the 
primary tumour was more often limited to T1, T2, or T3a for patients who 
underwent CN. CN-treated patients more often had just 1 metastatic site and 
had bone metastases less often than patients who did not undergo CN. Lastly, 
patients who underwent CN more often had a normal corrected serum cal-
cium level, and their time from diagnosis to start sunitinib was more often 
≥1 year. Observed patient and disease characteristics (without imputations) 
are provided in Table S3.1.
Of patients who underwent CN, 3% and 54% had a favourable or interme-
diate prognosis, respectively, whereas 0% and 46% of patients treated with 
sunitinib only had a favourable or intermediate prognosis according to the 
MSKCC risk score.
All but 1 of the 74 patients underwent a radical nephrectomy, either per-
formed by an open (n  =  38) or laparoscopic (n  =  27) approach; for 7 patients, the 
technique was unknown and 1 patient underwent an open partial nephrecto-
my. Eight of 74 patients also underwent an associated procedure such as an 
adrenalectomy during the same session. The median time from diagnosis to 
nephrectomy was 0 days (range: 0-135). The date of diagnosis for each patient 
was derived from the Dutch Cancer Registry. In this registry, dates of diagnosis 
are registered in a systematic way in the sense that a clinical diagnosis date 
is overruled with the first date at which histologic confirmation takes place. 
For that reason, the diagnosis date is the date of CN for more than 50% of our 
patient series. Median time from nephrectomy to start of first-line sunitinib 
was 85 days (range: 11-1048). For patients who did not undergo a nephrecto-
my prior to sunitinib, the median time from diagnosis to start of first-line 
sunitinib was 27 days (range: 0-352).
At last follow-up, 207 of 227 patients had died. Figure 3.1 shows the Kaplan-
Meier curves of OS in patients treated with CN prior to sunitinib and patients 
treated with sunitinib only. The unadjusted median OS of patients who un-
Table 3.1 Clinical factors, biochemical and haematological factors known to impact  
mRCC outcomes 
* Since all patients who did not undergo cytoreductive nephrectomy had a time from diagnosis to 
treatment of less than 1 year, this factor was excluded during the calculation of propensity scores. 
** Prior nephrectomy was excluded during the calculation of propensity scores.
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal.
Biochemical and haematologic factors
Corrected serum calcium >ULN
Neutrophil count >ULN
Platelet count >ULN
Alkaline phosphatase >ULN
Lactate dehydrogenase >ULN
Haemoglobin <LLN
Albumin <LLN
WHO performance status
Time from diagnosis to study start*
Number of metastatic sites
Prior nephrectomy**
Lung metastases 
Liver metastases 
Bone metastases
Clinical factors
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only. A multivariable Cox proportional hazard model showed that CN had an 
HR of 0.61 (95% CI 0.41-0.92), suggesting that CN may be effective. A comparable 
HR was found when the propensity score was included as the sole covariate in 
a Cox proportional hazards model. A subgroup analysis of patients with a time 
to targeted therapy of <1 year showed a median OS of 12.7 months for patients 
treated with CN prior to sunitinib compared to 8.0 months for matched pa-
tients treated with sunitinib only. The corresponding HR associated with CN 
was 0.67 (95% CI 0.46-0.98) after adjustment for other factors. All approaches 
indicate that CN is associated with improved survival. However, the benefit 
was modest when correcting for time from diagnosis to sunitinib.
Similar to our study, 3 other studies found an OS benefit in patients who 
underwent a nephrectomy prior to targeted therapies (HR 0.60, 95% CI 0.52-
0.69; HR 0.68, 95% CI 0.46-0.99; HR 0.43, 95% CI 0.28-0.68, respectively).57-59 In 
the studies by Heng et al and Choueiri et al, HRs were adjusted for the IMDC 
prognostic factors.57,58 Similar to our study, the study by Bamias et al took 
additional factors into account besides the IMDC prognostic factors.59 In all 
3 studies, a multivariable Cox proportional hazard model was used to cor-
rect for differences in baseline characteristics between treatment groups. 
An advantage of our study is that propensity score matching was performed 
before fitting a model. As such, the design of the study was separated from the 
analyses; we estimated the effect of CN on OS only after patient characteristics 
were sufficiently balanced.64,65 Furthermore, problems from a misspecified 
regression model are less severe when propensity score matching precedes 
conventional regression and characteristics have been balanced.65 Lastly, all 
3 studies included heterogeneous patient populations that were composed 
of patients from different countries treated with various systemic therapies 
(except the study by Bamias et al that selected patients treated with first-
Table 3.3 Multivariable analysis for factors associated with overall survival (based on covariate adjustment 
using the propensity score and based on kernel-matching)
Abbreviations: HR, hazard ratio; CI, confidence interval; ULN, upper limit of normal.
* A slightly different model was created based on forward selection with platelet count instead of WHO 
performance status. Variables considered for inclusion were: cytoreductive nephrectomy, gender, age, WHO 
performance status, site of metastasis, liver metastasis, lung metastasis, bone metastasis, haemoglobin, 
neutrophil count, platelet count, albumin, corrected serum calcium, alkaline phosphatase, lactate dehydrogenase 
and time from diagnosis to start sunitinib.
HR nephrectomy adjusted for 
propensity score (95% CI)
0.56 (0.40-0.80)
0.74 (0. 34-1.62)
Multivariable HR in the 
matched population (95% CI)*
0.61 (0.41-0.92)
2.26 (1.04-4.95)
2.30 (1.14-4.62)
1.87 (1.01-3.46)
4.45 (1.59-12.42)
Covariate
Cytoreductive nephrectomy (yes vs. no)
Propensity score
WHO performance status (2-4 vs. 0-1)
Liver metastasis (yes vs. no)
Corrected serum calcium (>ULN vs. normal)
Time from diagnosis to start sunitinib  
(< 1 year vs. >= 1 year)
Table 3.2 Patient characteristics before and after propensity score matching
Gender – n (%)
 Female
 Male
Median age – yr (range)
Histology – n (%)
 Clear cell
 Other
cTNM – T – n (%)
 T1-T3a
 T3b-T4
cTNM – n – n (%)
 N0
 N1
WHO performance status – n (%)
 0-1
 2-4
Site of metastasis – n (%)
 One
 More than one
Liver metastasis – n (%)
 No
 Yes
Lung metastasis – n (%)
 no
 yes
Bone metastasis – n (%)
 No
 Yes
Haemoglobin – n (%)
 Normal
 < LLN
Neutrophil count – n (%)
 Normal
 > ULN
Platelet count – n (%)
 Normal
 > ULN
Albumin – n (%)
 normal
 < LLN
Corrected serum calcium – n (%)
 Normal
 > ULN
Alkaline phosphatase – n (%)
 Normal
 > ULN
Lactate dehydrogenase – n (%)
 Normal
 > 1.5 times ULN
Time from diagnosis to start 
sunitinib – n (%)
 >= One year
 < One year
Sunitinib only
(n=153) p-value
Unmatched data Matched data
CN + sunitinib
(n=74)
CN + sunitinib
(n=73)*
Sunitinib only
(n=73)
48 (31%) 13 (18%)  13 (17%) 13 (18%)
105 (69%) 61 (82%) 0.030 60 (83%) 60 (82%)
64 (24-89) 61 (28-77) 0.010 64 (24-89) 62 (28-77)
101 (66%) 58 (78%)   57 (78%) 57 (78%)
52 (34%) 16 (22%) 0.059 16 (22%) 16 (22%)
103 (67%) 61 (82%)   59 (81%) 60 (82%)
50 (33%) 13 (18%) 0.020 14 (19%) 13 (18%)
71 (46%) 37 (50%)   32 (44%) 37 (50%)
82 (54%) 37 (50%) 0.657 41 (56%) 36 (50%)
126 (82%) 58 (79%)   60 (82%) 57 (78%)
27 (18%) 16 (21%) 0.698 13 (18%) 16 (22%)
39 (25%) 34 (46%)   39 (54%) 33 (45%)
114 (75%) 40 (54%) 0.002 34 (46%) 40 (55%)
129 (84%) 68 (92%)   68 (94%) 67 (92%)
24 (16%) 6 (8%) 0.120 5 (6%) 6 (8%)
36 (24%) 16 (22%)   24 (32%) 16 (22%)
117 (76%) 58 (78%) 0.749 49 (68%) 57 (78%)
88 (58%) 59 (80%)   61 (84%) 58 (79%)
65 (42%) 15 (20%) 0.001 12 (16%) 15 (21%)
53 (34%) 20 (27%)   17 (23%) 20 (27%)
100 (66%) 54 (73%) 0.264 56 (77%) 53 (73%)
96 (63%) 51 (68%)   49 (67%) 50 (68%)
57 (37%) 23 (32%) 0.568 24 (33%) 23 (32%)
109 (71%) 58 (79%)   58 (79%) 57 (79%)
44 (29%) 16 (21%) 0.257 15 (21%) 16 (21%)
100 (66%) 56 (75%)   51 (70%) 55 (75%)
53 (34%) 18 (25%) 0.217 22 (30%) 18 (25%)
94 (62%) 59 (79%)   57 (78%) 58 (79%)
59 (38%) 15 (21%) 0.037 16 (22%) 15 (21%)
108 (70%) 58 (78%)   59 (81%) 57 (78%)
45 (30%) 16 (22%) 0.291 14 (19%) 16 (22%)
91 (59%) 45 (61%)   39 (54%) 45 (62%)
62 (41%) 29 (39%) 0.781 34 (46%) 28 (38%)
0 (0%) 12 (16%) <0.001 0 (0%) 12 (16%)
153 (100%) 62 (84%)  153 (100%) 62 (84%)
Abbreviations: CN, cytoreductive nephrectomy; LLN, lower limit of normal; ULN, upper limit of normal.
* One patient was excluded, since his propensity score was higher than the maximum propensity scores of the controls.
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line sunitinib), whereas we selected primary mRCC patients from a Dutch 
population-based registry, all treated with first-line sunitinib. Warren et al 
also showed an improved OS associated with CN prior to treatment with ty-
rosine kinase inhibitors (HR 0.38, 95% CI 0.19-0.74).60 However, Warren et al’s 
study population comprised a mix of patients (because only some patients 
presented with mRCC) and treatments (tyrosine kinase inhibitor could be 
the first- or second-line therapy). Besides these studies, other studies have 
examined the effect of presurgical sunitinib.66-70 
The median OS of patients treated with sunitinib in the randomised phase 
III trial of sunitinib vs IFN-α was much longer than the OS observed in the cur-
rent study. The pivotal phase III trial reported a median OS of 26.4 months,34 
whereas we found an OS of 16.7 months for patients who underwent CN (meas-
ured from the date of CN) and 6.8 months for patients treated with sunitinib 
only (in the unmatched population). This difference can be explained by the 
fact that the pivotal trial had many more patients with a favourable prognosis 
than our study (i.e. 38% vs 1%). In addition, our study exclusively focuses on 
primary mRCC, whereas the phase III trial mainly included patients with 
metachronous mRCC. 
One important limitation of our study is the use of a population-based 
registry (with retrospectively collected data), which made it impossible to 
correct for unmeasured characteristics that could be associated with treat-
ment choices or survival. Only a prospective, randomised trial could over-
come this limitation.
A second limitation stems from our sample size of 74 patients who under-
went CN prior to sunitinib. Although this relatively small sample resulted in 
fairly wide CIs for the HRs for CN, the upper limits of the CIs are lower than 
one, suggesting that CN may be effective.
Third, patients who underwent CN prior to sunitinib more often received 
a second-line therapy (27 of 74 patients [36%]) than patients treated with su-
nitinib only (34 of 153 patients [22%]). But since this difference is relatively 
small, it does not likely explain the difference in OS. 
In addition, reasons for starting (or delaying) treatment with sunitinib 
have not been registered. Especially patients who underwent CN prior to 
sunitinib had a longer time from diagnosis to sunitinib (16%, ≥1 year). It is 
common practice in low-volume primary metastatic disease to perform a 
CN and to delay systemic therapy until further progression. This finding was 
also seen in the study by Heng et al, wherein 5% of the patients treated with 
sunitinib only and 29% of the patients who underwent CN prior to sunitinib 
had a time from diagnosis to targeted therapy of ≥1 year.57 We conducted a 
subgroup analysis of patients with a time to targeted therapy of <1 year.
Figure 3.1 Kaplan-Meier survival estimate of overall survival in primary mRCC patients treated with or 
without cytoreductive nephrectomy – observed patients
Figure 3.2 Kaplan-Meier survival estimate of overall survival in primary mRCC patients treated with or 
without cytoreductive nephrectomy – propensity score matched patients
Figure 3.3 Kaplan-Meier survival estimate of overall survival in a subgroup of primary mRCC patients 
(time to sunitinib < 1 year) treated with or without cytoreductive nephrectomy – propensity score matched 
patients
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Figure S3.1 Patient enrolment
Assessed for eligibility (n=714)
Follow-up (n=675)
Total population (n=645)
Population treated with first-line 
sunitinib (n=282)
Analysis (n=227)
Lost to follow-up (n=30)
•	 	Patients	continued	treatment	in	a	non-participating	hospital
Not eligible for the analysis (n=397)
•	 	Not	receiving	any	targeted	therapy	(n=309)
•	 	Not	treated	with	first-line	sunitinib	(n=54)
Not eligible for the analysis (n=55)
•	 	Unknown	whether	a	prior	nephrectomy	was	conducted	(n=1)
•	 	Bilateral	mRCC	(n=5)
•	 	Nephrectomy	was	conducted	after	start	of	first-line	sunitinib	(n=28)
•	 	Besides	a	nephrectomy,	a	metastasectomy	was	conducted	(n=21)
Excluded (n=39)
•	 	Not	meeting	inclusion	criteria	(n=26)
	 •	 	No	renal	cell	carcinoma	(n=12)
	 •	 	No	metastases	at	presentation	(n=6)
	 •	 	<	18	years	(n=7)
	 •	 	Other	(n=1)
•	 	Other	reasons	(n=13)
	 •	 	Diagnosed	and/or	treated	in	a	non-participating	hospital,	and	too	 
little information available on patient and disease characteristics  
(and treatment) (n=12)
	 •	 	Other	(n=1)
A further limitation results from our patient selection procedure. Specifically, 
since we selected patients treated with first-line sunitinib, we excluded pa-
tients who underwent a nephrectomy and were intended to receive sunitinib 
thereafter but ultimately did not receive it. Patients not receiving sunitinib 
could vary widely in prognosis from patients with deterioration of perfor-
mance due to surgery to patients with low-volume metastatic disease without 
postoperative progression. A combined analysis of 2 prospective randomised 
trials comparing CN plus IFN-α with IFN-α alone revealed that only a rather 
low percentage of patients ended up not receiving immunotherapy (5.6% 
and 1.8%, respectively).71 We therefore expect the exclusions of these patients 
from the analyses to have very little impact on the results, indicating that CN 
is associated with improved survival.
On the contrary, selecting patients treated with first-line sunitinib also 
provided advantages. As a result of this selection procedure, the study popula-
tion consisted of relatively homogeneous patients. Especially in the subgroup 
analysis, patients were relatively homogeneous, since all patients had a time 
to sunitinib < 1 year. Results of this analysis suggested that the benefit of CN is 
potentially less prominent than previously thought. This particular patient 
population is likely to represent the patients being included in the currently 
ongoing Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). 
In the CARMENA trial, patients presenting with mRCC are being randomised 
to either nephrectomy followed by sunitinib or sunitinib alone. The final 
data collection date for the primary outcome measure of the CARMENA trial 
is expected in September 2019, meaning that the results will not be reported 
until perhaps 2020.72 Furthermore, the role of presurgical targeted therapy is 
being evaluated in the SURTIME trial. However, this trial addresses a different 
research question compared to the research question we have addressed; that 
is, patients in the SURTIME trial are being randomised to immediate nephrec-
tomy followed by sunitinib or to 3 cycles of presurgical sunitinib followed by 
nephrectomy.73 
Conclusions
In accordance with other studies,57-60 our study showed that CN was associated 
with a low HR in primary mRCC patients, suggesting that CN may be effective. 
However, the benefit was modest when correcting for time from diagnosis 
to sunitinib. While we are waiting for the results of the ongoing RCTs to be 
known, the potential advantages of CN combined with the current evidence 
support the practice of performing CN prior to treatment with sunitinib in 
patients presenting with mRCC.
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Table S3.1 Patient characteristics (observed and imputed)
Abbreviations: CN, cytoreductive nephrectomy; LLN, lower limit of normal; ULN, upper limit of normal.
Sunitinib only 
(n=153)
Sunitinib only
(n=153)
Observed data
CN + sunitinib 
(n=74)
CN + sunitinib 
(n=74) p-value
Imputed data
48 (31%) 13 (18%) 48 (31%) 13 (18%) 
105 (69%) 61 (82%) 105 (69%) 61 (82%) 0.030
64 (24-89) 61 (28-77) 64 (24-89) 61 (28-77) 0.010
101 (66%) 58 (78%) 101 (66%) 58 (78%) 
52 (34%) 16 (22%) 52 (34%) 16 (22%) 0.059
85 (56%) 57 (77%) 103 (67%) 61 (82%) 
37 (24%) 13 (18%) 50 (33%) 13 (18%) 0.020
31 (20%) 4 (5%)   
56 (37%) 30 (41%) 71 (46%) 37 (50%) 
67 (44%) 30 (41%) 82 (54%) 37 (50%) 0.657
30 (20%) 14 (19%)   
68 (44%) 24 (32%) 126 (82%) 58 (79%) 
11 (7%) 4 (5%) 27 (18%) 16 (21%) 0.698
74 (48%) 46 (62%)   
39 (25%) 34 (46%) 39 (25%) 34 (46%) 
114 (75%) 40 (54%) 114 (75%) 40 (54%) 0.002
129 (84%) 68 (92%) 129 (84%) 68 (92%) 
24 (16%) 6 (8%) 24 (16%) 6 (8%) 0.120
36 (24%) 16 (22%) 36 (24%) 16 (22%) 
117 (76%) 58 (78%) 117 (76%) 58 (78%) 0.749
88 (58%) 59 (80%) 88 (58%) 59 (80%) 
65 (42%) 15 (20%) 65 (42%) 15 (20%) 0.001
52 (34%) 19 (26%) 53 (34%) 20 (27%) 
99 (65%) 52 (70%) 100 (66%) 54 (73%) 0.264
2 (1%) 3 (4%)   
66 (43%) 24 (32%) 96 (63%) 51 (68%) 
40 (26%) 11 (15%) 57 (37%) 23 (32%) 0.568
47 (31%) 39 (53%)   
106 (69%) 46 (62%) 109 (71%) 58 (79%) 
43 (28%) 13 (18%) 44 (29%) 16 (21%) 0.257
4 (3%) 15 (20%)   
78 (51%) 31 (42%) 100 (66%) 56 (75%) 
41 (27%) 10 (14%) 53 (34%) 18 (25%) 0.217
34 (22%) 33 (45%)   
72 (47%) 31 (42%) 94 (62%) 59 (79%) 
46 (30%) 6 (8%) 59 (38%) 15 (21%) 0.037
35 (23%) 37 (50%)   
101 (66%) 39 (53%) 108 (70%) 58 (78%) 
43 (28%) 11 (15%) 45 (30%) 16 (22%) 0.291
9 (6%) 24 (32%)   
83 (54%) 30 (41%) 91 (59%) 45 (61%) 
57 (37%) 19 (26%) 62 (41%) 29 (39%) 0.781
13 (8%) 25 (34%)   
0 (0%) 12 (16%) 0 (0%) 12 (16%) <0.001
153 (100%) 62 (84%) 153 (100%) 62 (84%) 
Gender - n (%)
 Female
 Male
Median age – yr (range)
Histology – n (%)
 Clear cell
 Other
cTNM – T – n (%)
 T1-T3a
 T3b-T4
 Missing
cTNM – N – n (%)
 N0
 N1
 Missing
WHO performance status – n (%)
 0-1
 2-4
 Missing
Site of metastasis – n (%)
 One
 More than one
Liver metastasis – n (%)
 No
 Yes
Lung metastasis – n (%)
 No
 Yes
Bone metastasis – n (%)
 No
 Yes
Haemoglobin – n (%)
 Normal
 < LLN
 Missing
Neutrophil count – n (%)
 Normal
 > ULN
 Missing
Platelet count – n (%)
 Normal
 > ULN
 Missing
Albumin – n (%)
 Normal
 < LLN
 Missing
Corrected serum calcium – n (%) 
 Normal
 > ULN
 Missing
Alkaline phosphatase – n (%)
 Normal
 > ULN
 Missing
Lactate dehydrogenase – n (%)
 Normal
 > 1.5 times ULN
 Missing
Time from diagnosis to start 
sunitinib – n (%)
 >= One year
 < One year
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Introduction
Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers.17 While the 
prognosis of patients with localised disease treated with surgery is relatively 
good, the prognosis of patients with advanced or metastatic disease (mRCC) 
is poor. Median overall survival (OS) ranges from 7.8 months for patients with 
a poor risk to 43.2 months for patients with a favourable risk according to the 
Heng criteria.22 Besides the impact of mRCC on survival, mRCC can be associ-
ated with severe symptoms, such as cachexia and/or anorexia, asthenia and/
or fatigue, pain, anaemia, and venous thromboembolism.74 These symptoms 
can impair the health-related quality of life (HRQoL). 
Since 2006, several new targeted therapies have been approved for the 
treatment of mRCC such as sunitinib, sorafenib, pazopanib and everolimus. 
In phase III studies, these therapies improved progression-free survival (PFS) 
of patients with mRCC over the diverse comparators,25-27,29,40,44,46,47 but the 
effect on OS was less pronounced, likely (partly) due to treatment crossover. 
It is assumed that one of the benefits of the new therapies is an improved 
HRQoL, or a delay in HRQoL deterioration as a result of a delay in progression 
of disease. However, little data are available supporting this relationship, 
although clinicians feel that a better PFS translates into a better HRQoL.75 In 
the context of the high prices of targeted therapies which form a strain on 
healthcare budgets, it is important to establish whether indeed a delay in 
progression delays HRQoL deterioration. Besides this clinical perspective, it 
is important to know if the potential benefit of improved HRQoL has signifi-
cance from an economic perspective. This economic perspective is generally 
captured through cost-utility analyses.
In cost-utility analyses benefits are expressed in terms of quality-adjusted 
life years (QALYs), which incorporate both changes in length of life and chang-
es in HRQoL. Utilities are used to adjust the life-years lived for the quality of 
life that is lived, and these can take on several values generally ranging from 
0 (death) to 1 (full health). They are interpreted as proxies for HRQoL. The 
EQ-5D is a generic questionnaire, which measures the health states patients 
are in. It considers various dimensions of quality of life (i.e. mobility, self-
care, usual activities, pain/discomfort and anxiety/depression).76 To derive 
utilities, a country specific algorithm (‘tariff’) is applied to the health states 
generated by the EQ-5D. This method to measure the health states patients 
are in, and value health (gains) is recommended by several reimbursement 
authorities across Europe.77,78 
Relatively little is known about HRQoL of patients with mRCC. This study 
is the first to provide insight into the most important determinants of HRQoL 
(including progression of disease) of patients with mRCC using data from a 
Abstract
Objective: Based on improvements of progression-free survival (PFS), new 
agents for metastatic renal cell carcinoma (mRCC) have been approved. It is 
assumed that one of the benefits is an improved health-related quality of life 
(HRQoL), or a delay in HRQoL deterioration as a result of a delay in progres-
sion of disease. However, little data are available supporting this relationship. 
This study aims to provide insight into the most important determinants of 
HRQoL (including progression of disease) of patients with mRCC. 
Methods: A patient registry (PERCEPTION) was created to evaluate treatment 
of patients with (m)RCC in the Netherlands. HRQoL was measured, using 
the EORTC QLQ-C30 and EQ-5D-5L, every three months in the first year of par-
ticipation in the study, and every six months in the second year. Random 
effects models were used to study associations between HRQoL and patient 
characteristics.
Results: Eighty-seven patients with mRCC completed 304 questionnaires. 
The average EORTC QLQ-C30 global health status was 68.88 (SD 18.92) before 
progression and 61.34 (SD 21.73) after progression of disease. Similarly, the 
average EQ-5D utility was 0.75 (SD 0.19) before progression and 0.66 (SD 0.30) 
after progression of disease. Presence of fatigue, nausea and vomiting, pain, 
dyspnoea, and the application of radiotherapy were associated with signifi-
cantly lower EQ-5D utilities.
Conclusions: Key drivers for reduced HRQoL in mRCC are disease symptoms. 
Since symptoms increase with progression of disease, targeted therapies that 
increase PFS can postpone reductions in HRQoL in mRCC.
62 63
Statistical analyses
For each scale of the QLQ-C30, the average of the items that contributed to that 
scale was calculated. They were then linearly transformed in line with the 
EORTC QLQ-C30 scoring manual.81 EQ-5D utilities were derived by combining 
the answers to the EQ-5D-5L with the Dutch EQ-5D-5L tariff.82 Mean EQ-5D util-
ities and HRQoL according to the EORTC QLQ-C30 were calculated by taking 
the average of the observations for each patient. The proportion of reported 
problems for each EQ-5D dimension were presented by taking the modus (i.e. 
the level reported most frequently) across observations for each patient. If 
two or more modes exist, the highest level was taken. 
HRQoL was evaluated separately for the periods before and after progres-
sion of disease. Moreover, within the period before progression of disease, 
a further distinction was made between the period in which patients did 
not receive any therapy (i.e. wait-and-see) and the period in which they were 
treated with (first-line) targeted therapy. The treatment period was assumed 
to last until progression of disease.
Since data on HRQoL were clustered, random effects models were used to 
study associations between HRQoL (i.e. EORTC QLQ-C30 global health status 
and EQ-5D utility) and patient and disease characteristics, symptoms and treat-
ment. Use of random effects models ensured that multiple measurements 
from the same patient were analysed appropriately and made it possible to 
distinguish between intraindividual and interindividual variation. Backward 
selection was used to select the covariates for the models; any non-significant 
covariates were excluded from the models one at a time (significance level of 
0.20 for entering and 0.10 for removing the explanatory variables). To control 
for heteroskedasticity, random effects models with robust standard errors 
were estimated. 
Additionally, random effects logit models were used to study associations 
between the individual EQ-5D dimensions and patient and disease charac-
teristics, symptoms and treatment. EQ-5D levels were dichotomised into ‘no 
problems/ (i.e. level 1) and ‘problems’ (i.e. levels 2 to 5). 
Missing data regarding patient and disease characteristics were handled 
using multiple imputations by chained equations. This method generated 
imputations based on a set of imputation models, one for each variable with 
missing values.39
The significance level was set at α  =  0.10. Data analyses were conducted 
using STATA statistical analysis software (StataCorp. 2015. Stata Statistical 
Software: Release 14. College Station, TX: StataCorp LP.).
patient registry in the Netherlands.79 Additionally, this study aims to assess 
if those measures used in economic evaluations to assess benefit (i.e. EQ-5D) 
can detect relevant changes in HRQoL of patients with mRCC. 
Patients and methods
Study population
A patient registry (i.e. PERCEPTION) was created to evaluate treatment of pa-
tients with (m)RCC in the Netherlands. Patients with RCC (all stages) of any 
histological subtype diagnosed from 2011 until June 30th 2013 in 25 of 32 hos-
pitals (both general and academic) in three regions in the Netherlands were 
invited to participate, and fill out HRQoL questionnaires. Eligible patients 
were identified through the hospitals’ registration systems. Additionally, the 
Netherlands Cancer Registry (NCR), which maintains a cancer registration 
database of all cancer patients in the Netherlands, was used to ensure that 
no patients were missed. 
The research protocol was approved by the medical ethics committee 
of Radboud university medical center in Nijmegen (CMO Region Arnhem-
Nijmegen) in May 2010.
Data collection
Cancer-specific HRQoL was measured using the EORTC (European Organisation 
for Research and Treatment of Cancer) QLQ-C30 questionnaire (v3.0).80 This 
measure includes five functional scales (physical, role, emotional, social and 
cognitive), three symptom scales (fatigue, nausea & vomiting and pain), a 
global health status/QOL scale and six single items (dyspnoea, insomnia, ap-
petite loss, constipation, diarrhoea and financial difficulties). In addition to 
the EORTC QLQ-C30, the EQ-5D-5L was used to measure HRQoL. The EQ-5D-5L 
is a preference-based generic measure, and measures HRQoL on five dimen-
sions, i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/
depression.76 Each dimension includes five severity levels. Patients were sent 
a HRQoL questionnaire every three months in the first year of participation 
in the study, and every six months in the second year. 
In addition to data on HRQoL, data on demographics, clinical and labo-
ratory factors were collected retrospectively from individual patient records 
by using uniform case report forms. Clinical and laboratory factors were col-
lected before the start of each new treatment (i.e. surgery, radiotherapy or 
targeted therapy). Furthermore, data on treatment schemes and treatment 
endpoints (e.g. survival) were derived from patient records. Data collection 
stopped at the end of 2013.
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the period before progression of disease, no significant difference was found 
between a period without therapy (i.e. wait-and-see) and a period with thera-
py; mean utilities were 0.76 (SD 0.21) and 0.76 (SD 0.18), respectively.
Figures 4.1 and 4.2 show the proportions of patients reporting levels 1 to 
5 by EQ-5D dimension, before progression of disease and after progression of 
disease. Both before and after progression of disease, most problems were 
reported on the mobility, usual activities and pain/discomfort dimensions.
Univariable analyses show several relationships between disease charac-
teristics, symptoms and treatment, and HRQoL (Table 4.3). Patients with brain 
metastases and patients with progression of disease reported a significantly 
lower HRQoL (according to the EORTC QLQ-C30 global health status and EQ-
5D). Patients with more than one metastatic site or bone metastases reported 
a significantly lower EQ-5D utility than other patients, a relationship that 
was not seen in the QLQ-C30 global health status. Additionally, symptoms 
(i.e. fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, 
constipation and diarrhoea) were associated with a lower HRQoL (according 
to the EORTC QLQ-C30 global health status and EQ-5D). Lastly, patients treated 
with radiotherapy reported a significantly worse HRQoL (according to the 
EORTC QLQ-C30 global health status and EQ-5D).
Multivariable analysis showed that fatigue, pain and appetite loss were 
significantly associated with the EORTC QLQ-C30 global health status. Besides 
these symptoms, the presence of more than one metastatic site, brain metas-
tases and progression of disease were significantly associated with the EORTC 
Table 4.1 Baseline characteristics at diagnosis
Variable Patients (n=87)
Male sex - n (%)
Age, median [range]
Non-clear cell pathology - n (%)
WHO performance status - n (%)
 0-1
 2-4
More than one metastatic site - n (%)
Liver metastasis - n (%)
Lung metastasis - n (%)
Bone metastasis - n (%)
Brain metastasis - n (%)
Haemoglobin < LLN - n (%)
Neutrophil count > ULN - n (%)
Platelet count > ULN - n (%)
Corrected serum calcium > ULN - n (%)
Lactate dehydrogenase > 1.5 times ULN - n (%)
Time since RCC diagnosis < one year
MSKCC risk score – n (%)
 favourable
 intermediate
 poor
71 (82%)
63 [40-79]
17 (20%)
82 (94%)
5 (6%)
48 (55%)
15 (17%)
48 (56%)
21 (24%)
3 (3%)
46 (52%)
18 (21%)
19 (22%)
26 (30%)
11 (12%)
78 (90%)
6 (7%)
54 (62%)
27 (31%)
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal.
Results
Four hundred-eleven patients participating in the study completed 1630 ques-
tionnaires. The average EORTC QLQ-C30 global health status of patients with 
localised disease (365 patients, 1,326 questionnaires) was 76.34 (SD 14.73), and 
the average EQ-5D utility was 0.82 (SD 0.17). 
Eighty-seven patients had mRCC (i.e. metastatic disease at initial presenta-
tion or after an initial diagnosis with localised disease). Of these patients, 
eighty-two percent was male, and the median age at diagnosis was 63 years 
(Table 4.1). Twenty-six percent of the population did not receive any systemic 
therapy during follow-up. Of the patients receiving systemic therapy, the ma-
jority (80%) was treated with first-line sunitinib. Twenty-three patients also 
received a second-line therapy within the follow-up period; the majority of 
these patients was treated with everolimus (13/23). Thirty-one percent of the 
population received radiotherapy during follow-up.
In total, 304 questionnaires were completed by patients with mRCC and 
the median number of questionnaires per patient was three (range; 1-7). Table 
4.2 shows HRQoL during the different stages of the disease. The EORTC QLQ-C30 
global health status was 67.24 (SD 19.19). Patients experienced most problems 
with role functioning (i.e. doing daily activities and pursuing leisure time 
activities). Symptoms most commonly reported were fatigue, pain, insomnia 
and dyspnoea. A significant difference was found in the EORTC QLQ-C30 global 
health status before and after progression of disease, i.e. 68.88 (SD 18.92) and 
61.34 (SD 21.73) (p  =  0.022). All functioning scales significantly decreased, except 
for emotional and cognitive functioning. Two symptom scales significantly 
increased; patients reported more problems regarding dyspnoea (p  =  0.031) 
and diarrhoea (p  =  0.057) after progression than before progression of disease.
Within the period before progression of disease, a similar HRQoL was 
found for a period without therapy (i.e. wait-and-see) and a period with ther-
apy; mean EORTC QLQ-C30 global health statuses were 69.28 (SD 22.29) and 
69.52 (SD 16.63), respectively. However, within the period before progression 
of disease, patients experienced fewer problems with emotional function-
ing during a period with therapy compared to a period without therapy 
(p  =  0.067). Additionally, patients reported fewer problems regarding con-
stipation (p  =  0.072), but more problems regarding diarrhoea during a period 
with therapy compared to a period without therapy (p  =  0.005). 
The average EQ-5D utility was 0.74 (SD 0.19). As with the EORTC QLQ-C30 
global health status, a significant difference was found in EQ-5D utility before 
progression of disease and after progression of disease; the average EQ-5D 
utility before progression of disease was 0.75 (SD 0.19), whereas the average 
EQ-5D utility after progression of disease was 0.66 (SD 0.30) (p  =  0.032). Within 
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Table 4.4 shows that fatigue was significantly associated with all EQ-5D di-
mensions, except with the mobility dimension. Pain was also significantly 
associated with all EQ-5D dimensions, except with the anxiety/depression 
dimension.
Discussion
This study on health-related quality of life (HRQoL) of patients with meta-
static renal cell carcinoma (mRCC) showed that the average EORTC QLQ-C30 
global health status was 67.24 (SD 19.19). A significant difference was found 
between the global health status before and after progression of disease, i.e. 
68.88 (SD 18.92) and 61.34 (SD 21.73), respectively. Based on these findings, tar-
geted therapies that increase progression-free survival (PFS) of patients with 
mRCC, can postpone reductions in HRQoL. The difference between HRQoL 
before and after progression of disease was also detected by the EQ-5D. The 
Figure 4.1 Proportion of patients reporting levels 1 to 5 by dimension, before progression of disease
Figure 4.2 Proportion of patients reporting levels 1 to 5 by dimension, after progression of disease
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QLQ-C30 global health status. An association was also found between fatigue 
and pain, and the EQ-5D utility. Furthermore, nausea and vomiting, dyspnoea 
and treatment with radiotherapy appeared to be significantly associated with 
HRQoL according to EQ-5D.
Although the univariable analyses showed several relationships between 
disease characteristics (e.g. the presence of bone or brain metastases and 
progression of disease) and HRQoL, these characteristics were no longer as-
sociated with a deterioration of HRQoL in multivariable analyses after cor-
rection for symptoms (at a significance level of 0.05 and 0.01, except for the 
presence of brain metastases in the model with the EORTC QLQ-C30 global 
health status as the dependent variable). This seems to imply that symptoms 
might increase due to progression of disease (and/or due to the spread of the 
cancer to the bone or brain), which explains the reduced HRQoL.
Table 4.2 Health-related quality of life based on the EQ-5D and QLQ-C30
Total
n=87 patients  
(304 obs.)
Before progression 
n=81 patients  
(246 obs.)
After progression
n=27 patients  
(58 obs.)
Mean (SD)
Total
Mean (SD)
No systemic 
therapy  
n=47  
(125 obs.*)
Mean (SD)
First-line therapy
n=50  
(119 obs.)
Mean (SD)
Total
Mean (SD)
EQ-5D 
 Utility
EORTC QLQ-C30 
 Global health status
Functioning scales
 Physical functioning
 Role functioning
 Emotional functioning
 Cognitive functioning
 Social functioning
Symptom scales
 Fatigue
 Nausea & vomiting
 Pain
Single items
 Dyspnoea
 Sleeping
 Appetite loss
 Constipation
 Diarrhoea
 Financial difficulties
0.74 (0.19) 0.75 (0.19) 0.76 (0.21) 0.76 (0.18) 0.66 (0.30)
67.24 (19.19) 68.88 (18.92) 69.28 (22.29) 69.52 (16.63) 61.34 (21.73)
69.31 (23.20) 70.89 (22.62) 72.74 (22.48) 69.36 (23.43) 62.08 (29.18)
58.83 (28.21) 61.04 (29.21) 60.84 (29.71) 61.85 (28.66) 52.37 (32.75)
79.03 (16.29) 80.31 (17.50) 77.40 (19.05) 81.67 (18.88) 73.35 (18.95)
79.70 (20.12) 80.12 (21.81) 81.27 (21.44) 79.32 (24.67) 76.34 (21.83)
75.57 (22.23) 77.50 (21.96) 77.42 (20.36) 78.12 (22.03) 67.44 (27.95)
40.78 (25.26) 39.14 (26.51) 36.44 (26.70) 40.76 (26.74) 47.94 (29.93)
12.11 (17.35) 12.70 (20.46) 7.58 (13.48) 16.69 (23.84) 10.34 (11.51)
28.64 (23.71) 27.30 (23.86) 23.92 (24.60) 28.77 (26.09) 34.47 (30.16)
24.31 (24.27) 23.15 (23.88) 23.26 (24.91) 25.74 (28.35) 29.32 (33.56)
27.59 (26.04) 26.37 (27.46) 24.32 (27.43) 26.51 (29.61) 35.08 (31.17)
19.18 (25.50) 17.70 (25.07) 15.04 (25.90) 21.00 (25.99) 22.12 (32.44)
9.56 (16.71) 8.96 (17.43) 12.35 (23.82) 4.50 (10.14) 12.14 (21.45)
19.70 (25.95) 18.88 (27.45) 12.75 (26.67) 23.15 (27.91) 22.43 (26.25)
9.79 (18.00) 9.41 (18.14) 9.30 (20.64) 10.80 (19.00) 7.82 (21.09)
Abbreviations: Obs, observations; SD, standard deviation.
* Observations of patients who died within 90 days after being diagnosed with mRCC were excluded from this subgroup (n=2), since 
these measurements would not contribute to the estimation of the HRQoL of a patient awaiting therapy.
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toms was expected, which could explain why disease characteristics (such 
as progression) were no longer statistically significant in the multivariable 
analyses. Indeed, this study showed that symptoms increase as the disease 
progresses, and in addition, symptoms appeared to be significantly associated 
to reduced HRQoL. Similarly, bone metastases were no longer associated with 
a deterioration of HRQoL in multivariable analyses. However, pain appeared 
to be significantly associated to reduced HRQoL. Since bone pain is a symp-
tom of cancer that has spread to the bone, this might explain the reduced 
HRQoL. This seems to imply that symptoms increase due to progression of 
disease (and/or due to the spread of the cancer to the bone), which explains 
the reduced HRQoL.
Besides the relationship between symptoms and HRQoL, a significant 
association was found between radiotherapy and HRQoL (in the model with 
the EQ-5D utility as the dependent variable). It is possible that this observed 
association is not due to radiotherapy itself, but instead due to the selection 
of which mRCC patients are to receive radiotherapy. That is, radiotherapy is 
mostly reserved for palliation of local and symptomatic disease or to prevent 
the progression of metastatic disease in critical sites (i.e. bones and brain).55 
Either way, radiotherapy appears to be a significant determinant of HRQoL, 
Table 4.4 Associations between the EQ-5D dimensions and patient and disease characteristics, symptoms and treatment
Mobility Self-care Usual activities
Pain/ 
Discomfort
Anxiety/
Depression
OR SE OR SE OR SE OR SE OR SE
Patient characteristics
 Male sex
 Age (per year)
Disease characteristics
 Presence of liver metastases
 Presence of lung metastases
 Presence of bone metastases 
 MSKCC risk score
  favourable
  intermediate
  poor
 Disease duration
Symptoms
 Fatigue   
 Nausea & vomiting
 Pain
 Dyspnoea
 Sleeping
 Appetite loss
Treatment
 Radiotherapy
0.149** 0.112 NS  0.095** 0.110 NS  NS
1.078** 0.032 NS  NS  NS  NS
4.427* 3.395 NS  NS  NS  NS
NS  NS  NS  NS  0.300* 0.191
4.733** 2.961 NS  15.054*** 14.768 NS  NS
NS  NS  NS  0.041*** 0.049 NS
NS  NS  NS  0.143 0.176 NS
NS  1.073** 0.033 NS  NS  NS
NS  1.044*** 0.012 1.128*** 0.028 1.034*** 0.012 1.021** 0.010
0.967** 0.015 NS  NS  NS  NS
1.029*** 0.009 1.030*** 0.010 1.029* 0.015 1.143*** 0.023 NS
1.025*** 0.009 NS  1.024* 0.014 NS  NS
NS  NS  NS  NS  1.016* 0.009
1.031*** 0.011 NS  NS  NS  NS
NS  6.062*** 3.971 NS  NS  NS
Note: Odds ratios based on models created using multivariable logistic regression.
Abbreviations: OR, odds ratio; SE, standard error. 
* Significant at α = 0.1 ** Significant at α = 0.05 *** Significant at α = 0.01.
average EQ-5D utility of patients with mRCC is 0.74 compared to an average of 
0.84 (SD 0.18) in the Dutch population aged 60 to 69.82 Whereas the average 
EQ-5D utility was 0.75 before progression of disease, the average EQ-5D utility 
was 0.66 after progression of disease.
The differences between HRQoL before and after progression of disease 
were found in univariable analyses. Progression of disease was no longer as-
sociated with a deterioration of HRQoL in multivariable analyses after cor-
rection for symptoms (at a significance level of 0.05 and 0.01). In line with 
Wilson and Cleary,83 a relationship between disease characteristics and symp-
Table 4.3 Associations between HRQoL and patient and disease characteristics, symptoms and treatment
EQ-5D utility EORTC QLQ-C30 global health status
Univariable  
analysis
Multivariable 
analysis
Univariable  
analysis
Multivariable 
analysis
Coefficient SE Coefficient SE Coefficient SE Coefficient SE
Patient characteristics
 Male sex
 Age (per year)
 WHO performance score
  0-1
  2-4
Disease characteristics
 More than one metastatic site
 Presence of liver metastases 
 Presence of lung metastases 
 Presence of bone metastases 
 Presence of brain metastases 
 MSKCC risk score
  favourable
  intermediate
  poor
 Progression of disease
 Disease duration (in months)
Symptoms
 Fatigue
 Nausea & vomiting
 Pain
 Dyspnoea
 Sleeping
 Appetite loss
 Constipation
 Diarrhoea
Treatment
  Systemic therapy vs.  
no systemic therapy
 Radiotherapy
Model intercept
R2 (overall)
Wald test (p-value)
  0.077 0.069  NS   2.748  5.198  NS
 - 0.001 0.002  NS  - 0.257  0.223  NS
 - 0.080 0.072  NS  - 5.919 7.304  NS
 - 0.068* 0.035  NS  - 5.048  3.342  4.048*  2.276
 - 0.027 0.050  NS  - 3.992  4.779  NS
 - 0.021 0.041  NS   0.465  4.074  NS
 - 0.085** 0.040  NS  - 3.390  3.915  NS
 - 0.285* 0.170  NS  - 21.143*  10.239 - 13.586***  2.438
  0.015 0.062  NS  - 0.431  8.924  NS
  0.054 0.063  NS   2.485  9.220  NS
 - 0.082** 0.036  NS  - 6.897*  3.000 - 3.859*  2.249
 - 0.002 0.001  NS  - 0.081  0.117  NS
 - 0.004*** 0.001 - 0.003***  0.001 - 0.451*** 0.035 - 0.316***  0.042
 - 0.001* 0.001   0.001**  0.001 - 0.360*** 0.050  NS
 - 0.004*** 0.000 - 0.002***  0.000 - 0.324*** 0.036 - 0.143***  0.035
 - 0.003*** 0.000 - 0.001***  0.000 - 0.222*** 0.040  NS
 - 0.002*** 0.000  NS  - 0.219*** 0.035  NS
 - 0.002*** 0.000  NS  - 0.274*** 0.034 - 0.111***  0.035
 - 0.002*** 0.001  NS  - 0.186*** 0.054  NS
 - 0.001* 0.000  NS  - 0.089** 0.040  NS
  0.026 0.027  NS  - 0.487  2.408  NS
 - 0.150*** 0.042 - 0.115***  0.036 - 10.017***  3.306  NS 
       
    0.943***  0.016    85.380***  1.903
     0.559     0.534
     <0.001     <0.001
Note: Several comorbidities at diagnosis were considered for inclusion in the multivariable analyses, but all appeared to be not 
significantly associated with HRQoL.
Abbreviations: SE, standard error; NS, not significant.
* Significant at α = 0.1 ** Significant at α = 0.05 *** Significant at α = 0.01.
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events have a high impact on HRQoL, an association between adverse events 
and HRQoL would not be found if the proportion of patients with grade 3 
or 4 adverse events is relatively low. Hypertension and fatigue are the most 
commonly reported grade 3 or 4 adverse events in the randomised phase 3 
trial of sunitinib,25 but these adverse events occurred in only 8% and 7% of the 
population. Therefore, a very large sample size is needed to find any difference 
in EQ-5D utilities between different types of targeted therapies. Additionally, 
it is unknown whether the improved HRQoL due to prolonged PFS outweighs 
reductions in HRQoL due to treatment-related adverse events. Importantly, 
this study did not find differences in HRQoL of patients treated with systemic 
therapy and patients not treated with systemic therapy, or between periods 
with or without systemic therapy. However, this study may have been under-
powered to find such differences. 
To conclude, key drivers for reduced HRQoL in mRCC are symptoms of the 
disease. Since this study showed that symptoms increase with progression of 
disease, targeted therapies that increase PFS can help to delay loss in HRQoL. 
This study also showed that the EQ-5D is able to detect changes in HRQoL of 
patients with mRCC, as it found associations between well-known symptoms 
of mRCC and EQ-5D utilities. Similar associations were found between these 
symptoms and the disease-specific EORTC QLQ-C30.
even after correction for patient and disease characteristics (including bone 
and brain metastases) and symptoms.
74% of the study population was treated with a targeted therapy (the ma-
jority received sunitinib). The average EQ-5D utility of these patients was 0.76 
before progression of disease. In a study by Cella et al, a similar EQ-5D utility 
was reported for patients treated with sunitinib (i.e. 0.75).84 In the economic 
evaluation of bevacizumab and sunitinib by Thompson-Coon et al,85 a health 
state utility of 0.78 (95% CI 0.76-0.80) was used for progression-free survival 
and 0.70 (95% CI 0.66-0.74) for progressive disease. These utilities were de-
rived from the data presented in the sunitinib submission to NICE and are 
somewhat higher than the utilities that we found in our study. The economic 
evaluation of sunitinib by Remák et al86 was based on the results of a phase 
II trial of sunitinib as second-line treatment in mRCC;87 utilities of 0.72 and 
0.76 were used for progression-free survival (i.e. during treatment or rest, 
respectively), whereas utilities of 0.63 and 0.55 were used for progressive dis-
ease (i.e. during second-line treatment or after termination of second-line 
treatment, respectively). The latter utilities are below the utilities found in 
our study, but this might be explained by differences in the study population, 
e.g. patients with progression on first-line cytokine therapy were enrolled in 
the phase II trial.
This study has several limitations. First, a significance level of 0.10 instead 
of 0.05 was used to study associations between patient characteristics and 
HRQoL in order to avoid missing any relevant association. Although we might 
have reported associations that achieved statistical significance due to chance 
alone, we did not find associations between patient characteristics and HRQoL 
that we could not interpret. Second, a significant association between WHO 
performance status and HRQoL, and the MSKCC risk score and HRQoL was not 
found, although such a relationship would have been expected. The MSKCC 
risk score divides patients into three risk groups, and gives an indication of 
the life expectancy of patients with mRCC.23 Whereas HRQoL was measured 
several times during the follow-up period, data on patient characteristics (e.g. 
WHO performance status) and disease characteristics (e.g. laboratory factors, 
which are part of the MSKCC risk score) were collected only once before the 
start of a new treatment. As a consequence, too few observations on patient 
and disease characteristics might have been available to detect a significant 
association between WHO performance status and the MSKCC risk score, and 
HRQoL. 
A third limitation is that our study sample was too small to find any dif-
ference in EQ-5D utilities between different types of targeted therapies, while 
these therapies differ in toxicity profiles.88 Nevertheless, although adverse 
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Introduction
Attention for the cost-effectiveness of cancer treatments is swiftly increasing, 
particularly prompted by the advent of so-called molecularly targeted agents. 
This class of agents has clearly improved outcomes in several tumour types, 
but also substantially increased costs.89 One of the tumour types for which 
targeted treatments are available is metastatic renal cell carcinoma (mRCC). 
In 2008, there were an estimated 88,400 new cases of kidney cancer in 
Europe.90 The European mean age-standardised 5-year survival was 60.6%, 
but substantial differences were seen within European regions.91 Besides reg-
istration artefacts, differences in cancer biology, the use of diagnostic tests 
and screening, and access to high-quality care might explain the differences 
in cancer survival.91 
While previous studies demonstrated a survival benefit from targeted ther-
apies in metastatic renal cell carcinoma,28,29,34,42,43 a Dutch population-based 
registry showed that many treatment-eligible patients do not receive sunitin-
ib (or any other targeted therapy) in daily practice.92 This was also seen in 
England where one in three patients with mRCC eligible for either sunitinib 
or pazopanib did not receive the drug.50 Patient and disease characteristics 
might play a role in the decision to not prescribe targeted therapy. Another 
possible reason is that it is not cost-effective to treat these patients.
There is little known about the effect that the potential underuse of tar-
geted therapy in daily clinical practice has on health outcomes and costs. The 
aim of this study was to estimate the real-world cost-effectiveness of several 
treatment strategies applied in patients with mRCC comprising one or more 
sequentially administered drugs. 
Patients and methods
Study population and data
From the Dutch Cancer Registry, all patients newly diagnosed with mRCC, i.e. 
metastatic disease at first presentation, from January 2008 until December 
2010 in 42 hospitals (both general and academic) in four regions, covering 
approximately half of the Netherlands, were included in the PERCEPTION 
registry. In this registry, data on patient characteristics, treatment schemes, 
treatment endpoints and resource use were retrospectively collected from pa-
tient records. Data had been anonymised and de-identified prior to analyses, 
thus no written informed consent was required. The research protocol was 
approved by the medical ethics committee of Radboud university medical 
center in Nijmegen (CMO Region Arnhem-Nijmegen) in May 2010. 
Abstract
Objective: Randomised controlled trials have shown that targeted therapies 
like sunitinib are effective in metastatic renal cell carcinoma (mRCC). Little is 
known about the current use of these therapies, and their associated costs and 
effects in daily clinical practice. We estimated the real-world cost-effective-
ness of different treatment strategies comprising one or more sequentially 
administered drugs.
Methods: Analyses were performed using patient-level data from a Dutch 
population-based registry including patients diagnosed with primary mRCC 
from January 2008 to December 2010 (i.e. treated between 2008 and 2013). The 
full disease course of these patients was estimated using a patient-level sim-
ulation model based on regression analyses of the registry data. A healthcare 
sector perspective was adopted; total costs included healthcare costs related 
to mRCC. Cost-effectiveness was expressed in cost per life-year and cost per 
quality-adjusted life year (QALY) gained. Probabilistic sensitivity analysis was 
conducted to estimate the overall uncertainty surrounding cost-effectiveness.
Results: In current daily practice, 54% (336/621) of all patients was treated with 
targeted therapies. Most patients (84%; 282/336) received sunitinib as first-line 
therapy. Of the patients receiving first-line therapy, 30% (101/336) also received 
second-line therapy; the majority was treated with everolimus (40%, 40/101) 
or sorafenib (28%, 28/101). Current treatment practice (including patients not 
receiving targeted therapy) led to 0.807 QALYs; mean costs were € 58,912. This 
resulted in an additional € 105,011 per QALY gained compared to not using 
targeted therapy at all. Forty-six percent of all patients received no targeted 
therapy; of these patients, 24% (69/285) was eligible for sunitinib. If these pa-
tients were treated with first-line sunitinib, mean QALYs would improve by 
0.062-0.076 (where the range reflects the choice of second-line therapy). This 
improvement is completely driven by the health gain seen amongst patients 
eligible to receive sunitinib but did not receive it, who gain 0.558-0.684 QALYs 
from sunitinib. Since additional costs would be € 7,072-9,913, incremental 
costs per QALY gained are € 93,107-111,972 compared to current practice. 
Conclusions: Health can be gained if more treatment-eligible patients receive 
targeted therapies. Moreover, it will be just as cost-effective to treat these 
patients with sunitinib as current treatment practice.
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a similar WHO performance status. For example, the probability of having 
more than one metastatic site was 64% for patients with a WHO performance 
status of 0-1, but 73% for patients with a WHO performance status of 2-4. In 
addition, the previous measurement (e.g. number of metastatic sites before 
first-line treatment) was taken into account when simulating patient and 
disease characteristics before second-line treatment.
The TTE1 for each simulated patient was determined by drawing random 
numbers from two parametric survival models; that is, one model was used to 
calculate TTE1 until 12 months while a second model was used to calculate TTE1 
after 12 months. Two models were used since the probability of an event (i.e. 
second-line treatment or death) from 12 months onwards was underestimat-
ed when only one single model was used. The type of event (i.e. second-line 
treatment or death) was determined using a separate model. The TTE2 was 
calculated in a similar manner. 
If a patient’s modelled time to an event was longer than the remaining 
life expectancy based on national vital statistics data,93 we used national vital 
statistics data to estimate TTE1 and TTE2 because it is not plausible for someone 
with mRCC to have a longer than average life expectancy. 
Treatment scenarios
In the base-case scenario, patients were treated as they were in the real world 
(Figure 5.1). A multinomial logistic regression model based on patient-level 
data from the PERCEPTION registry was used to predict the type of treatment in 
both first- and second-line, using values for WHO performance status, haemo-
globin, corrected serum calcium and lactate dehydrogenase (i.e. 4/5 Memorial 
Sloan Kettering Cancer Center [MSKCC] criteria).23 
Alternative scenarios included no targeted therapy for all patients, or 
treating all patients just as they were in reality, except for one difference, 
namely that first-line sunitinib followed by sorafenib, everolimus or another 
second-line treatment was given to patients who did not receive any target-
ed treatment even though they fulfilled the SUTENT trial eligibility criteria 
(Figure 5.1). A patient was classified as fulfilling SUTENT trial eligibility criteria 
if he had a clear-cell subtype, a WHO performance status of 0 or 1 and no brain 
metastases.25 
The potential health outcomes and costs of all treatment scenarios were 
calculated by running the model for 621 simulated patients.
Health outcomes
Health outcomes were estimated in terms of life-years (LYs) and quality-ad-
justed life years (QALYs). QALYs were calculated by weighting LYs for the qual-
Model structure and design
A patient-level simulation (PLS) model was developed to model the full disease 
course of patients newly diagnosed with mRCC. The model comprised entities 
(i.e. patients), attributes assigned to the entities, and events. Attributes were 
obtained from patient-level data from the PERCEPTION registry by selecting 
clinical factors, biochemical and hematologic factors known to impact mRCC 
outcomes.37,38 Events were either second-line treatment or death. The time 
horizon of the model spanned the patients’ lifetime. The total structure of 
the model is presented in Figure S5.1. 
Parameter estimation and time-to-event
For each patient in the PERCEPTION registry, time from diagnosis of mRCC 
until the first event (TTE1) (i.e. second-line treatment or death) was calculated. 
Similarly, the time from start of second-line treatment until the second event 
(TTE2) (i.e. death) was calculated. 
We then compared a range of parametric models to extrapolate the surviv-
al data. The fit of different models was assessed systematically by performing 
Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) 
tests. Additionally, visual inspection was performed by comparing the para-
metric survival models with the Kaplan-Meier curves. 
Clinical factors, biochemical and hematological factors, and the type of 
targeted treatment were considered for inclusion in the models; TTE1 was 
also considered as a covariate to estimate TTE2. Backward selection was used 
to select the attributes for the model; any non-significant attributes (α  =  0.10) 
were excluded from the model one at a time. Forward selection was used to 
create an alternative model. When two different models were created, AIC 
and BIC tests were performed, and visual inspection was used to decide on 
the final model. 
Missing data were handled using multiple imputations by chained equa-
tions.39 All statistical analyses were conducted using STATA statistical analysis 
software (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, 
TX: StataCorp LP).
Model calculation
Populations of 621 patients (i.e. the same sample size as the original study 
population) were repeatedly simulated, one population at a time. Each sim-
ulation started with assigning patient and disease characteristics to each pa-
tient, based on patient profiles observed in the PERCEPTION registry. That is, 
random numbers were drawn from predefined distributions for all patient 
and disease characteristics; similar distributions were used for patients with 
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Probabilistic sensitivity analysis (PSA) was conducted to examine the impact 
of the joint uncertainty regarding all input parameters on the results.
Results
Study population and treatment
714 patients in the Dutch Cancer Registry fulfilled the inclusion criteria. 39 
patients were excluded (Figure S5.2), and an additional 30 patients were lost 
to follow-up. Complete follow-up up to three years after diagnosis was availa-
ble for 645 patients. Twenty-four of these patients received a metastasectomy 
(combined with a nephrectomy) with a possible curative intention, making 
targeted treatment redundant. These patients were therefore excluded from 
the analyses. 
Patient characteristics are shown in Table 5.1, along with the characteris-
tics after multiple imputation. The distribution of patients according to the 
MSKCC risk score showed a high proportion of patients (55%) with a poor prog-
nosis. 42% of the patients had an intermediate prognosis. Since all patients 
presented with metastatic disease, very few patients (3%) had a favourable 
prognosis (e.g. 86% of the patients had a time from diagnosis to treatment, 
which is one of the MSKCC criteria, of less than one year).
Fifty-four percent (336/621) of all patients was treated with targeted ther-
apies. Of these patients, 84% (282/336) received sunitinib as first-line therapy. 
Other first-line treatments given were temsirolimus (7%, 24/336) and sorafenib 
(3%, 11/336). 101 patients also received a second-line therapy; the majority was 
treated with everolimus (40%, 40/101) or sorafenib (28%, 28/101). Median over-
all survival (OS) of patients treated with targeted therapies was 12.6 months 
(95% CI 10.5-14.8).
Almost half (46%, 285/621) of all patients did not receive any targeted thera-
py. Of these 285 patients, 69 patients (24%) fulfilled the SUTENT trial eligibility 
criteria. Most patients (76%) did not fulfill the SUTENT trial eligibility criteria; 
168 patients (78%) did not have a clear-cell subtype, 46 patients (21%) did not 
have a WHO performance status of 0 or 1 and 2 patients (1%) had brain me-
tastases. Median OS of patients not treated with targeted therapies was 2.6 
months (95% CI 2.1-3.5); 10.6 months (95% CI 3.8-18.6) for patients fulfilling the 
SUTENT trial eligibility criteria and 1.9 months (95% CI 1.6-2.6) for patients not 
fulfilling the SUTENT trial eligibility criteria.
Table 5.2 shows the final models with their covariates (e.g. patient and 
disease characteristics) and corresponding coefficients to estimate TTE1, the 
type of event after TTE1 and TTE2. For example, a WHO performance status of 
2-4 means a shorter TTE1.
ity of life during these years using utility weights derived from the published 
literature (Table S5.1).94-96 
Resource use and costs
This cost-effectiveness analysis (CEA) was conducted from a healthcare sector 
perspective, but only included healthcare costs related to mRCC, i.e. drug 
costs as well as resource utilisation costs, such as hospitalisations, outpatient 
visits and medical imaging services. Hospitalisations due to adverse events 
were included while other types of costs due to adverse events, such as con-
comitant medications, were not. The calculation of drug costs and resource 
utilisation costs is described in the supplementary information.
Costs were reported in Euro 2014. Wherever necessary, costs were adjusted 
to 2014 using the general price index derived from Statistics Netherlands.97 
Costs and effects were discounted at 4% and 1.5%, respectively.98 
Model validation
The model was internally validated by comparing patient characteristics and 
OS observed in the PERCEPTION registry to patient characteristics and health 
outcomes according to the model.99 Health outcomes from the model were 
presented as the mean of 1,000 iterations with a 95% confidence interval (CI) 
using the standard deviation of 1,000 iterations as standard error of the mean. 
The model’s internal validity was assessed by evaluating whether OS observed 
in the PERCEPTION registry fell within the 95% CI of the OS according to the 
base-case scenario of the model.
Sensitivity analysis
Univariate sensitivity analyses were performed to examine the impact of alter-
native input parameters on the incremental cost-effectiveness ratios (ICERs). 
Figure 5.1 First-line therapies in the various treatment scenarios
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Internal validation
Observed data from the PERCEPTION registry showed a median OS of 7.3 
months (0.6 LYs) (95% CI 6.3-8.4) for the total population (in which 54% of 
the patients received a targeted therapy). Median OS in the model was 7.0 
months (0.6 LYs) (95% CI 5.7-8.3) if patients were treated as they were in the real 
world (i.e. base-case scenario). The OS derived from the PERCEPTION registry 
fell within the 95% CI of the outcome of the model. Additionally, the observed 
Kaplan Meier curves (TTE1, TTE2 and OS) were closely followed by the survival 
curves derived from the model (Figures S5.3-S5.5). 
Effectiveness
The model yielded an estimated mean survival of 1.2 LYs (14.4 months) if pa-
tients were treated as they were in the real world (in which 54% of the pa-
tients received a targeted therapy). If all treatment-eligible patients would be 
treated with first-line sunitinib followed by sorafenib, everolimus or another 
second-line treatment (if they did not die after first-line treatment), mean 
survival would increase to 1.3 LYs (15.6 months). If none of the patients were 
to be treated with any targeted therapy, mean survival would decrease to 0.9 
LYs (10.8 months) (Table 5.3).
If patients were treated as they were in the real world, mean QALYs are 
0.807. If all treatment-eligible patients would be treated with first-line su-
nitinib followed by sorafenib, everolimus or another second-line treatment, 
mean QALYs would increase to 0.883, 0.868 or 0.841 respectively. If none of 
the patients were to be treated with any targeted therapy, mean QALYs would 
decrease to 0.576 (Table 5.3).
Costs
Mean total costs per treatment strategy are presented in Table 5.3. Mean total 
costs per patient amount to € 58,912 if patients were treated as they were in the 
real world. If all treatment-eligible patients were to be treated with first-line 
sunitinib followed by sorafenib, everolimus or another second-line treatment, 
mean total costs would increase to € 65,984, € 65,825 or € 65,062 respectively. If 
none of the patients would be treated with any targeted therapy, mean total 
costs would decrease to € 34,733.
Cost-effectiveness
Compared to a scenario in which none of the patients receives a targeted 
therapy, the real-world treatment mix results in a QALY gain of 0.230 and a 
cost increase of € 24,179. Thus, an additional € 105,011 per QALY gained is spent 
compared to the scenario of not using targeted therapy.
Table 5.1 Patient and disease characteristics before start of first- and second-line treatment
First-line Second-line
Real-world data 
(n=621)
Average of imputed 
datasets (n=621)
Real-world data 
(n=101)
Average of imputed 
datasets (n=101)
Sex – n (%)
 Female
 Male
Median age – yr (range)
Histology – n (%)
 Clear cell
 Other *
WHO performance status – n (%)
 0-1
 2-4
 Missing
Site of metastasis – n (%)
 One
 More than one
 Missing
Liver metastasis – n (%)
 No
 Yes
 Missing
Lung metastasis – n (%)
 No
 Yes
 Missing
Bone metastasis – n (%)
 No
 Yes
 Missing
Brain metastasis – n (%)
 No
 Yes
 Missing
Prior nephrectomy – n (%)
 No 
 Yes
 Missing
Haemoglobin – n (%)
 Normal
 < LLN
 Missing
Neutrophil count – n (%)
 Normal
 > ULN
 Missing
Platelet count – n (%)
 Normal
 > ULN
 Missing
Albumin – n (%)
 Normal
 < LLN
 Missing
Corrected serum calcium – n (%)
 Normal
 > ULN
 Missing
Alkaline phosphatase – n (%)
 Normal
 > ULN
 Missing
Lactate dehydrogenase – n (%)
 Normal
 > 1.5 times ULN
 Missing
213 (34%) 213 (34%) 27 (27%) 27 (27%)
408 (66%) 408 (66%) 74 (73%) 74 (73%)
66 (23-93) 66 (23-93) 62 (23-79) 62 (23-79)
354 (57%) 354 (57%) 69 (68%) 69 (68%)
267 (43%) 267 (43%) 32 (32%) 32 (32%)
204 (33%) 430 (69%) 34 (34%) 73 (72%)
61 (10%) 191 (31%) 9 (9%) 28 (28%)
356 (57%)  58 (57%)  
195 (31%) 206 (33%) 19 (19%) 19 (19%)
398 (64%) 415 (67%) 82 (81%) 82 (81%)
28 (5%)  0 (0%)  
487 (78%) 509 (82%) 74 (73%) 74 (73%)
106 (17%) 112 (18%) 27 (27%) 27 (27%)
28 (5%)  0 (0%)  
163 (26%) 173 (28%) 21 (21%) 21 (21%)
430 (69%) 448 (72%) 80 (79%) 80 (79%)
28 (5%)  0 (0%)  
375 (60%) 393 (63%) 58 (57%) 58 (57%)
218 (35%) 228 (37%) 43 (43%) 43 (43%)
28 (5%)  0 (0%)  
546 (88%) 571 (92%) 92 (91%) 92 (91%)
47 (8%) 50 (8%) 9 (9%) 9 (9%)
28 (5%)  0 (0%)  
452 (73%) 453 (73%) 43 (43%) 43 (43%)
168 (27%) 168 (27%) 58 (57%) 58 (57%)
1 (0%)  0 (0.0%)  
171 (28%) 205 (33%) 20 (20%) 20 (20%)
347 (56%) 416 (67%) 78 (77%) 81 (80%)
103 (17%)  3 (3%)  
203 (33%) 383 (62%) 67 (66%) 88 (87%)
108 (17%) 238 (38%) 10 (10%) 13 (13%)
310 (50%)  24 (24%)  
358 (58%) 452 (73%) 66 (65%) 70 (69%)
140 (23%) 169 (27%) 29 (29%) 31 (31%)
123 (20%)  6 (6%)  
247 (40%) 391 (63%) 51 (51%) 75 (74%)
136 (22%) 230 (37%) 18 (18%) 26 (26%)
238 (38%)  32 (32%)  
243 (39%) 421 (68%) 45 (45%) 72 (71%)
116 (19%) 200 (32%) 18 (18%) 29 (29%)
262 (42%)  38 (38%)  
324 (52%) 432 (70%) 65 (64%) 74 (73%)
139 (22%) 189 (30%) 24 (24%) 27 (27%)
158 (25%)  13 (13%)  
277 (45%) 372 (60%) 63 (62%) 71 (70%)
174 (28%) 249 (40%) 28 (28%) 30 (30%)
170 (27%)  10 (10%) 
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal. 
* mRCC was clinically established without histopathological confirmation in 17% of patients and mRCC was classified as not 
otherwise specified without further subtyping in 13% of patients. It is likely that a substantial proportion of these patients had a clear 
cell subtype.
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the north-east quadrant indicating more QALYs and higher costs compared to 
the real-world treatment mix. For the scenario in which none of the patients 
received a targeted therapy, 99.4% of all simulations fell in the south-west 
quadrant indicating less QALYs and lower costs.
Cost-effectiveness acceptability curves are presented in Figure 5.4, show-
ing the likelihood that treatment strategies would be cost-effective at a given 
willingness-to-pay threshold. Treating according to the real-world treatment 
mix never attains more than 16% of simulations. Treating all patients with 
sunitinib followed by sorafenib or everolimus would be favoured; these sce-
narios have a probability of 34% and 15%, respectively, of being cost-effective 
at a willingness-to-pay threshold of € 106,000. Not treating any patient with a 
targeted therapy would be preferred at willingness-to-pay thresholds below 
€ 106,000, but this scenario results in health loss.
Discussion
To the best of our knowledge, this is the first study that models the full disease 
course of patients with mRCC using real-world data. We found that real-world 
treatment of mRCC patients yields a QALY gain of 0.230 with incremental costs 
of € 24,179 compared to a scenario in which none of the patients would receive 
a targeted therapy. Thus, we currently pay € 105,011 per QALY gained. However, 
only 54% of the patients in our study population received a targeted therapy 
and this raises the question about what the potential impact would be if all 
treatment-eligible patients were to receive targeted therapy. Compared to 
real-world treatment, health can be gained if all eligible patients were to be 
treated with first-line sunitinib followed by sorafenib or everolimus. The costs 
to gain health by treating all eligible patients with these treatment strate-
gies, i.e. € 93,107 and € 111,972 per QALY gained, respectively, are similar to the 
current costs per QALY gained. These costs include the costs of both first- and 
second-line therapy.
The proportion of patients not being treated in this series is high at 46% 
(285/621). However, not all these patients were eligible for targeted therapy. 
We found that one in four patients (69/268; 26%) fulfilling SUTENT trial eligibil-
ity criteria did not receive any targeted therapy. Also in England, one in three 
patients with mRCC eligible for either sunitinib or pazopanib did not receive 
the drug.50 Previous analyses indicated that patients aged 65+ years were less 
likely to receive targeted therapy than younger patients after adjustment for 
other factors.92 However, the exact causes underlying the remarkably high 
proportion of non-treated patients deserve further study. Importantly, all 
drugs studied in this project were available in the Netherlands during the 
study period without any limitations for patients or prescribers, so this could 
Compared to the real-world treatment mix, first-line sunitinib followed by 
sorafenib, everolimus or another second-line treatment leads to a QALY gain of 
0.076, 0.062 and 0.035 at the population level, respectively. When combined 
with the corresponding incremental costs (i.e. € 7,072, € 6,913 and € 6,150), the 
incremental costs per QALY gained are € 93,107, € 111,972 and 177,226, respec-
tively (Table 5.3). Note that the health gains are achieved by changing the 
treatment of a relatively small group of patients representing 11% of the pop-
ulation. These are patients who were eligible to receive sunitinib but did not 
receive it in real life; in this group, sunitinib leads to a gain of 0.684, 0.558 or 
0.315 QALYs per patient.
Sensitivity analyses
The tornado diagram (Figure 5.2) shows the variability in the ICER of sunitinib 
followed by everolimus compared to the real-world treatment mix as a con-
sequence of changes in the values of various input parameters. Varying the 
unit costs of first-line sunitinib has the highest impact on the ICER.
Figure 5.3 shows the uncertainty around the total costs and QALYs as ob-
tained from the PSA. For sunitinib followed by sorafenib, everolimus or an-
other second-line treatment, 88.3%, 82.3% and 72.1% of all simulations fell in 
Table 5.2 Covariates and corresponding coefficients of the survival models and logistic regression model
Time to event 1 
(first 12 months)
Time to event 1
(> 12 months) Type of event 1* Time to event 2
Model type
Covariate
 Loglogistic
 Coefficient (SE)
 Exponential
 Coefficient (SE)
 Logistic
 Coefficient (SE)
 Weibull
 Coefficient (SE)
Constant
Age (yr)
Sex (male vs. female)
Histology (non-clear cell vs. clear cell)
Prior nephrectomy (yes vs. no)
Number of metastatic sites (more than 1 vs. 1)
WHO performance status (2-4 vs. 0-1)
Liver metastases (yes vs. no)
Bone metastases (yes vs. no)
Brain metastases (yes vs. no)
Thrombocytes (>ULN vs. normal)
Neutrophil count (>ULN vs. normal)
Albumin (<LLN vs. normal)
Alkaline phosphatase (>ULN vs. normal)
First-line sunitinib (vs. no targeted therapy)
First-line temsirolimus (vs. no targeted therapy)
First-line other (vs. no targeted therapy)
Second-line everolimus (vs. sorafenib)
Second-line other (vs. sorafenib)
TTE 1 (TTE 1 > 12 months vs. TTE 1 <= 12 months)
Shape parameter
  1.060 (0.393)  5.227 (0.663) - 1.778 (0.790)  2.804 (0.249)
  0.012 (0.005) - 0.027 (0.009)  0.037 (0.013) 
    - 0.382 (0.185)
 - 0.229 (0.112)   
  0.783 (0.130)   
 - 0.306 (0.120)   - 0.387 (0.199)
 - 0.585 (0.136)   
 - 0.459 (0.137)    0.632 (0.164)
  0.277 (0.113) - 0.330 (0.170)  - 0.421 (0.150)
    - 0.657 (0.238)
    0.587 (0.320) - 0.360 (0.183)
 - 0.258 (0.136)   
 - 0.290 (0.137)   1.074 (0.381) - 0.388 (0.196)
 - 0.269 (0.129)
  0.915 (0.124) - 0.602 (0.201)
  0.580 (0.244) - 1.529 (0.611)
  0.992 (0.273)  0.339 (0.375)
    - 0.143 (0.191)
    - 0.388 (0.181)
   - 0.641 (0.270)  0.537 (0.147)
  0.669 (0.028)    1.625 (0.137)
Note: Lung metastases, haemaglobin, corrected serum calcium and lactate dehydrogenase were considered for inclusion in the 
survival models and logistic regression model, but excluded through backward and/or forward selection.
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal; SE, standard error; TTE 1, time to event 1. 
*0 = second-line therapy/ 1 = death.
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not explain why many eligible patients in Dutch daily clinical practice did 
not receive targeted therapy.
Multiple economic evaluations of targeted therapies in mRCC have been 
published using data from RCTs, 86,100-103 two of which examined the cost-ef-
fectiveness of sunitinib. Several explanations exist for differences regarding 
the cost-effectiveness of sunitinib between our study and these two studies 
(by Remák et al86 and Benedict et al102). To start with, we used real-world data 
(using the PERCEPTION registry) while the other studies used data from key 
clinical trials. In addition, we looked at all patients with mRCC (at the initial 
presentation), while the other two studies just studied one subgroup (i.e. 
sunitinib-eligible patients). 
Some limitations to the data and methods deserve mentioning. First, since 
data from all patients newly diagnosed with mRCC at the initial presentation 
in 42 hospitals (both general and academic) were collected, it is likely that 
these patients are representative of average patients with mRCC at initial 
diagnosis and the average treatment in the Netherlands. However, these pa-
tients account for only 40%-70% of the total mRCC population.104 This total 
population also includes patients who initially presented with non-metastat-
ic disease and later developed distant metastases. It is likely that a lot more 
of these patients are being treated; a CEA based on these patients will likely 
yield different results.
Second, the model was populated using data from primary mRCC patients 
diagnosed between January 2008 and December 2010 (i.e. treated between 
2008 and 2013), whereas new treatments have become available since then. 
The PERCEPTION registry also included a cohort of (m)RCC patients diagnosed 
between January 2011 and June 2013, but since inclusion criteria differed, pa-
tients were identified differently and the duration of follow-up varied, it was 
not feasible to include these patients in the current study. Nevertheless, we 
Figure 5.2 Results of the univariate sensitivity analyses
Unit costs sunitinib +/- 25%
Unit costs everolimus +/- 25%
Effectiveness first-line sunitinib 95% CI limits
Utility weight favorable or intermediate prognosis at diagnosis 
+/- 10%
0% discount rate costs
Utility weight favorable or intermediate prognosis before start 2nd 
line +/-
Utility weight poor prognosis before start 2nd line +/- 10%
Utility weight poor prognosis at diagnosis +/- 10%
0% discount rate effects
 € 80,000 € 90,000 € 100,000 € 110,000 € 120,000 € 130,000 € 140,000
Cost per QALY (sunitinib-everolimus vs. real-world treatment mix)
 Lower bound
 Upper bound
Table 5.3 Summary of the cost-effectiveness results
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did not observe an increase in the proportion of patients receiving targeted 
therapies in this population.92 Therefore, we believe that the conclusion of 
this study still applies, and health can be gained if more treatment-eligible 
patients receive targeted therapies.
Third, the alternative scenarios included in this model assume that all 
treatment-eligible patients can be treated with a certain targeted therapy. This 
assumption may overestimate the number of eligible patients since some of 
these patients eligible on the basis of the data captured in the PERCEPTION 
registry, may not actually be eligible because of poor organ function or 
comorbidities.
Fourth, treatment costs were overestimated somewhat since we did not 
adjust for dose reductions. However, the effect on the incremental costs and 
ICERs will be minimal since the treatment costs of 54% of the patients in the 
base-case real-world scenario were also overestimated somewhat. Another 
limitation of this study is the amount of missing data in baseline character-
istics. Multiple imputations by chained equations were conducted to over-
come this problem.39 This method ensures that all patients are included in the 
analysis but simultaneously guarantees that the uncertainties from missing 
data are retained.
In conclusion, RCTs have shown that targeted therapies like sunitinib 
are effective in mRCC treatment. RCT-based cost-effectiveness analyses with 
a lifetime time horizon provide important information about the cost-ef-
fectiveness of these therapies. However, these analyses are limited in scope, 
since they are conducted in a selected population. A full disease model and 
real-world data as presented here are essential in estimating cost-effectiveness 
ratios that are externally valid. We found that one in four patients eligible 
for sunitinib did not receive it. It is difficult to state with certainty why these 
patients did not receive sunitinib. One possible reason is a limited health gain 
from treatment with sunitinib, but this reasoning seems unlikely since we 
estimated that its use may add 0.684 QALYs (or eight months in perfect health) 
to individual patients. Another possible reason is that it is not cost-effective 
to treat these patients. However, we found that it is just as cost-effective to 
treat these patients with sunitinib as current treatment practice.
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Figure 5.3 Cost-effectiveness plane for various treatment scenarios versus real-world treatment mix
Figure 5.4 Cost-effectiveness acceptability curves representing the probability that each treatment strategy 
is cost-effective for a given maximum willingness-to-pay threshold per QALY gained
Note: The y-axis shows the likelihood that strategies would be considered cost-effective for a given cost-
effectiveness willingness to pay threshold.
   No targeted therapy
   Sunitinib-Sorafenib
   Sunitinib-Everolimus
   Sunitinib-Other
     Real-world treatment patterns
       No targeted therapy
     Sunitinib-Sorafenib
     Sunitinib-Everolimus
     Sunitinib-Other
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Table S5.1 Utility weights
Prognosis Utility (mean) Source
Favourable or intermediate prognosis at diagnosis
Poor prognosis at diagnosis
Favourable or intermediate prognosis  
before start second-line therapy
Poor prognosis before start second-line therapy
0.725* 94
0.590 95
0.700** 96
0.590 95
* Average of utility at baseline for patients receiving pazopanib and patients receiving placebo
** Average of utility for patients treated with axitinib and patients treated with sorafenib.
Table S5.2 Drug costs
Prognosis Dose and frequency Costs (€ ) Costs per month (€ ) Source
Sunitinib
Temsirolimus
Sorafenib
Everolimus
50 mg daily for 4 weeks,  
followed by 2-week rest period
25 mg once per week
400 mg twice daily
10 mg daily
184 per 50 mg 3,727 105
928 per dose 4,030 105
35 per 200 mg 4,243 105
129 per 10 mg 3,931 105
Supplementary information: Calculation of drug 
costs and resource utilisation costs 
Drug costs were calculated by multiplying monthly costs of a therapy105 by the 
time to an event (Table S5.2). The PERCEPTION registry showed that, if patients 
did not undergo a cytoreductive nephrectomy prior to drug treatment, they 
started drug treatment 1.4 months (SD 1.7, n  =  219) after diagnosis. If patients 
underwent cytoreductive nephrectomy prior to drug treatment, they started 
drug treatment 8.6 months (SD 9.8, n  =  116) after diagnosis. Therefore, in the 
model we assumed patients started drug treatment one month after diagno-
sis, except for patients who underwent a nephrectomy prior to drug treat-
ment; we assumed that these patients started drug treatment nine months 
after diagnosis. 
We also assumed patients discontinued drug treatment either one month 
before start of second-line treatment or three months before death. These 
assumptions are also based on the PERCEPTION registry, but since the date 
of discontinuation was often lacking in the PERCEPTION registry, it was not 
possible to calculate the time between discontinuation and either start of 
second-line treatment or death for all patients in the registry. This assumption 
was therefore verified by a clinical expert who participated in the registry. 
A maximum first-line treatment duration of 41 months, and a maximum 
second-line treatment duration of 34.1 months was assumed based on the 
results from other studies.34,48 
Monthly resource use per treatment strategy was derived from patient-lev-
el data (Table S5.3). Total costs were calculated by multiplying monthly re-
source use by unit costs,106,107 and the time to an event.
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Figure S5.1 Model structure
Input parameters Model structure Outcomes
Loglogistic model with the following 
covariates:
age, (sex), histology, prior nephrectomy, nr 
of metastatic sites, WHO performance 
status, (lung metastases), liver metastases, 
bone metastases, (brain metastases), 
(haemoglobin), neutrophil count, (platelet 
count), albumin, (corrected serum calcium), 
alkaline phosphatase, (lactate 
dehydrogenase), first-line treatment 
Time to event 1  
(TTE 1)
(until 12 months)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations, 
outpatient visits and medical imaging 
services
Effects: Life years and quality-adjusted life 
years
Exponential model with the following 
covariates:
age, (sex), (histology), (prior nephrectomy), 
(nr of metastatic sites), (WHO performance 
status), (lung metastases), (liver 
metastases), bone metastases, (brain 
metastases), (haemoglobin), (neutrophil 
count), (platelet count), (albumin), 
(corrected serum calcium), (alkaline 
phosphatase), (lactate dehydrogenase), 
first-line treatment 
Time to event 1  
(TTE 1)
(> 12 months)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations. 
outpatient visits and medical imaging 
services
Effects: Life years and quality-adjusted life 
years
Logistic regression with the following 
covariates:
age, (sex), (histology), (prior nephrectomy), 
(nr of metastatic sites), (WHO performance 
status), (lung metastases), (liver 
metastases), (bone metastases), (brain 
metastases), (haemoglobin), (neutrophil 
count), platelet count, albumin, (corrected 
serum calcium), (alkaline phosphatase), 
(lactate dehydrogenase), (first-line 
treatment), TTE 1
Type of event 1 
(second-line 
treatment or 
death)
Weibull model with the following 
covariates:
(age), sex, (histology), (prior nephrectomy), 
nr of metastatic sites, (WHO performance 
status), (lung metastases), liver metastases, 
bone metastases, brain metastases, 
(haemoglobin), (neutrophil count), platelet 
count, albumin, (corrected serum calcium), 
(alkaline phosphatase), (lactate 
dehydrogenase), (first-line treatment),  
TTE 1, second-line treatment
Time to event 2 
(TTE 2)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations. 
outpatient visits and medical imaging 
services
Effects: Life years and quality-adjusted life 
years
Type of event 2 
(death)
Note: Covariates between brackets were 
considered for inclusion in the survival models 
and logistic regression model, but excluded 
through backward and/or forward selection.Re
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Table S5.3 Unit costs and resource use per treatment strategy per month
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Figure S5.3 Comparison of time to event 1 (i.e. time from diagnosis to second-line treatment or death) 
between original and simulated data
Pr
ob
ab
ili
ty
 o
f s
ur
vi
va
l (
%
) (
ev
en
ts
  
ar
e 
se
co
nd
-li
ne
 tr
ea
tm
en
t o
r d
ea
th
100
90
80
70
60
50
40
30
20
10
0
 0 12 24 36 48 60 72 84 96 108 120
     TTE 1 according to PLS model 
(base-case scenario)
     TTE 1 based on real-world data
Abbreviations: TTE 1, Time to event 1, 
representing time from diagnosis of 
mRCC until second-line treatment or 
death; PLS, patient-level simulation.
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Figure S5.4 Comparison of time to event 2 (i.e. time from start of second-line treatment to death)  
between original and simulated data
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Figure S5.5 Comparison of overall survival (i.e. time from diagnosis to death)  
between original and simulated data
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Figure S5.2 Patient enrollment
Assessed for eligibility (n=714)
Excluded (n=39)
•	 	Not	meeting	inclusion	criteria	(n=26)
	 •	 	No	renal	cell	carcinoma	(n=12)
	 •	 	No	metastases	at	presentation	(n=6)
	 •	 	<	18	years	(n=7)
	 •	 	Other	(n=1)
•	 	Other	reasons	(n=13)
	 •	 	Diagnosed	and/or	treated	in	a	non-participating	hospital,	 
and too little information available on patient and disease  
characteristics (and treatment) (n=12)
	 •	 	Other	(n=1)
Follow-up (n=675)
Lost to follow-up (n=30)
•	 	Patients	continued	treatment	in	a	non-participating	hospital	
Excluded (n=24)
•	 	Metastasectomy	(combined	with	a	nephrectomy)	with	a	possible	 
curative intention, making systemic treatment redundant
Analysis (n=621)
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Introduction
Globally, there is an increasing trend to use real-world data to inform decision 
making in healthcare. Real-world data are often collected using a patient 
registry. A patient registry can be defined as “an organized system that uses 
observational study methods to collect uniform data (clinical and other) to 
evaluate specified outcomes for a population defined by a particular disease, 
condition, or exposure, and that serves one or more predetermined scientific, 
clinical, or policy purposes”.108
Regulatory authorities (United States Food and Drug Administration and 
European Medicines Agency [EMA]) can require real-world data collection for 
safety surveillance and risk assessment (e.g. Risk Evaluation and Mitigation 
Strategy by the Food and Drug Administration and risk management plan by 
the EMA).109 Furthermore, reimbursement agencies increasingly use real-world 
data in decision making. This was, for example, seen in the Netherlands where 
a coverage with evidence development policy was implemented in 2006.9 
This policy aims to guarantee early access to expensive drugs that have an 
added therapeutic value and an expected budget impact of at least 2.5 million 
Euros.13 In exchange, it is required to collect data regarding appropriate drug 
use, effectiveness, and cost-effectiveness in real-world clinical practice. These 
data are intended to complement the findings from clinical trial(s), and to 
evaluate a drug’s real-world value after 4 years of initial reimbursement. As 
a consequence of the introduction of this policy, the number of patient reg-
istries has been rapidly increasing in the Netherlands. 
In this article, we provide practical guidance in setting up patient regis-
tries for the collection of real-world data. Although guidance for designing pa-
tient registries exists,108 we specifically address practical issues. This article is 
based on our involvement in setting up patient registries in the Netherlands 
for various types of cancer (i.e. melanoma, lung, prostate, renal cell, haema-
tological, colorectal, and head and neck cancer). We first discuss the mission 
and goals (‘the Why’) of patient registries and highlight issues related to stake-
holders and funding (‘the Who’). After that, challenges and solutions will be 
discussed regarding the type and content of a patient registry (‘the What’) 
and the identification and recruitment of patients, data handling, and phar-
macovigilance (‘the How’). Last, we discuss the main challenges in balancing 
the optimal and the feasible in setting up patient registries.
Mission and goals (‘the Why’)
Why use a patient registry and how to guarantee valorisation of outcomes?
The mission of most registries is improving patient health by improving the 
quality of patient care; monitoring and evaluating patient care is therefore 
Abstract
Objective: The aim of this article was to provide practical guidance in setting 
up patient registries to facilitate real-world data collection for healthcare 
decision making. 
Methods: This guidance was based on our experiences and involvement in 
setting up patient registries in oncology in the Netherlands. All aspects were 
structured according to 1) mission and goals (‘the Why’), 2) stakeholders and 
funding (‘the Who’), 3) type and content (‘the What’), and 4) identification 
and recruitment of patients, data handling, and pharmacovigilance (‘the 
How’). 
Results: The mission of most patient registries is improving patient health 
by improving the quality of patient care; monitoring and evaluating patient 
care is often the primary goal (‘the Why’). It is important to align the objec-
tives of the registry and agree on a clear and functional governance structure 
with all stakeholders (‘the Who’). There is often a tradeoff between reliability, 
validity, and specificity of data elements and feasibility of data collection (‘the 
What’). Patient privacy should be carefully protected, and address (inter-)
national and local regulations. Patient registries can reveal unique safety 
information, but it can be challenging to comply with pharmacovigilance 
guidelines (‘the How’). 
Conclusions: It is crucial to set up an efficient patient registry that serves its 
aims by collecting the right data of the right patient in the right way. It can 
be expected that patient registries will become the new standard alongside 
randomised controlled trials due to their unique value.
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relevant prognostic factors. Last, a user-friendly (Web-based) application is 
needed to facilitate a quality-of-care feedback loop.
Stakeholders and funding (‘the Who’)
Who are involved in the registry?
Broad support for the registry is needed to maximize its benefits. Identifying 
and engaging relevant stakeholders is key to the success of a patient registry. 
Stakeholders include clinicians, patients, researchers, governmental parties, 
healthcare insurers, and manufacturers. Involvement from professional or-
ganisations and clinical experts (including key opinion leaders) improves 
the valorisation of results. Involvement of patient representatives secures 
patient participation and may help ensure that the aims of the registry are 
pursued with minimal burden to patients. Participation of manufacturers 
may support funding of the registry. Table 6.2 illustrates the involvement of 
stakeholders in the registries in which we are involved.
Stakeholders can, however, have conflicting interests. An essential and 
potentially time-consuming step is aligning the aims of the registry with 
these interests. It is important to determine the main objectives with key 
stakeholders at an early stage. It is also crucial to establish a clear and func-
tional governance structure including a description of tasks, responsibilities, 
and decision-making processes. In the prostate cancer registry (CAstration-
resistant Prostate cancer RegIstry), clinical data and health-related quality 
of life data are collected in two separate projects with separate funding and 
study protocols; however, both projects are carried out by the same project 
team. The project team is the core executive body, responsible for the day-to-
day management of the registry, coordination, and adherence to the planning 
and protocol. The project team is advised by a clinical steering committee as 
well as a general assembly. The clinical steering committee has decision-mak-
ing power regarding the clinical and scientific aspects of the registry (e.g. data 
collection and publication of results) and includes balanced representatives 
of urologists, medical oncologists, and radiotherapists of the participating 
hospitals and the Dutch uro-oncology study group. The general assembly rep-
resents all relevant stakeholders (including all involved manufacturers and 
representatives of the Dutch prostate cancer patient organisation). Scientific 
proposals are judged by the steering committee, and the writing team in-
cludes the involved project team members and a selection of the steering 
committee and the subinvestigators from the participating hospitals.
Another issue may be related to data ownership (including publishing 
rights), (level of) data access, and data sharing. For example, when multi-
ple manufacturers fund the registry, they may not be willing to share prod-
often the primary goal. This goal may be operationalised in several ways. For 
example, patient registries are one of EMA’s tools to gain insight into risks of 
a product in real-world clinical practice.109 Patient registries can also provide 
information on appropriate use (i.e. is a product used in the right way in the 
right patients), effectiveness, costs, and cost-effectiveness in real-world clin-
ical practice.110 Furthermore, registries can include essential information on 
patient-reported outcome measures (PROMs) in case data are prospectively 
collected. Moreover, patient registries can inform public health planning 
(e.g. registering causes of disease to illustrate the need for a prevention pro-
gram).111 It is important to be very specific about how the primary goal of mon-
itoring and evaluating patient care will be operationalised and/or interpreted. 
Ultimately, this will ease the other steps in setting up patient registries. 
Monitoring and evaluating patient care may not immediately improve 
patient health but may improve the health of future patients. It is essential 
to frequently discuss findings with clinicians and ensure a quality-of-care 
feedback loop. Furthermore, outcomes can be used in the development of 
clinical guidelines. Table 6.1 provides an overview of the mission and goals 
of the registries in which we are involved. All registries ensure transparency 
to the public through presentations and publications.112-119 However, only 
the melanoma registry (Dutch Melanoma Treatment Registry [DMTR]) fort-
nightly provides clinicians with online benchmarked feedback regarding a 
predefined set of quality indicators developed by the professional organisa-
tion. These quality indicators will be shared at a hospital level with healthcare 
insurers, patient organisations, and the general public in the near future. 
Quality-of-care improvement by using a structured feedback loop to clinicians 
was not part of the initial aims of most of the registries. This may be explained 
by the fact that most of the registries in which we are involved were funded 
by manufacturers and mainly set up for reimbursement purposes. Besides 
reimbursement purposes, the melanoma registry (DMTR) was set up for mon-
itoring quality of care, which was obligated by the professional organisation.
Important lessons to feedback loops are that agreement needs to be 
reached on the type of indicators that will be collected, how they will be 
measured, and the way they will be presented. In addition, the data need to 
be representative for all patients within a certain hospital (e.g. starting data 
collection on patients with a worse prognosis will initially lead to biased 
feedback) and the data need to be case-mix corrected to allow valid compari-
sons between hospitals (or clinicians), especially when it concerns outcomes 
indicators. To correct for differences between patients at baseline, the registry 
should contain a sufficient number of observations and sufficient data on the 
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uct-specific data. In this case, detailed product-specific data can be shared 
with the product owner, whereas aggregated data can be shared with other 
companies. By allowing variation in the level of data sharing,121 competing 
parties can participate and benefit from collaboration within the same 
registry.
Who funds the registry?
It is crucial to secure sufficient funding for all activities related to the reg-
istry to ensure viability and sustainability. Activities include designing the 
registry (e.g. stakeholder meetings, writing and revising the study protocol, 
defining data sets, and ethical approval) and running the registry (e.g. data 
collection, data analyses, writing, and reporting). Ensuring funding can be 
challenging, especially in case of extensive data collection and/or long-term 
follow-up. Long-term funding arrangements are essential for the sustaina-
bility of a registry.
Registries can be funded from one or multiple sources including public 
and private sources. Potential funding sources are manufacturers, healthcare 
insurers, governmental parties, patient organisations, professional associa-
tions, private foundations, and advocacy groups. Funding for the registries 
in which we are involved was often provided by multiple manufacturers. 
These registries were largely motivated by the need to collect real-world data 
on the performance of drugs in line with the Dutch coverage with evidence 
development policy. Some of these registries also received governmental 
funding (including [unrestricted] research grants).
Multisponsor registries have the advantage of decreasing the financial 
burden for each party and securing wider support. However, sponsors may 
have conflicting interests and different ideas about the design and planning 
of the registry. For example, multiple manufacturers were involved in the 
haematological registry (Population-based HAematological Registry for 
Observational Studies 1). They had products for various indications in differ-
ent treatment lines. Because the optimal approach to collect data may differ 
per party (e.g. dependent on treatment line), priorities needed to be set and 
needed to be acceptable for all parties.
Another example is the lung cancer registry (Prospective Observational 
Study Examining Investments and Derived Outcomes in NSCLC), aimed to 
start in four hospitals. Although the set-up started 3 years ago, it is currently 
unknown whether data collection will actually commence. Over time, more 
stakeholders became involved and the objectives became concurrently broad-
er. For example, one of the objectives was to collect detailed biomarker infor-
mation for scientific purposes and in order to conduct economic evaluations Ta
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of targeted therapies. However, collecting data on biomarkers increases the 
requirements for infrastructure and funding. Furthermore, different stake-
holders had different ideas about the type of biomarker data to be included. 
Agreement between all stakeholders has not yet been reached.
A practical solution for future registries is to carefully consider the num-
ber and type of stakeholders and their specific role in decision making. The 
inclusion of more stakeholders increases potential benefits, but it can also 
complicate decision making.
Type and content (‘the What’)
What is a suitable type and content?
A patient registry can be intervention-based or disease-based.108 An interven-
tion-based registry addresses research questions regarding appropriate use, 
effectiveness, cost-effectiveness, and safety. Disease-based registries provide 
additional information and facilitate studying the full disease course includ-
ing (sequential) treatment pathways.116 Furthermore, such a registry provides 
information on the number of untreated patients and whether these patients 
would have been eligible for treatment. It should be noted, however, that this 
also adds to complexity, time, and costs of a registry. Table 6.3 provides an 
overview of the type and content of the registries in which we are involved.
Both intervention-based and disease-based registries can include all pa-
tients who meet the inclusion criteria or include a sample of this population. 
Including all patients adds to time and costs, whereas selecting a sample can 
be more efficient but can have pitfalls as well. In particular, the representative-
ness of the patient population may be hampered (external validity). Although 
causal studies about how nature works do not necessarily need a represent-
ative sample, representativeness is crucial in studies describing a specific 
population at a specific point in time.122 As a consequence, a representative 
sample is needed when monitoring and evaluating patient care. A random 
sample or a cluster sample can enhance representativeness. A cluster sample 
includes patients in a certain cluster (e.g. a region or a hospital) based on the 
assumption that the cluster is representative of other clusters.
To increase efficiency, it may be an option to use multiple-phase sampling. 
For example, in a two-phase design, limited data are first collected in a large 
sample, after which detailed data are collected in a subsample. The melano-
ma registry (DMTR) uses such an approach. Minimal data are collected on 
patients who are not treated in a melanoma centre (due to a worse prognosis), 
whereas full data (clinical, economic, PROMs) are collected for all patients 
who received treatment in 1 of the 14 melanoma centres. In addition, more 
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detailed data (additional healthcare resource use, productivity losses, and 
informal care) are only collected in a selection of 4 of the 14 centres.
Despite the sampling procedures, which initially enhance representative-
ness, representativeness is hampered in case patients who do not want to par-
ticipate differ from those who participate, or in case patients are not randomly 
lost to follow-up. In addition, sampling from a complete sampling frame is 
not always feasible, especially for registries using a prospective design.
What data elements?
What data elements to include largely depends on the goal of the registry. If 
the goal is to improve the quality of patient care by providing information 
on appropriate use, effectiveness, and cost-effectiveness in real-world clinical 
practice, comprehensive data are needed on patient and disease characteris-
tics, treatment, and outcomes (health and economic outcomes). However, if 
the goal is explicitly focused on effectiveness and safety in order to improve 
the quality of patient care, the choice of data elements can be more selective. 
To select the most important data elements, an analysis plan can be created. 
Describing the future data analyses helps identifying those data elements 
that are essential and those elements that are academically ‘interesting’.123
Data elements should, preferably, be based on data standards (e.g. Clinical 
Data Interchange Standards Consortium), current data sets (e.g. national dis-
ease registry), and/or standard terminology (e.g. Systematized Nomenclature 
of Medicine). This facilitates comparison to other studies and creates the 
opportunity to link different data sets.
Consultation of experts ensures the selection of appropriate data ele-
ments.124 It is important to involve clinical experts as well as experts in using 
real-world data. Clinical experts who are not experienced with real-world 
data may advise on data elements that are difficult to collect in a real-world 
setting. It is always recommended to test the availability of data elements. In 
case there is a lack of reliable data about a certain variable, it may be possible 
to use a proxy (e.g. time to next treatment as a proxy for time to progression).
Using real-world data always implies balancing between reliability, va-
lidity, and specificity of data elements on the one hand and the feasibility 
of data collection (affordability and completeness) on the other hand. The 
available sources will set boundaries to what can be collected and influence 
the manner of data collection. For example, data on adverse events in clinical 
trials are commonly reported using the Common Terminology Criteria for 
Adverse Events as graded by the clinician. This is, however, often not feasible 
in a registry, unless the Common Terminology Criteria for Adverse Events are 
consistently used and concisely reported in medical charts in clinical practice. Ta
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e 
6.
3 
Ty
pe
 a
nd
 co
nt
en
t o
f t
he
 re
gi
st
ry
 (‘
th
e 
W
ha
t’)
N
am
e 
of
 re
gi
st
ry
Th
e 
W
ha
t
PH
AR
O
S 
1
CA
PR
I a
nd
 
PR
O
-C
AP
RI
DM
TR
M
el
an
om
a
M
et
as
ta
tic
 
co
lo
re
ct
al
 
ca
rc
in
om
a
PE
RC
EP
TI
O
N
N
on
-s
m
al
l  
ce
ll 
lu
ng
 
ca
rc
in
om
a
PO
SE
ID
O
N
 
(n
ot
 ru
nn
in
g)
Lo
ca
lly
 
ad
va
nc
ed
 
H
ea
d 
&
 N
ec
k
Re
cu
rr
en
t 
an
d/
or
 
m
et
as
ta
tic
 
H
ea
d 
&
 N
ec
k
Di
se
as
e
CL
L,
 M
M
, N
H
L
CR
PC
M
el
an
om
a 
(u
nr
es
ec
ta
bl
e 
st
ag
e 
III
c/
IV
)
M
el
an
om
a 
(s
ta
ge
 I-
IV
)
m
CR
C
m
RC
C
N
SC
LC
N
SC
LC
(L
A)
 S
CC
H
N
(R
M
) S
CC
H
N
Ty
pe
:
Sc
op
e:
 Co
nt
en
t:
    D
at
a-
co
lle
ct
io
n:
•	
	D
is
ea
se
-b
a
se
d
•	
	In
te
rv
en
tio
n-
b
a
se
d
•	
	Po
p
ul
a
tio
n-
b
a
se
d
•	
	Sa
m
p
le
-b
a
se
d
•	
	Pa
tie
nt
	a
nd
	d
is
ea
se
	
ch
ar
ac
te
ris
tic
s/
 tr
ea
tm
en
t
•	
	Cl
in
ic
a
l	o
ut
co
m
es
•	
	Ec
on
om
ic
	o
ut
co
m
es
•	
	Pa
tie
nt
	re
p
or
te
d
	o
ut
co
m
es
•	
	Q
ua
lit
y	
of
	c
a
re
	in
d
ic
a
to
rs
**
•	
	Pa
tie
nt
	m
a
te
ria
l
•	
	Pr
os
p
ec
tiv
e
•	
	Re
tr
os
p
ec
tiv
e
•	
	St
a
rt
	a
nd
	e
nd
	d
a
te
•	
	Ye
a
rs
	o
f	d
ia
gn
os
is
 
X 
X 
X 
X 
 
X 
X 
X 
 
 
 
 
 
 
X 
 
 
 
X 
X
 
 
 
X 
 
 
 
 
 
 
X 
X 
 
X 
X 
X 
X 
X 
X 
X
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X
 
X*
 
X 
X 
 
 
X 
 
X 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
Fu
tu
re
 a
im
 
 
 
X 
 
To
 b
e 
de
ci
de
d 
 
 
 
X 
X 
 
 
X 
 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
X 
X
 
Fr
om
 2
01
0 
20
12
–2
01
7 
Fr
om
 2
01
3 
20
12
–2
01
5 
20
10
–2
01
3 
20
11–
20
14
 
20
12
–2
01
4 
To
 b
e 
de
ci
de
d 
20
11 
20
11–
20
13
 
Fr
om
 2
00
4 
20
10
–2
01
5 
Fr
om
 2
01
2 
20
03
–2
01
1 
20
03
–2
01
3 
20
08
–2
01
3 
20
09
–2
01
1 
To
 b
e 
de
ci
de
d 
20
07
–2
01
0 
20
06
–2
01
3
Ab
br
ev
ia
tio
ns
: P
H
AR
O
S,
 P
op
ul
at
io
n-
ba
se
d 
H
Ae
m
at
ol
og
ic
al
 R
eg
ist
ry
 fo
r O
bs
er
va
tio
na
l S
tu
di
es
; C
AP
RI
, C
As
tr
at
io
n-
re
sis
ta
nt
 P
ro
st
at
e 
ca
nc
er
 R
eg
Ist
ry
; P
RO
-C
AP
RI
, P
at
ie
nt
 R
ep
or
te
d 
O
ut
co
m
es
 in
 th
e 
CA
st
ra
tio
n-
re
sis
ta
nt
 P
ro
st
at
e 
ca
nc
er
 R
eg
Ist
ry
; D
M
TR
, D
ut
ch
 M
el
an
om
a 
Tr
ea
tm
en
t R
eg
ist
ry
; P
ER
CE
PT
IO
N
, P
ha
rm
ac
oE
co
no
m
ic
s i
n 
Re
na
l C
El
l c
ar
ci
no
m
a:
 a
 P
op
ul
aT
IO
N
-b
as
ed
 re
gi
st
ry
; P
O
SE
ID
O
N
, 
Pr
os
pe
ct
iv
e 
O
bs
er
va
tio
na
l S
tu
dy
 E
xa
m
in
in
g 
In
ve
st
m
en
ts
 a
nd
 D
er
iv
ed
 O
ut
co
m
es
 in
 N
SC
LC
 tr
ea
tm
en
t; 
CL
L,
 ch
ro
ni
c l
ym
ph
oc
yt
ic
 le
uk
em
ia
; M
M
, m
ul
tip
le
 m
ye
lo
m
a;
 N
H
L,
 N
on
 H
od
gk
in
 ly
m
ph
om
a;
 C
RP
C,
 
ca
st
ra
tio
n-
re
sis
ta
nt
 p
ro
st
at
e 
ca
nc
er
; m
CR
C,
 m
et
as
ta
tic
 c
ol
or
ec
ta
l c
ar
ci
no
m
a;
 m
RC
C,
 m
et
as
ta
tic
 re
na
l c
el
l c
ar
ci
no
m
a;
 N
SC
LC
, N
on
-s
m
al
l-c
el
l l
un
g 
ca
rc
in
om
a;
 L
A 
SC
CH
N
, l
oc
al
ly
 a
dv
an
ce
d 
Sq
ua
m
ou
s C
el
l 
Ca
rc
in
om
a 
of
 th
e 
H
ea
d 
an
d 
N
ec
k;
 R
M
 S
CC
H
N
, r
ec
ur
re
nt
 a
nd
/o
r m
et
as
ta
tic
 S
qu
am
ou
s C
el
l C
ar
ci
no
m
a 
of
 th
e 
H
ea
d 
an
d 
N
ec
k.
* D
at
a 
on
 h
ea
lth
-r
el
at
ed
 q
ua
lit
y 
of
 li
fe
 w
as
 c
ol
le
ct
ed
 in
 T
he
 P
ro
fil
es
 re
gi
st
ry
120
 **
 Q
ua
lit
y 
of
 c
ar
e 
in
di
ca
to
rs
 c
an
 b
e 
de
riv
ed
 fr
om
 a
ll 
re
gi
st
rie
s (
e.
g.
 le
ng
th
 o
f a
 st
ay
 in
 a
 h
os
pi
ta
l).
 H
ow
ev
er
, t
he
 D
M
TR
 is
 th
e 
on
ly
 re
gi
st
ry
 p
ro
vi
di
ng
 o
nl
in
e 
be
nc
hm
ar
ke
d 
fe
ed
ba
ck
 to
 cl
in
ic
ia
ns
, h
os
pi
ta
ls 
an
d 
m
an
uf
ac
tu
re
rs
.
106 107
In the lung cancer study, data were retrospectively collected from medical 
charts. Only 8.5% of adverse events (81 of 956) were graded by a clinician us-
ing a standardised grading system and reported in the medical chart. Only 
51% were sufficiently reported to retrospectively derive a grade, as judged by 
data managers. Therefore, a tension may exist between optimizing reliability 
(register and grade an adverse event only if recorded by the treating clinician) 
and optimizing other properties of the registry such as data completeness. 
When selecting the data elements, one has to be aware of such trade-offs so 
as to optimize the attributes most important to the registry.
Identification and recruitment of patients,  
data handling, and pharmacovigilance (‘the How’)
How to identify patients?
Any type of registry may have issues regarding the identification of eligible 
patients. In population-based patient registries, it is essential to identify and 
include all eligible patients (e.g. with the diagnosis of interest or treated with 
the intervention of interest). In contrast, a sample of the population can be 
drawn, and existing databases can be used to identify eligible patients. It is 
crucial to ensure representativeness when using an existing database (e.g. 
national databases, hospital databases, and clinicians [databases]). Drawing 
a sample from patients joining a patient association may, for example, lead 
to selection bias (e.g. a higher educated group of patients). The potential 
for bias can be evaluated by examining different studies addressing similar 
research questions and comparing patient and disease characteristics to the 
characteristics of the patients in the registry. Table 6.4 illustrates how patients 
were identified in the registries in which we are involved.
In the retrospective part of the renal cancer registry (Pharmaco-Economics 
in Renal CEll carcinoma: a PopulaTION-based registry [PERCEPTION]), eligible 
patients were identified through the Netherlands Cancer Registry, which 
includes basic information on 95% of all cancer patients. A cluster sample was 
selected for inclusion in this registry (i.e. all patients with metastatic renal 
cell carcinoma in 42 from 51 hospitals in four regions, covering approximately 
half the country). A practical hurdle arises when (sufficient) information is 
not available on the population. For the prospective part of this registry, the 
Netherlands Cancer Registry could not provide a timely and complete list of 
eligible patients. Therefore, lists of patients diagnosed with metastatic renal 
cell carcinoma were fortnightly derived from hospitals’ financing systems, 
in addition to the Netherlands Cancer Registry.
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The process of data collection should be designed to maximize participation 
and response, data quality, and efficiency while minimizing patient burden.
To improve the quality of clinical data, clinicians can be requested to 
register or verify data. This is, however, often not feasible because clinicians 
often lack time to review large volumes of patient data. In case registry data 
are used for the evaluation of the quality of care in multiple hospitals, ex-
ternal data managers may increase objectivity and may ensure uniformity 
of data collection. In the melanoma registry (DMTR), all data recorded by 
data managers need to be validated by clinicians. This validation process 
is, however, time-consuming. Validation efforts should therefore preferably 
focus at the most important variables (such as toxicities) that may not relia-
bly be captured by data managers. Uniformity of data collection in the DMTR 
was improved by initially recording data on 10% of all patients by two data 
managers (one external).
It is essential to adequately and continuously train data managers support-
ed by a detailed and up-to-date manual. This also includes guidance on when 
to record a value as missing, unknown, or as negative. For example, there is 
a difference between a patient who had no test for locating metastases and a 
patient who had a test but no metastases were found. Inconsistencies in data 
recording hamper a valid interpretation of the results. Training data manag-
ers and preliminary analyses of the collected data allow for identification of 
and sharing information on common mistakes.
Furthermore, it is crucial to ensure patients’ privacy, in particular for pa-
tient identifiers. Training in Good Clinical Practice (to the extent the princi-
ples are relevant for patient registries) and awareness of (inter-)national and 
local regulations will help in designing a registry that guarantees patient 
privacy. This includes anonymisation or pseudonymisation of data to ensure 
that information cannot be traced to an individual patient. Anonymisation 
may hamper specific registry functionalities (e.g. combining different data 
sources). Pseudonymisation involves replacing identifying items by artifi-
cial identifiers, or pseudonyms. Pseudonymisation can be performed by a 
trusted third party, guarding the encryption to the procedure while enabling 
re-identification when required. However, even in case a trusted third party 
is used, the inclusion of patient identifiers in the CRF should be carefully 
scrutinised and allowed only when absolutely necessary; approval should 
be obtained from a medical-ethical committee.
How should pharmacovigilance be incorporated?
Patient registries have the potential to reveal unique pharmacovigilance in-
formation because their follow-up allows identification of long-term toxicity. 
How to recruit patients?
The recruitment of patients can be a serious challenge. Participation can be 
voluntary or compulsory for patients and/or clinicians. To increase partic-
ipation rates, it could be made compulsory to gain access to and/or reim-
bursement of a product (e.g. an expensive drug). This was partly the case in 
the melanoma registry (DMTR). The Dutch minister made the financing of an 
expensive melanoma drug conditional on the set-up of a population-based 
registry and centralisation of melanoma care in 14 specialist centres (en-
dorsed by health insurers).
However, participation in most registries is voluntary. Patients can have 
multiple incentives to participate. Because a registry most likely does not 
change current treatment, improving future patients’ health may be the most 
important incentive. Clinicians or hospitals may be incentivised by a par-
ticular research interest or the ability to achieve other goals (e.g. reimburse-
ment, transparency, and improvement in quality of care).108 Furthermore, a 
(financial) compensation for time invested by either clinicians or patients 
may help to increase participation.
How to handle the data?
Paper or electronic case report forms (CRFs) can be used to record informa-
tion. Electronic CRFs offer the advantage of automatic validation checks and 
do not require transferring data from paper to an electronic database. The 
database needs to be suitable for the registry, including the level of detail of 
the data.
Furthermore, electronic and paper-based patient questionnaires can 
be used to collect PROMs. In the PERCEPTION registry, patients were sent a 
health-related quality-of-life questionnaire every 3 months in the first year of 
participation in the study and every 6 months in the second year. Experiences 
from the PERCEPTION registry showed that most patients who gave informed 
consent returned the questionnaire on a short notice; response rates varied 
between 80% and 90%. However, response rates can vary substantially be-
tween studies, and may depend on the study population and the burden of the 
questionnaire(s). To increase participation and response, it may be an option 
to use both electronic and paper-based patient questionnaires especially in 
case most patients are elderly. In addition, in case this matches the required 
measuring moments, questionnaires can be completed at clinic visits, for 
example, in the waiting room (e.g. by using a tablet). Furthermore, especially 
in case of immobile or terminally ill patients, telephone calls or house visits 
by study staff may be needed to collect the required patient-reported data. 
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Interim analyses in the prostate cancer registry (CAstration-resistant Prostate 
cancer RegIstry) revealed that about half of the patients had a recorded hospi-
talisation or death during treatment. Although this percentage included both 
related and unrelated adverse events, all needed to be reported (see Table 6.4). 
This illustrates that serious adverse events are common and may significantly 
add to data management time and thus costs of running a registry. However, 
it also emphasizes that pharmacovigilance may be an important aspect in 
improving patient health.
Lessons learned
Patient registries provide valuable information on real-world patients, re-
al-world practice, real-world costs, real-world effects, and real-world cost-ef-
fectiveness. If well designed and well executed, registries can support decision 
making at different levels. Regulatory authorities and local reimbursement 
agencies can use real-world data in market access and reimbursement de-
cisions. Furthermore, sharing real-world outcomes can improve decision 
making at the patient level, and, ultimately, can improve patient health.
Because patient registries can serve multiple goals and inform decision 
making at different levels, practical guidance in setting up a registry is impor-
tant to ensure a proper design and execution. This article provided practical 
guidance on ‘the Why,’ ‘the Who,’ ‘the What,’ and ‘the How’ in setting up a 
patient registry, which is based on our experiences and involvement in mul-
tiple registries in the Netherlands for various types of cancer. It is essential 
to cooperate with all relevant stakeholders and collect the right data from 
the right patients in the right way. The ‘right’ is, however, not always the most 
extensive approach. It is crucial that the registry is designed in such a way that 
it serves its aims and is as efficient as possible. It is, therefore, particularly im-
portant to balance the optimal and the feasible to maximize the gains within 
the constraints of the available resources.
This article has a number of limitations. First, our experiences in setting 
up patient registries are based on registries in cancer only; nevertheless, we 
believe that this practical guidance is applicable to patient registries in other 
disease areas. In addition, in most of the registries in which we are involved, 
patients were selected using existing databases, such as the Netherlands 
Cancer Registry, and most of the registries were largely informed by chart 
reviews conducted by trained data managers. Nevertheless, we believe that 
our experiences in the Netherlands will benefit researchers in other contexts 
and other countries.
Moreover, real-world toxicities may differ from toxicity profiles in clinical 
trials because of differential populations, treatment patterns, adverse event 
handling, and clinician experience.125 However, it can be challenging to com-
prehensively collect safety data within a registry, especially in case data are 
collected retrospectively.
With respect to pharmacovigilance requirements, the EMA guideline on 
good pharmacovigilance practices differentiates between noninterventional 
postauthorisation studies with primary data collection and noninterven-
tional postauthorisation studies based on secondary use of data.126 First, in 
case of postauthorisation studies with primary data collection, ‘for all col-
lected adverse events comprehensive and high quality information should 
be sought in a manner which allow for valid individual case safety reports 
to be reported within the appropriate timeframes’.126 These time frames are 
intended to allow manufacturers and authorities to take immediate action 
when needed to prevent serious adverse events occurring in other patients. 
However, this requires a clear workflow and an appropriate infrastructure. 
Second, in case of secondary use of data (e. g., medical chart reviews), the 
reporting of suspected adverse reactions in the form of individual case safety 
reports is not required; ‘reports of adverse events should be summarized as 
part of any interim safety analysis and in the final study report unless the 
protocol provides for different reporting’.126 The distinction between non-
interventional postauthorisation studies with primary data collection and 
noninterventional postauthorisation studies based on secondary use of data, 
and its consequences regarding pharmacovigilance, was not always interpret-
ed similarly between stakeholders in some of the registries in which we are 
involved. This has resulted in substantial registration burden (e.g. reporting 
within 24 hours of recording) under pressure from manufacturers.
Designing a solid plan for pharmacovigilance is part of setting up any 
patient registry. This plan needs to be consistent with national and inter-
national guidelines, and agreed upon by all stakeholders and the relevant 
medical-ethical bodies. Ideally, all safety information should be registered 
and reported by the clinician at the moment of occurrence.
It may be difficult to comprehensively collect safety information within 
a registry, while being dependent on the available data sources. It may be 
impossible to determine causality without involving the treating clinician. 
It is therefore crucial to have short communication lines with treating clini-
cians, and ensuring medical expertise in the study team is recommended. 
Alternatively, adverse event reporting can be outsourced to knowledgeable 
hospital personnel.
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Future prospects of registries
The number of patient registries will continue to rise in the near future.127 
Their importance was shown in many areas including general practice,128 
neurology,129,130 orthopedics,131,132 and oncology.133,134
Various initiatives exist that facilitate designing high-quality registries, 
such as the High-Value Health Care Project135 and the cross-border PAtient 
REgistries iNiTiative (PARENT) project. The PARENT project supports member 
states of the European Union with the implementation of interoperable pa-
tient registries and created a registry of registries available online.136
Several trends may influence the design of future patient registries. First, 
there will be a further evolution of data standards and an improvement in in-
teroperability of registries with electronic health records.137 Moreover, there 
is an increasing trend in setting up multi-institution and multicountry reg-
istries.138 Especially in rare diseases, multicountry registries are needed to 
include sufficient numbers of (comparable) patients. Finally, the content of 
registries will reflect important clinical developments (e.g. biobanking).139
Considering the unique value of and increasing demand for real-world 
evidence, we expect that patient registries will become the new standard 
alongside randomised controlled trials.
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Introduction
As more treatments become available (within and beyond treatment lines), 
traditional economic evaluations may not provide sufficient information, 
since these do not assess costs and effects of treatment strategies spanning 
multiple treatment lines and are not able to determine the optimal order (i.e. 
sequence) in which treatments should be provided. As a consequence, full 
disease models comprising multiple treatment lines are expected to increase 
in importance, but experience is scarce. Tosh et al called for a methodological 
framework for economic evaluations of sequential therapy for chronic con-
ditions, since they found that methods have not been consistently applied, 
which has led to varied estimates of cost-effectiveness and uncertainty in 
respect of the most appropriate analytic methods.140 Although guidelines for 
good modelling practices are available including the series commissioned by 
the ISPOR-SMDM Task Force,141 they are sometimes too brief to help researchers 
develop models that are valid and credible. 
This study provides practical recommendations in constructing a discrete 
event simulation (DES) model to support cost-effectiveness analyses of treat-
ment strategies spanning multiple treatment lines. Best practices derived 
from the ISPOR-SMDM Task Force and additional sources are cited, followed by 
a description of how these were implemented in our DES models to estimate 
the real-world cost-effectiveness of new treatments in metastatic renal cell 
carcinoma (mRCC) and multiple myeloma (MM). 
Case studies
Metastatic Renal Cell Carcinoma
115,200 patients were diagnosed with kidney cancer in Europe in 2012.18 Renal 
cell carcinoma represents 80% of all kidney cancers. Median overall survival 
(OS) of patients with advanced disease is 43, 27 and 8.8 months for patients 
with a favourable, intermediate or poor prognosis, respectively.55 Health out-
comes are influenced by prognostic factors.38
A number of first- and second-line targeted therapies (e.g. sunitinib, 
sorafenib and everolimus) for mRCC have been introduced since 2006.55 
These therapies improve health outcomes, such as progression-free survival 
(PFS) and OS.25,34,40,41,44,45 However, a Dutch population-based registry showed 
that almost half of the patients presenting with mRCC did not receive any 
targeted therapy.142 A DES model was developed to study the real-world cost-ef-
fectiveness of several treatment strategies applied in patients with mRCC 
comprising one or more sequentially administered drugs. Potential health 
outcomes and costs of hypothetical treatment scenarios were calculated by 
Abstract
Objective: Although full disease models comprising multiple treatment lines 
are increasing in importance, experience is scarce and while guidelines for 
good modelling practices are available, they are sometimes too brief. This 
study provides practical recommendations in constructing a discrete event 
simulation (DES) model to support real-world cost-effectiveness analyses 
(CEAs) of treatment strategies spanning multiple treatment lines.
Methods: Based on experiences with two DES models used in CEAs of treat-
ment strategies in cancer, we discuss how best practices, mainly derived 
from the ISPOR-SMDM Task Force, can best be implemented. Additional rec-
ommendations were provided wherever best practices were unavailable or 
not applicable.
Results: Modelling multiple treatment lines using a DES model and real-world 
data imposes several challenges. First, it is necessary to correct effectiveness 
and costs for patient characteristics and the effect of previous treatment. This 
could be addressed by including patient characteristics and the effectiveness 
of previous treatments as covariates in survival models. Second, when mod-
elling a heterogeneous population, valid extrapolation of survival outcomes 
beyond observation is required. This could be achieved by using multiple 
survival models. Third, the timing of competing events needs to be addressed 
appropriately. As recommended by the Task Force, one single survival model 
should be used together with a regression technique to determine event type.
Conclusions: Developing good-quality models comprising multiple treat-
ment lines requires guidance beyond the existing guidelines and practical 
recommendations are currently lacking. The guidance based on hands-on 
experience with two DES models can improve validity and credibility of future 
disease models and CEAs.
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patients have a large impact on the costs and effects of treatment. In order to 
incorporate individual patients and allow for variability between patients, 
DES models were developed to calculate the cost-effectiveness of various treat-
ment scenarios as recommended by the ISPOR-SMDM Task Force.149,150 DES 
models allow individual patients to have their own characteristics, such as 
age and health state, which may also change over time.151 
Furthermore, treatment of both mRCC and MM is characterised by sequen-
tially administered drugs. Instead of modelling single treatment options, a 
comparison of complete treatment strategies was needed. DES models can 
easily include the effect of previous therapies, in contrast to Markov models, 
which cannot incorporate history of patients without constructing a large 
amount of health states. Therefore, a DES model seemed a better choice for 
modelling treatment strategies spanning multiple treatment lines for mRCC 
and MM.149 Caro et al also argued that a DES provides an alternative, more 
natural, way to simulate clinical reality, whereas a Markov model requires all 
aspects of a disease including patient and disease characteristics and treat-
ment history to be captured in a health state.141 Although various methods 
exist which can include memory in Markov models (e.g. tracker variables), 
the required number of tracking variables would have been quite large in a 
model of sequential therapies. 
In addition, data from the mRCC registry and MM registry revealed that 
some patients died very soon after treatment was initiated while some pa-
tients survived much longer. In a microsimulation Markov model, patients 
can only experience one transition per cycle and this would require many 
cycles with a small cycle length, which favoured a DES model allowing to in-
clude time continuously.
The DES models for mRCC and MM comprised entities (i.e. patients), at-
tributes assigned to the entities, and events. Attributes were obtained from 
patient-level data from either the mRCC or MM registry by selecting clinical 
factors, biochemical and haematologic factors known to impact mRCC or MM 
outcomes, respectively. Events were either second-line treatment, third-line 
treatment (in the MM model only) or death. The time horizon of the models 
spanned the patients’ lifetime. The structures of the mRCC and MM model 
are presented in Figures 7.1 and 7.2. Characteristics and sources for input pa-
rameters of both models are presented in Table 7.1.
assuming that all treatment-eligible patients were treated according to a par-
ticular treatment strategy.
Multiple myeloma
In 2012, 38,900 patients were diagnosed with MM in Europe.18 MM is a hetero-
geneous disease with a wide variation in OS.143,144 Depending on the stage of 
the disease, median OS ranges from 29–62 months.145 
Like for many cancers, treatment of MM is characterised by sequential 
treatment lines aiming to prolong PFS and OS. In the past decade, several 
treatment options have become available including the thalidomide-, borte-
zomib- and lenalidomide-based regimens. While most of these treatments 
were first recommended as treatment for third or subsequent lines, they are 
now recommended as induction therapy. Health outcomes are also influ-
enced by prognostic factors, mainly patient and disease characteristics.146,147 A 
DES model was developed to study the real-world cost-effectiveness of sequen-
tial use of novel agents for elderly MM patients.116 Furthermore, by studying 
treatment sequences, we aimed to identify the optimal treatment strategy.
Comprehensive data on patient and disease characteristics of patients with 
mRCC and MM, as well as data on treatments and outcomes were collected 
in two population-based registries, the mRCC registry (PERCEPTION) and the 
MM registry (PHAROS).92,148
Model structure and design
Best practice:
 “ If, [...], a valid representation of any aspect of the decision problem would lead 
to an unmanageable number of states, then an individual-level state-transition 
model is recommended”.149 
 “ DES is an attractive option in nonconstrained models [...] when individual 
pathways through the model are influenced by multiple characteristics of the 
entity; and when recording individual entity experience is desirable”.150 
The first stage in developing a decision model involves choosing an appro-
priate model structure. According to the best practice commissioned by the 
ISPOR-SMDM Task Force, DES is the preferred modelling method if it is difficult 
to model the disease course of the average patient, and when the course of 
the disease, including its treatment, would require too many health states. 
As stated in the previous paragraph, patients with mRCC and MM in daily 
practice represent a heterogeneous population, and characteristics of these 
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Figure 7.1 Model structure – metastatic renal cell carcinoma model
Input parameters Model structure Outcomes
Loglogistic model with the following 
covariates:
age, (sex), histology, prior nephrectomy, nr 
of metastatic sites, WHO performance 
status, (lung metastases), liver metastases, 
bone metastases, (brain metastases), 
(haemoglobin), neutrophil count, (platelet 
count), albumin, (corrected serum calcium), 
alkaline phosphatase, (lactate 
dehydrogenase), first-line treatment 
Time to event 1  
(TTE 1)
(until 12 months)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations, 
outpatient visits and medical imaging 
services
Effects: Life years and quality-adjusted life 
years
Exponential model with the following 
covariates:
age, (sex), (histology), (prior nephrectomy), 
(nr of metastatic sites), (WHO performance 
status), (lung metastases), (liver 
metastases), bone metastases, (brain 
metastases), (haemoglobin), (neutrophil 
count), (platelet count), (albumin), 
(corrected serum calcium), (alkaline 
phosphatase), (lactate dehydrogenase), 
first-line treatment 
Time to event 1  
(TTE 1)
(> 12 months)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations. 
outpatient visits and medical imaging 
services
Effects: Life years and quality-adjusted life 
years
Logistic regression with the following 
covariates:
age, (sex), (histology), (prior nephrectomy), 
(nr of metastatic sites), (WHO performance 
status), (lung metastases), (liver 
metastases), (bone metastases), (brain 
metastases), (haemoglobin), (neutrophil 
count), platelet count, albumin, (corrected 
serum calcium), (alkaline phosphatase), 
(lactate dehydrogenase), (first-line 
treatment), TTE 1
Type of event 1 
(second-line 
treatment or 
death)
Weibull model with the following 
covariates:
(age), sex, (histology), (prior nephrectomy), 
nr of metastatic sites, (WHO performance 
status), (lung metastases), liver metastases, 
bone metastases, brain metastases, 
(haemoglobin), (neutrophil count), platelet 
count, albumin, (corrected serum calcium), 
(alkaline phosphatase), (lactate 
dehydrogenase), (first-line treatment),  
TTE 1, second-line treatment
Time to event 2 
(TTE 2)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations. 
outpatient visits and medical imaging 
services
Effects: Life years and quality-adjusted life 
years
Type of event 2 
(death)
Note: Covariates between brackets were 
considered for inclusion in the survival models 
and logistic regression model, but excluded 
through backward and/or forward selection.
Time-to-event 
Best practice:
 “ It is [...] very important to justify the particular extrapolation approach chosen, 
to demonstrate that extrapolation has been undertaken appropriately and so 
that decision makers can be confident in the results of the associated economic 
analysis”.152 
As survival data is often not fully observed, extrapolation beyond the observa-
tion period is needed. The method to extrapolate this data should be chosen 
in a systematic way in order to ensure valid and clinical plausible extrapola-
tion. Time-to-event data derived from either the mRCC or MM registry were 
extrapolated using a range of parametric models (Exponential, Weibull, Log-
logistic, Log-normal, Gamma and Gompertz). These models were assessed 
for their goodness of fit to the data using the Akaike Information Criterion 
(AIC) and Bayesian Information Criterion (BIC). Furthermore, each parametric 
function was assessed graphically as recommended by Latimer.152
For the mRCC model, a loglogistic distribution best fitted the time to 
the first event (TTE1) and the time to the second event (TTE2). Nevertheless, 
visual inspection showed that TTE1 was underestimated after 12 months. 
Additionally, as a consequence of the functional form of this distribution, 
mean TTE1 was highly influenced by a small proportion of the population with 
very long TTE1 estimates. Therefore, an alternative model (i.e. exponential) 
was chosen for TTE1 after 12 months, based on the AIC and BIC. This approach 
was also conducted by Leunis et al, who specified different survival models 
for different time periods.153 For the MM model, a Weibull distribution best 
fitted the time to the first, second and third event. A Weibull distribution 
had the best goodness of fit based on the AIC/BIC and was also considered 
appropriate based on visual inspection.
Competing events
Best practice:
 “ Where feasible, when estimating times to competing events, methods of 
analysis that estimate the timing of competing events jointly are preferred to 
approaches that estimate separate time to event curves for each event”.150 
In survival analysis, competing events are present when an individual is at risk 
of several different types of events but can have only one event at a time.150,154 
For the mRCC and MM models, time to next treatment was calculated from 
patient level data. Since some patients died before a new treatment was in-
itiated, next treatment and death were competing events. Generally, there 
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Figure 7.2 Model structure – multiple myeloma model
Input parameters Model structure Outcomes
Weibull model with the following 
covariates:
age, sex, WHO performance status, 
haemoglobin, platelet count, albumin, 
serum calcium, other haematological 
malignancies, study treatment, first-line 
treatment
Time to event 1  
(TTE 1)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations 
and outpatient visits
Effects: Life years and quality-adjusted life 
years
Logistic regression with the following 
covariates:
age, WHO performance status, first-line 
treatment, TTE 1
Type of event 1 
(second-line 
treatment or 
death)
Weibull model with the following 
covariates:
haemoglobin, albumin, lactate 
dehydrogenase, creatinine, TTE 1, second-
line treatment
Time to event 2  
(TTE 2)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations 
and outpatient visits
Effects: Life years and quality-adjusted life 
years
Logistic regression with the following 
covariates:
age, WHO performance status, 
haemoglobin, TTE 1, second-line treatment, 
TTE 2
Type of event 2  
(third-line 
treatment or 
death)
Weibull model with the following 
covariates:
age, WHO performance status, first-line 
treatment, TTE 1
Time to event 3  
(TTE 3)
Costs: Costs of therapy and resource 
utilisation costs, such as hospitalisations 
and outpatient visits
Effects: Life years and quality-adjusted life 
years
Type of event 3 
(death)
are two approaches to analyse competing events.150 The first approach is to 
perform separate survival analysis for each event where the other event is 
treated as censored. Then, for each event a time is sampled, with the patient 
moving to the event with the shortest time. The second approach is to perform 
one single survival analysis but make no distinction between the competing 
events; a separate sampling process in the model determines which event a 
patient will experience.
The second approach was adopted in the mRCC and MM models, as recom-
mended by the ISPOR-SMDM Task Force.150 Whereas survival analysis assumes 
that censoring is non-informative, we hypothesised that death was mostly 
treatment-related and, as a consequence, that censoring the patients who 
died might have altered the probability of experiencing a next treatment. 
Furthermore, the graphic presentation and interpretation of the single sur-
vival analysis are straightforward whereas the interpretation of the two sep-
arate survival curves is less intuitive. 
While the second approach was adopted in the mRCC and MM models, we 
applied the first approach to validate our results and hypothesis. Interestingly, 
both methods yielded very similar results in the models. Since there is no dif-
ference between the two methods in terms of ease or speed (i.e. both methods 
require the estimation of two statistical models), we decided to align with 
current guidelines.
Assigning patient and disease characteristics
Best practice:
 “ The expected costs and benefits across the sampled group [...] provide an 
unbiased estimate provided that a sufficiently large sample is simulated and 
any covariance between the different patient characteristics is correctly taken 
into account”.155 
While the mRCC and MM registries provided patient level data, simulation of 
the population including patient and disease characteristics was needed to 
study what would have happened to a patient if that patient had been treated 
differently. No recommendations were made by the ISPOR-SMDM Task Force 
about simulating a population. However, Davis et al emphasises the need to 
account for the covariance between patient and disease characteristics.155
In the mRCC and MM models, patient and disease characteristics were 
simulated similarly; random numbers were drawn from predefined distri-
butions. These distributions were derived from patient-level data from the 
mRCC registry or the MM registry, respectively.
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the effectiveness of all treatment sequences. Recommendations to account 
for previous therapies in full disease models do not exist.
Therefore, we chose to correct for the effectiveness of previous therapies by 
including the TTE of the previous line in estimating the TTE of the subsequent 
therapy. For example, TTE1 was included in the parametric survival model 
estimating TTE2. This allowed us to obtain the effectiveness of second-line 
treatment accounting for the effectiveness of first-line treatment given the 
patient’s characteristics. 
In the MM model TTE1 had a significant association with TTE2 as well as with 
the type of event. The coefficient corresponding to TTE1 was not treatment 
specific, i.e. a TTE1 of 2 months obtained by treatment with thalidomide is 
similar to a TTE1 of 2 months obtained by treatment with bortezomib. Since 
adding type of treatment to the model did not improve its explanatory value, 
Table 7.1 Model characteristics and sources for input parameters of the DES models
Metastatic renal cell carcinoma Multiple myeloma
Model characteristics
  Aim
  Perspective
  Patients
  Outcomes
  Model type
  Time horizon
  Parametric distribution
  Disease pathways (base-case)
  Disease pathways (scenarios)
  Sensitivity analysis
Sources for input parameters
  Data
  (Patient and disease 
characteristics, treatment 
effects and patterns,  
healthcare utilisation)
  Unit prices
  Discount rates
  Utilities
To model real-world cost-effectiveness 
for patients with metastatic renal cell 
carcinoma
Healthcare
Patients with metastatic renal cell 
carcinoma
Effects (OS and QALYs) and costs (€)
Discrete event simulation
Lifetime
Loglogistic and exponential 
distribution (line one) and loglogistic 
distribution (line two)
Real-world treatment including  
two subsequent lines
Hypothetical pathways including  
two lines of treatment
  No targeted therapy
  Sunitinib - Sorafenib
  Sunitinib - Everolimus
  Sunitinib - Other
Univariate and probabilistic sensitivity 
analyses (1,000 simulations)
Real-world data from the mRCC 
registry (PERCEPTION)
Dutch reference price lists  
and literature
Dutch guidelines  
(effects 1.5%, costs 4%)
Literature
To model real-world cost-effectiveness 
for elderly patients with multiple 
myeloma
Healthcare
Elderly patients with multiple 
myeloma
Effects (OS and QALYs) and costs (€)
Discrete event simulation
Lifetime
Weibull distribution for all lines
Real-world treatment including three 
subsequent lines
Hypothetical pathways including 
three lines of treatment
  MP-thalidomide-bortezomib
  MP-thalidomide-lenalidomide
  Thalidomide-bortezomib- 
lenalidomide
  Thalidomide-lenalidomide- 
bortezomib
Univariate and probabilistic sensitivity 
analyses (1,000 simulations)
Real-world data from the MM registry 
(PHAROS)
Dutch reference price lists  
and literature
Dutch guidelines  
(effects 1.5%, costs 4%)
Cross-sectional study
Abbreviations: OS, overall survival; QALYs, quality-adjusted life years; MP, melphalan prednison.
To account for the covariance between characteristics, different distribu-
tions were used for patients with a different prognosis. For example, in the 
mRCC model, first WHO performance status before treatment was simulated 
by drawing random numbers from a predefined distribution as obtained 
from the PERCEPTION registry. In simulating additional patient and disease 
characteristics; for each characteristic, a different distribution was used for 
patients with a WHO performance status of 0-1, and for patients with a WHO 
performance status of 2-4. This method was adopted to increase the likelihood 
that the combination of patient and disease characteristics per individual 
matched the original data.
Besides patient and disease characteristics, treatment needed to be as-
signed to each patient. Two multinomial logistic regression models (i.e. one 
to assign first-line treatment and one to assign second-line treatment) were 
used, including patient and disease characteristics as well as treatment his-
tory as covariates, to assign real-world treatment patterns to the patients in 
the mRCC model. This process guaranteed that the patients who received 
the treatments in the model were similar to the patients who received these 
treatments in daily clinical practice. This method was not feasible in the MM 
model, since some novel agents (i.e. bortezomib and lenalidomide) were 
prescribed to very few patients during the follow-up period. These numbers 
were too small to run a multinomial logistic regression model. Treatment in 
the MM model was therefore simulated in the same way as patient and disease 
characteristics; the probability of receiving a certain treatment was based 
on the distribution of treatments as observed in daily clinical practice using 
different distributions for patients with a different WHO performance status. 
Having simulated patient and disease characteristics, and treatment for 
all patients, the patient’s time to an event (either TTE1, TTE2 and TTE3) was 
estimated taking these characteristics into account. 
Accounting for previous therapies
The mRCC and MM model aimed to calculate the cost-effectiveness of sever-
al treatment strategies comprising one or more sequentially administered 
treatments. Therefore, it was important to correct for the effectiveness of pre-
vious treatments when estimating the effectiveness of second- and third-line 
treatments. In addition, the effectiveness of subsequent therapies should be 
taken into account when estimating overall survival of first- and second-line 
treatments. Ideally, the effectiveness of, for example, bortezomib after tha-
lidomide is solely based on patients treated with thalidomide followed by 
treatment with bortezomib. Although the registries included a substantial 
number of patients, these were not adequate to provide a stable estimate of 
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While a Markov model with a fixed cycle length provides a convenient struc-
ture to discount future costs and effects, discounting future costs and effects 
in a DES model including treatment strategies comprising one or more se-
quentially administered treatments is more challenging. First, a DES model 
produces individual TTE estimates, and as a consequence LYs and QALYs need 
to be discounted for each patient separately. Furthermore, different utility 
values were assigned to the treatment lines in the mRCC model and there-
fore, total QALYs needed to be discounted for each treatment line separately. 
Second, unit costs per month differed between treatment lines. For example, 
a patient with MM treated with melphalan-prednisone, followed by a borte-
zomib-based regimen, and then followed by a lenalidomide-based regimen, 
incurs different hospital and drug costs per month during first-, second- and 
third-line treatment. As a consequence, total costs need to be discounted for 
each treatment line separately.
Since total costs per treatment line were obtained by multiplying unit 
costs per month by the corresponding TTE, it was decided to discount TTE 
and multiply unit costs per month by the discounted TTE. The same approach 
was adopted to discount future QALYs in the mRCC model. While discount-
ing time was a convenient approach in our models, this is not possible for 
DES models where costs are obtained from multivariable regression models. 
Since these models include undiscounted time as an explanatory variable, 
it is not possible to calculate and discount the total costs per line. Instead, 
costs should be calculated and discounted for different time frames, e.g. per 
year, which adds both complexity and computational burden to the model.
Probabilistic sensitivity analysis
Best practice:
 “ The inner loop evaluates the outcomes across the simulated population for the 
given parameter values, and the outer loop samples those parameter values to 
reflect uncertainty in the model inputs. In a cohort-level model, only the outer 
loop is required, thus PSA [probabilistic sensitivity analysis] computation time 
for a cohort-level model is likely to be lower than for an equivalent patient-level 
model”.155 
In other words, the inner loop aims to calculate costs and effects for one simu-
lated population (with constant patient and disease characteristics), whereas 
the outer loop changes all input parameters according to their probability 
distributions to examine the impact of the joint uncertainty across all input 
parameters. In the model for mRCC and MM, the values of input parameters 
varied across simulations. Due to the probabilistic structure of the models, 
we believe this method can be used to correct for the effectiveness of previous 
therapies. 
Costs and outcomes
Best practice:
 “ Costs and quality of life weights are attached to events and time spent with 
different health conditions to estimate long term costs and health outcomes”.150 
Total life years (i.e. OS) were calculated by summing TTE1, TTE2 (and TTE3). 
Besides total life years, total quality-adjusted life years (QALYs) were calcu-
lated by weighting LYs for the quality of life during these years using utility 
weights. In the mRCC model, various utility weights were used for patients 
with a favourable or intermediate prognosis, and patients with a poor prog-
nosis before either first-line therapy or second-line therapy since their qual-
ity of life was expected to differ. Treatment-specific (including the effect of 
adverse events) or utility weights for different risk groups (or disease stages) 
were unavailable for elderly patients with MM. Therefore, an average utility 
weight was used in the MM model, obtained from a Dutch population-based 
cross-sectional study in MM. 
Based on real-world data, average treatment-specific resource use per 
month was obtained in order to calculate total costs per month, e.g. the num-
ber of outpatient visits per month for mRCC patients treated with sunitin-
ib or the number of hospital days per month for MM patients treated with 
thalidomide. Average total costs per patient were calculated by multiplying 
treatment specific total costs per month with TTE.
Discounting
Best practice:
 “ A (common) real discount rate should be applied to future costs and, when 
used in a cost-effectiveness analysis, to future outcomes”.156 
 “ Discounting methods should accord with general guidelines for economic 
evaluation”.157 
Future effects and costs should be converted to their present value in order 
to account for factors such as time preferences and uncertainty. As recom-
mended, future costs and effects in the mRCC and MM model were discounted 
to their present value using discount rates based on the Dutch guideline for 
pharmacoeconomic research.98
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it possible to derive more valid estimates of costs and effectiveness. Second, 
using multiple survival models per treatment line ensures valid extrapola-
tion of survival outcomes beyond observation for a heterogeneous popula-
tion. Third, as recommended by the ISPOR-SMDM Task Force, when competing 
events exist, one single survival model should be used together with a regres-
sion technique to determine which event type will occur.
Although the mRCC and MM models enabled the estimation of the cost-ef-
fectiveness of several treatment strategies comprising one or more sequential-
ly administered drugs,116,142 these models could have been improved further. 
Based on our experiences, the following recommendations can be made to 
improve future models of treatment strategies spanning multiple treatment 
lines. First, in our models, patient and disease characteristics were simulat-
ed by drawing random numbers from predefined distributions. Covariance 
between characteristics was accounted for by using different distributions 
for patients with a different prognosis. This method does, however, not guar-
antee valid relationships between all patient and disease characteristics. 
Multivariable regression models could overcome this problem, as illustrat-
ed by Goossens et al in a study on propensity score matching.65 This method 
generated patient and disease characteristics based on a set of regression 
models; one for each characteristic. While the first characteristic was defined 
using a predefined distribution, all other characteristics were simulated using 
regression models that included as covariates all of the characteristics already 
assigned to the patient; this preserved the covariance between the different 
characteristics that was observed in the original data. 
Second, in the mRCC and MM models, total costs per patient were derived 
by multiplying mean monthly costs (per treatment) by the individual pa-
tient’s time to an event. However, the distribution of cost data is skewed, 
which means that a limited number of patients is responsible for a high 
proportion of the costs.3 As a consequence, by multiplying mean monthly 
by the individual patient’s time to an event, total costs per patient might 
be overestimated. Again, multivariable regression models could solve this 
problem. Besides type of treatment and time to event, these models could 
include patient and disease characteristics as covariates to estimate total costs 
per patient. In this way, overestimation of costs will be prevented. 
This practical guide is a first attempt to document how best practices in 
modelling, derived from the ISPOR-SMDM Task Force and additional sources, 
can be interpreted and implemented. Experiences in implementing best prac-
tices were based on two studies only; these studies had rather similar aims, 
they both focussed on treatment strategies in cancer, and the available data 
was comparable. Although treatment strategies spanning multiple treatment 
the values of input parameters could also vary within one simulation. For 
example, an inpatient day could cost € 402 while calculating costs of treat-
ment scenario A and € 646 while calculating costs of treatment scenario B. 
Furthermore, patient and disease characteristics could vary within one sim-
ulation. For instance, 26% of the population could be assigned a WHO perfor-
mance status of 2-4 while calculating costs and effects of treatment scenario A 
and 35% could be assigned a WHO performance status of 2-4 while calculating 
costs and effects of treatment scenario B. However, in each single simulation, 
parameters that are not related to a certain treatment scenario should have 
the same values in all treatment scenarios. This approach reduces the ‘noise’ 
or random variation that is introduced by setting unit costs and patient and 
disease characteristics twice in each simulation, once for Scenario A and once 
again for scenario B. It also increases the model’s efficiency, since fewer simu-
lations are needed to get a stable estimate of the incremental cost-effective-
ness ratio (ICER). 
Apart from probabilistic sensitivity analysis, univariate sensitivity analy-
ses can be performed to examine the impact of alternative input parameters 
on the ICERs as illustrated in the mRCC model. 
Discussion
Economic evaluations mostly require a lifetime time horizon in order to 
capture all health and economic consequences.3 Such a time horizon makes 
a full disease model including treatment strategies spanning multiple treat-
ment lines inevitable. However, the development of the full disease models 
for mRCC and MM revealed several challenges, including the optimal ways 
to correct effectiveness and costs for patient characteristics (including the 
effectiveness of previous treatments), extrapolate survival outcomes beyond 
observation for a heterogeneous patient population, and estimate the timing 
of competing events. Best practices, including solutions to these challenges, 
were not always found in the literature. Also, existing disease models did 
not often provide suitable solutions to these challenges since these models 
differed in aim, characteristics of the disease or treatment varied and com-
prehensive data was unavailable. Therefore, guidance beyond the existing 
guidelines and practical recommendations are necessary to improve validity 
and credibility of future disease models.
Based on hands on experiences with two DES models the following recom-
mendations can be made in constructing a DES model to support real-world 
cost-effectiveness analyses of treatment strategies spanning multiple treat-
ment lines. First, the inclusion of patient characteristics (including the ef-
fectiveness of previous treatments) as covariates in survival models, makes 
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lines are common in other disease areas (e.g. rheumatoid arthritis), we rec-
ommend further research to be done to ascertain whether this practical guide 
helps others with different goals working in other disease areas with different 
data sources. We therefore recommend them to share their findings from 
constructing and using a DES model including treatment strategies spanning 
multiple treatment lines. 
It should be clear that a DES model is not necessarily the best choice when 
constructing a full disease model. While a DES model was a feasible option to 
study the cost-effectiveness of several treatment strategies comprising one or 
more sequentially administered drugs for patients with mRCC and MM, disad-
vantages of this model structure may include the type and amount of required 
data as well as the time needed for model building and simulation.158 Data 
for the mRCC and MM model were derived from population based registries. 
In these registries comprehensive data were collected on patient and disease 
characteristics. In addition, compared to randomised trials, both registries 
had a long follow-up duration. This enabled us to study the impact of multiple 
treatment lines on overall survival. If comprehensive data is not available, a 
different model structure might be more appropriate. Additionally, the time 
needed for model building and simulation should be balanced against the 
benefits of modelling patients individually in a DES model.
Conclusions
In order to secure the validity and credibility of models, guidelines were de-
veloped summarising best practices in modelling.149,150,152,155-157 Unfortunately, 
these guidelines are sometimes too brief to be used in constructing full dis-
ease models comprising multiple treatment line. Extra instruction is there-
fore needed. This study aimed to help in filling this gap by providing practical 
guidance on constructing a DES model. Specifically, it explores how to apply 
the guidelines by describing how they were actually implemented in two 
DES models, and it provides additional recommendations, which may help 
to further improve the validity of full disease models.
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Farmaceutische Hulp] concluded that the cost-effectiveness of these drugs 
was insufficiently substantiated.159,160 
The manufacturer of sunitinib was exempted from providing evidence 
supporting the cost-effectiveness of the drug.161 The manufacturer of paz-
opanib was also exempted from providing evidence on cost-effectiveness, 
because the therapeutic value of pazopanib was found to be similar to the 
therapeutic value of sunitinib, which was already added to the Medicine 
Reimbursement System [in Dutch: Geneesmiddelenvergoedingssysteem, 
GVS].162 Despite the absence of (valid) estimates of the cost-effectiveness of 
the drugs for mRCC, all are reimbursed in the Netherlands. Bevacizumab 
and temsirolimus were initially funded on the condition that data regarding 
appropriate drug use, effectiveness and cost-effectiveness in clinical practice 
were to be collected.
In contrast to the Netherlands, the UK National Institute for Health and 
Care Excellence (NICE) did not recommend bevacizumab and temsirolimus 
as first-line treatment options for patients with advanced and/ or metastatic 
renal cell carcinoma. Results from the Assessment Group model showed an 
incremental cost-effectiveness ratio (ICER) of £171,301 per quality-adjusted life 
year (QALY) gained for bevacizumab plus interferon alfa (IFN-α) compared 
with IFN-α alone, and an ICER of £94,385 per QALY gained for temsirolimus 
compared with IFN-α. NICE concluded that these therapies would not be a 
cost-effective use of National Health Service (NHS) resources.163 
Similar to the Netherlands, sunitinib is recommended by NICE as a pos-
sible first-line treatment, based on an assessment of the drug’s effectiveness 
and cost-effectiveness. Results from the Assessment Group model showed an 
ICER of £104,715 per QALY gained for sunitinib compared with IFN-α (including 
the agreed patient access scheme of the first cycle of sunitinib being free to 
the NHS). Since sunitinib met the criteria for being a life-extending end-of-
life treatment, the appraisal committee concluded that sunitinib could be 
recommended as a cost-effectiveness use of NHS resources.164
Decisions about reimbursement guide the use of drugs in clinical prac-
tice, and this ultimately determines a drug’s real-world value.4 To assess a 
drug’s real-world value, manufacturers of expensive inpatient drugs in the 
Netherlands were obliged to collect data regarding appropriate drug use, 
effectiveness and cost-effectiveness in clinical practice, during a four-year 
period of conditional funding. A population-based registry (i.e. PERCEPTION) 
was, therefore, created to include patients with mRCC. Despite the evidence 
of effectiveness and the indications of cost-effectiveness of bevacizumab and 
temsirolimus in the Netherlands, the PERCEPTION renal cell cancer showed 
that few patients with mRCC were treated with one of these drugs in Dutch 
The growing pressure on healthcare budgets increases the need to make 
choices between the reimbursement of healthcare procedures, services and 
programs.3 These choices are made using many criteria. Two of these criteria 
are effectiveness and cost-effectiveness.4 However, information about effec-
tiveness and cost-effectiveness is often associated with uncertainty at the time 
a new procedure, service or program is introduced. 
The effectiveness of drugs is often demonstrated in large clinical trials 
(strictly speaking, the efficacy of drugs is demonstrated in clinical trials, i.e. the 
effect of drugs under ideal circumstance). Data from these trials are often used 
to estimate a drug’s cost-effectiveness. However, as with other procedures, 
services and programs, the effectiveness and cost-effectiveness of new drugs 
are uncertain at the time they are introduced. As a consequence, conditional 
funding was implemented in the Netherlands in 2006 to guarantee equal and 
early access to expensive drugs, while data about uptake, use, and outcomes in 
clinical practice were to be collected. This funding policy also applied to two 
expensive inpatient drugs for metastatic renal cell carcinoma (mRCC), that 
is, bevacizumab and temsirolimus. The collection and analyses of data about 
uptake, use and outcomes of these new drugs for mRCC in clinical practice 
form the focus of the present thesis and this final chapter shows how this 
evidence contributed to the decision about future funding of these drugs. 
Additionally, this chapter illustrates the possibilities and impossibilities (or 
limitations) of evaluating uptake, use and outcomes in clinical practice, and 
reflects on the difficulties of making decisions about future funding (based 
on evidence from clinical practice). 
This chapter is written along the lines of statements. 
Positive decisions about reimbursement do  
not directly translate into uptake and use in  
clinical practice
As outlined in chapter 1, randomised controlled trials (RCTs) demonstrat-
ed that targeted therapies for mRCC improve progression-free surviv-
al.25-27,29,40,44,46,47 As a consequence of these findings, several targeted therapies 
for mRCC have entered the market since 2006, such as the first-line therapies 
sunitinib, temsirolimus, bevacizumab and pazopanib, and the second-line 
therapies sorafenib, everolimus and axitinib. 
Indications of the cost-effectiveness of bevacizumab and temsirolimus 
were provided to the Dutch National Health Care Institute by the manufac-
turers of the drugs in line with the then prevailing policy for expensive drugs. 
However, the Dutch Committee of Pharmaceutical Aid [in Dutch: Commissie 
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the pivotal phase III trial of sunitinib, such as patients with a worse perfor-
mance status, brain metastases or a non-clear-cell subtype.
The relative effectiveness and cost-effectiveness of sunitinib versus oth-
er active treatments could not (reliably) be evaluated. In the pivotal phase 
III clinical trial, sunitinib was compared with IFN-α. Since sunitinib largely 
replaced IFN-α as first-line standard of care, a comparison between the two 
could not be made. Also a reliable comparison with other active treatments, 
such as bevacizumab plus IFN-α and pazopanib, could not be made, due to the 
small number of patients treated with these drugs. Nevertheless, since many 
treatment-eligible patients did not receive sunitinib (or any other targeted 
therapy) in clinical practice, a comparison between sunitinib and no treat-
ment with targeted therapy could be made. Compared to a scenario in which 
none of the patients receives a targeted therapy, clinical practice, which is 
dominated by treatment with sunitinib, results in an ICER of € 105,011 per QALY 
gained. As discussed in chapter 5, health can be gained if more treatment-eligi-
ble patients with mRCC receive targeted therapies (like sunitinib). However, 
the ICER is far beyond the upper limit of the cost-effectiveness threshold of 
€ 80,000 per QALY, as proposed by the Dutch Council for Public Health.166
Patient registries can provide important information 
about uptake and use in clinical practice
As illustrated with the PERCEPTION renal cell cancer registry, patient registries 
can provide important information about uptake and use of new therapies in 
clinical practice. If data on the use of new therapies in different time periods 
are collected, it is possible to see how rapidly their use increases after new 
(clinical) guidelines are published. Additionally, if data on patient and disease 
characteristics are captured in the registry, registries can provide insight into 
the use of therapies during end of life or in patient subgroups. For example, 
the PERCEPTION registry showed that targeted therapies are frequently used 
in patients with a non-clear cell subtype, even though the evidence base for 
targeted therapies in this subgroup is very limited. This information enables 
discussions about possible ineffective and/or unnecessary care. Lastly, if a reg-
istry is disease-oriented, it can provide additional information, for example 
on the frequency of untreated patients and how often these patients would 
have been eligible for treatment. This information can be used to study pos-
sible variation in the use of (new) therapies within or between hospitals, and 
facilitate discussions if therapies are used to their full potential.
Besides questions about uptake and use of new therapies in clinical prac-
tice, additional research questions can be answered using data from patient 
registries, especially registries that are disease-oriented. For example, in 
clinical practice. Most patients were treated with sunitinib; this targeted ther-
apy has largely replaced IFN-α as first-line standard of care in the Netherlands. 
However, as discussed in chapter 2, many treatment-eligible patients did not 
receive sunitinib (or any other targeted therapy) in clinical practice. Since 
bevacizumab, temsirolimus and sunitinib are all recommended in Dutch 
clinical guidelines and reimbursed in the Netherlands, other factors must 
explain the low uptake and use. Positive decisions about reimbursement, 
thus, do not directly translate into uptake and use of new cancer drugs in 
clinical practice, as was stated before by Jönsson et al.4
Also in the United Kingdom (UK), the actual use of cancer drugs with en-
dorsements from NICE is rather low.165 For example, one in three patients with 
mRCC eligible for either sunitinib or pazopanib did not receive the drug.50 
Sufficient patient numbers are needed to provide 
evidence on outcomes in clinical practice 
Although a drug’s effectiveness and cost-effectiveness (only for certain types 
of drugs) are assessed at the time the drug is introduced, evidence on out-
comes in clinical practice are relevant in order to assess a drug’s real-world 
value. Additionally, these outcomes might be able to reduce the uncertainty 
about a drug’s effectiveness and cost-effectiveness. Information on outcomes 
in clinical practice was required for bevacizumab and temsirolimus in ac-
cordance with the Dutch policy for expensive inpatient drugs. However, little 
evidence became available during the four years of conditional funding, be-
cause only a few patients were treated with bevacizumab or temsirolimus in 
clinical practice. As a consequence, no assessment took place about the drugs’ 
real-world values, given the drugs’ limited budget impact for this indication. 
The PERCEPTION renal cell cancer registry was disease-oriented, thereby 
making it possible to assess the real-world (cost-)effectiveness of other drugs, 
such as sunitinib. A reassessment of the effectiveness and cost-effectiveness 
of sunitinib in clinical practice was not required by the Dutch National 
Health Care Institute, since this only applied to expensive inpatient drugs. 
Nevertheless, the PERCEPTION registry provided evidence on outcomes of 
sunitinib in clinical practice. As shown in chapter 2, median overall survival 
(OS) of patients treated with sunitinib in Dutch clinical practice was much 
shorter than the OS of patients treated with sunitinib in the pivotal phase III 
clinical trial. In clinical practice, the patient population was heterogeneous, 
whereas the outcomes of the clinical trial were based on a homogeneous and 
relatively young and healthy population (due to strict in- and exclusion crite-
ria). Chapter 2 also provides important insight into the outcomes of sunitinib 
in subgroups, for example in patients who were not eligible to participate in 
138 139
With instrumental variable methods, the problem of selection on unobserved 
confounders is addressed by an instrumental variable, which is correlated 
with the treatment but only correlated with the outcome through its effect 
on treatment.168 In practice, it might be difficult to find such a variable, be-
cause treatment choice often depends on a patient’s prognosis, which also 
influences the outcome of treatment.
A second reason why patient registries are seldom able to assess the rela-
tive effectiveness and cost-effectiveness of a drug is the difficulty to include 
the minimum number of patients needed to detect true and clinically impor-
tant differences between treatments. In chapter 3, the relatively small sample 
(i.e. 74 patients underwent cytoreductive nephrectomy prior to sunitinib) 
resulted in fairly wide confidence intervals for the hazard ratios for cytore-
ductive nephrectomy. In chapter 5 (about real-world cost-effectiveness), the 
cost-effectiveness of first-line sunitinib compared to first-line pazopanib (or 
bevacizumab plus IFN-α) could not be estimated, while this would have been 
relevant because these therapies are both recommended for mRCC patients 
with a favourable or intermediate prognosis. Pazopanib has only been rec-
ommended since 2010, which (partly) explains why an increase in its use 
was only seen from 2012. Since data collection for the PERCEPTION registry 
stopped at the end of 2013, only limited data were available on patients treated 
with pazopanib. Nevertheless, we expect the number of patients treated with 
first-line pazopanib to rise, given the results of a recent study that shows that 
pazopanib has a more favourable safety and quality-of-life profile.88 Although 
sunitinib and pazopanib (and bevacizumab plus IFN-α) are both recommend-
ed for the same patient group, we expect the problem of insufficient patient 
numbers to grow in the near future, since new therapies often target small 
patient subgroups. 
Lastly, observational studies are seldom able to assess drug interactions, 
where the effectiveness of a second-line therapy depends on the type of first-
line therapy. The demand for such evidence increases with the advent of tar-
geted agents intended for various lines of therapy. In chapter 5, a patient level 
simulation model was built, and time from diagnosis to second-line therapy 
(either obtained by first-line sunitinib or first-line bevacizumab plus IFN-α 
[the latter therapy was not evaluated in this thesis]) was taken into account 
when estimating the effectiveness of second-line therapy. In this way, the effec-
tiveness of previous therapy was considered. However, this method assumes 
that the effectiveness of second-line therapy is not influenced by the type of 
previous therapy. This assumption most likely does not hold; for example, the 
effect of second-line sorafenib has been demonstrated in patients treated with 
first-line cytokines (e.g. IFN-α). Whether the effect of second-line sorafenib 
chapter 3 large variation in clinical practice was observed in the use of a cy-
toreductive nephrectomy (CN) prior to treatment with sunitinib in patients 
presenting with mRCC. Results from this chapter suggest that a CN may be 
effective, but the absolute benefit may be modest after correction for time 
from diagnosis to sunitinib. 
Although patient registries can provide important information about 
uptake and use in clinical practice, timely information is needed to enable a 
quick response if, for example, not all patients who are eligible to receive a 
certain drug actually receive the drug. Timely information about uptake and 
use can more easily be provided if continuous registries would exist. 
Patient registries are seldom able to assess the 
relative effectiveness and cost-effectiveness of drugs 
Although patient registries are an important source to provide insight into 
the uptake and use of new therapies in clinical practice, registries are sel-
dom able to assess the relative effectiveness and cost-effectiveness of a drug. 
First, physicians may have profound reasons to choose a particular treatment 
over another, and these reasons will often relate to a patient’s prognosis. As 
a consequence, it is not only treatment that causes a difference in outcome, 
but also the difference in prognosis. In general, there are two ways to reduce 
confounding in observational studies: prevention in the design phase (e.g. 
restriction or matching) and adjustment using statistical techniques (e.g. 
stratification or multivariable techniques).167 Two methods have been applied 
in this thesis. In chapter 3, the effect of cytoreductive nephrectomy on over-
all survival in primary mRCC patients treated with first-line sunitinib was 
evaluated using propensity score matching, and in chapter 5, the real-world 
cost-effectiveness of several mRCC treatment strategies was estimated using a 
patient level simulation model and several multivariable techniques. Besides 
regression on a matched sample and multivariable regression as applied in 
this thesis, the NICE DSU technical support document on the use of observa-
tional data recommends some additional methods to estimate treatment 
effectiveness, such as regression adjustment, inverse probability weighting 
and doubly robust methods.168 All these methods assume no selection on 
unobserved confounders, while it is almost impossible to assume that all 
possible confounders are observed (and measured), and have been adjusted 
for. In addition, these statistical methods are often complicated by missing 
values in patients’ baseline characteristics, which is inherent to observational 
studies.
The NICE DSU technical support document also describes methods that can 
adjust for unobserved confounders, such as instrumental variable methods.168 
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Additionally, as described before, evaluating outcomes in clinical practice is 
associated with limitations, which impact the internal validity of estimates 
of effectiveness and cost-effectiveness. This was for example seen in the UK 
multiple sclerosis risk sharing scheme; patients treated with interferon beta 
or glatiramer acetate were closely monitored to study long-term progres-
sion of disease, with an agreement that prices of these drugs would be re-
duced if patient outcomes were worse than predicted.171 A direct benefit of 
the scheme was that drug costs were reduced to achieve a cost-effectiveness 
of £36,000 per QALY.172 The first interim analysis after two years showed that 
patient outcomes were much worse than predicted.171 However, it was ar-
gued that further follow-up and analyses were needed, because important 
methodological issues needed to be addressed, including the need for addi-
tional data about the comparator and the potential bias from missing data. 
Results at six years showed that patient outcomes (as reported in the clini-
cal trials) were maintained, and that interferon beta and glatiramer acetate 
represent value for money.173 As these findings were based on data from 4,137 
patients who started a disease-modifying therapy in the UK, and data from 
898 (historical) untreated patients from British Columbia, the question arises 
if a similar observational study in the Netherlands would have been able to 
demonstrate this effect. Additionally, this approach is limited if treatment 
paradigms change over time. 
The value of a patient registry must outweigh  
its costs
The design and implementation of a patient registry can take a long time, 
as was experienced with the initiation of the PERCEPTION renal cell cancer 
registry. After the approval of the research protocol by the medical ethics 
committee, every single hospital started an evaluation of the study’s local 
feasibility (using varying procedures). As a consequence, the recruitment of 
patients for the prospective part of the PERCEPTION registry started later than 
originally planned, and in fewer hospitals than originally planned. The ad-
ministrative burden complicated the provision of timely information about 
uptake, use and outcomes in clinical practice, and led to higher-than-expected 
start-up costs. 
Continuous patient registries (in contrast to time-restricted registries) 
might more easily provide timely information about uptake and use of new 
drugs in clinical practice, if data entry is rapid. The existence of continuous 
registries would avoid the preparation required to start a patient registry to 
answer every new research question, which would reduce the time needed to 
obtain answers to those questions. Additionally, continuous registries might 
is similar for patients treated with first-line sunitinib is unknown, but the 
effect might be less favourable, since sorafenib and sunitinib have a similar 
mechanism of action, i.e. both drugs primarily target tumour angiogenesis 
by inhibiting a variety of tyrosine kinases.169 As a consequence, even larger 
patient numbers are needed to have sufficient statistical power to be able to 
detect a true difference between treatment strategies comprising one or more 
sequentially administered drugs.
Thus, although registries are able to provide valuable information about 
the uptake and use of new (expensive) therapies, registries should not be used 
to assess the relative effectiveness and cost-effectiveness of new therapies, un-
less patient numbers are sufficiently large and sufficient data on confounding 
variables (or instrumental variables) are available to reduce confounding. 
Continuous registries (or registries with a long follow-up) might be able to 
provide sufficient data from patients treated with standard or usual treat-
ment and patients treated with the new drug. If patient numbers are small, 
collaboration between countries is inevitable. 
Nevertheless, evidence on outcomes in clinical practice are only worth-
while if it would affect the decision about future funding, or if it would affect 
the quality of patient care in a different way.
Decisions about future funding based on evidence 
on outcomes in clinical practice are difficult
Besides the challenges associated with the evaluation of a drug’s relative effec-
tiveness and cost-effectiveness in clinical practice, it appeared to be difficult 
to decide about future funding based on these outcomes, after four years 
of conditional funding. In accordance with the Dutch policy for expensive 
drugs, data were collected on patients treated with bevacizumab plus IFN-α 
or temsirolimus, regarding appropriate drug use, effectiveness and cost-ef-
fectiveness. After four years of initial funding, the Dutch National Health 
Care Institute decided not to reassess these drugs, based on the rule that a 
reassessment was only required if the budget impact was at least 2.5 million 
Euros. However, for many other expensive inpatient drugs in various disease 
areas, an assessment of the drugs’ real-world value (including effectiveness 
and cost-effectiveness) after four years of initial funding did not (yet) take 
place either or did not lead to an alternative decision. Recent research showed 
that the decision to stop reimbursement is more difficult than the decision 
to not reimburse a therapy from the start.170 Only in some cases outcomes 
research influenced the decision-making process, e.g. a pay-for-performance 
agreement prevented the exclusion of omalizumab from the basic health 
insurance package after four years of conditional funding. 
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usual care. As a consequence, policy makers do not always have the informa-
tion they need to decide about reimbursement. This problem might be solved 
using indirect comparisons to estimate the effectiveness and cost-effective-
ness of a new drug compared with standard or usual treatment. 
It is important to use the results of cost-effectiveness analyses to keep our 
healthcare system financially sustainable as the number of cancer patients 
increases and the number of innovative, expensive drugs grows. If cost-ef-
fectiveness ratios are above a given (equity weighted) threshold that reflects 
societal willingness to pay for health gains, price negotiations (or other meas-
ures) are essential to improve the relationship between costs and effects of a 
new drug, and allow reimbursement from the basic health insurance package. 
For sunitinib, an estimate of its cost-effectiveness was not made at the time 
of the initial reimbursement decision. Moreover, an assessment of the drug’s 
real-world value after four years was not required. The results of a cost-effec-
tiveness analysis could have been used to negotiate with the manufacturer 
about the price of the drug, as was for example seen in the UK where the first 
cycle of sunitinib is free to the NHS. Although the budget impact of sunitinib 
is much larger than the budget impact of bevacizumab or temsirolimus for 
mRCC, it is still relatively small compared to new drugs for cancer types like 
non-small cell lung cancer or breast cancer. Nevertheless, combined savings 
in small disease areas could be substantial, and make money available for 
other uses in the healthcare system. 
Recently, in the Netherlands, results of a cost-effectiveness analysis were 
used to negotiate about the price of nivolumab, a new drug for non-small 
cell lung cancer. Since the cost-effectiveness of nivolumab was estimated to 
be 134,000 Euros per QALY gained,174 the Dutch National Health Care Institute 
recommended not to reimburse nivolumab unless the manufacturer was 
willing to reduce the price of nivolumab to improve the ICER. After price nego-
tiations with the manufacturer led to a reduction that was kept confidential, 
the Dutch Minister of Health decided to include nivolumab for treatment of 
patients with non-small cell lung cancer in the basic health insurance pack-
age. Interestingly, the financial arrangements she made with the manufactur-
er also apply to all other (future) indications for treatment with nivolumab, 
including melanoma and mRCC. However, it is currently unknown whether 
the price reduction of nivolumab will lead to ICERs in melanoma and mRCC 
that are similar to the ICER of nivolumab for non-small cell lung cancer, since 
cost-effectiveness analyses in these indications are still to be conducted.
While there certainly are limitations to the use of data about outcomes 
in clinical practice in decisions about future funding, registries such as the 
PERCEPTION renal cell cancer registry can be of great value. Information about 
be able to provide data from patients treated with the standard or usual treat-
ment, data which are usually unavailable when a registry starts when a new 
drug has been introduced. Since the introduction of a new drug may mean 
that patients will no longer receive standard or usual treatment, a comparison 
between a new drug and standard or usual treatment is hindered. 
Nationwide patient registries could increase patient numbers (in com-
parison with registries restricted to certain regions or hospitals). If patient 
numbers are small, collaboration between countries is inevitable. 
However, continuous nationwide registries will not solve all problems. 
First, problems associated with confounding remain, which will present 
important challenges when evaluating the relative effectiveness and cost-ef-
fectiveness of new drugs in clinical practice. Although sufficient data on 
confounding variables (or instrumental variables) combined with statistical 
techniques could reduce confounding, it will never minimise imbalances in 
confounding variables to the same extent as randomisation would. Second, 
expanding registries in both length (i.e. from a time-restricted registry to a 
continuous registry) and width (i.e. from a registry restricted to certain re-
gions or hospitals to a nationwide registry) will increase the time and costs 
of data collection. Collecting data on confounding variables (or instrumental 
variables) will further increase costs. It is, therefore, important to consider 
the overall costs of a registry in relation to its value. 
Costs might be reduced if patient registries could be maintained digitally 
using electronic health records, instead of having data managers copying 
data from individual patient records into the registry. One type of electronic 
health record in all hospitals across the country (instead of different types) 
might ease this process.
General conclusion and policy implications
In line with the current policy on so-called specialist drugs (including expen-
sive inpatient and outpatient drugs),13 the present thesis argues to limit the 
use of conditional funding and put more emphasis on initial reimbursement 
decisions, because of the limitations of evidence on outcomes in clinical prac-
tice, and the difficulties with making decisions about future funding based 
on these outcomes. Results of cost-effectiveness analyses should be used to 
inform (initial) reimbursement decisions. Only in specific cases (e.g. orphan 
drugs) outcomes research is able to provide a more robust estimate of cost-ef-
fectiveness. These cases should be selected carefully in order to minimize the 
costs of extensive data collection.
A notable problem with the available evidence at the initial reimburse-
ment decision is that new drugs are not always compared with standard or 
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nicians stressed the need to evaluate the use of targeted therapies in clinical 
practice using up-to-date data. The Dutch National Health Care Institute has 
recently started this evaluation (‘Meaningful care’ [in Dutch: Zinnige Zorg]) 
based on data from the PERCEPTION registry, complemented with data from 
other sources. Additionally, plans are currently underway to start a new renal 
cell cancer registry to systematically monitor the use of targeted therapies and 
thereby supplement the data currently captured in the Dutch Cancer Registry.
uptake and use of new drugs, as derived from these registries, could more of-
ten be used to monitor whether these drugs are used in patients in whom the 
drug is known to be effective and cost-effective, and to evaluate if all patients 
who are eligible to receive the drug actually receive the drug. This could help 
to determine if the drug is being used to its full potential. The Dutch National 
Health Care Institute has recently started such a programme (‘Meaningful 
care’ [in Dutch: Zinnige Zorg]). The aim of this programme is to identify and 
discourage ineffective or unnecessary care in order to improve the quality of 
patient care, improve health outcomes and avoid unnecessary costs. Patient 
registries appeared to be a valuable source to fulfill this aim.
Limitations and research implications 
Several limitations of the research presented in this thesis need to be men-
tioned, in addition to the limitations that are already mentioned in the sep-
arate chapters. 
First, not all available statistical techniques to estimate treatment effec-
tiveness based on observational data have been applied in this thesis, es-
pecially those, such as instrumental variable methods, that can adjust for 
unobserved confounders. In practice, it might be difficult to find an instru-
mental variable, which is correlated with the treatment but only correlated 
with the outcome through its effect on treatment. Nevertheless, it is worth-
while to test its usefulness in future analyses of outcomes in clinical practice. 
Second, as this thesis showed, conditional funding (i.e. the condition to 
collect data on effectiveness and/ or cost-effectiveness in clinical practice) has 
its limitations. As a consequence, in addition to the research by Claxton et al175 
further research might indicate under what circumstances conditional fund-
ing may be an appropriate measure to guarantee early access, while additional 
evidence on outcomes in clinical practice are to be collected. Furthermore, 
other policy measures should be studied more closely, such as a more struc-
tural application of the so-called ‘sluice’ for expensive inpatient drugs. Due 
to this sluice expensive drugs do not automatically enroll in the basic health 
insurance package. Instead, the Dutch Minister of Health first seeks advice 
from the Dutch National Health Care Institute, and then takes measures for 
a (financially) sound introduction of the new drug. This measure was first 
applied in 2015 with the introduction of nivolumab. 
Final remarks
This research revealed that many treatment-eligible mRCC patients did not 
receive any targeted therapy. This was also seen during the evaluation of the 
Dutch clinical guideline in 2011/12. As a consequence of this evaluation, cli-
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The new targeted therapies for mRCC have been shown to increase progres-
sion-free survival (PFS) and overall survival (OS). However, it is unknown 
whether or not cytoreductive nephrectomy (CN) (i.e. CN aims to remove as 
much of the tumour as possible) further prolongs the survival of patients 
with primary mRCC treated with sunitinib (or another targeted agent), given 
the lack of evidence from randomised controlled trials (RCTs). This has led to 
a large variation in clinical practice, reflected by data from the PERCEPTION 
registry showing that 33% of the patients presenting with mRCC underwent 
CN prior to sunitinib. In chapter 3 it is suggested that CN may be effective in 
this patient group, based on data from the PERCEPTION registry and propensity 
score matching. However, the benefit appeared to be modest after correction 
for the time from diagnosis to the start of treatment with sunitinib.
As previously indicated, the new targeted therapies for mRCC have been 
shown to increase PFS. It is assumed that one of the associated benefits is a 
delay in health-related quality of life (HRQoL) deterioration, as a result of a 
delay in progression of disease. However, little data are available supporting 
this relationship. Chapter 4 shows that disease symptoms, such as fatigue 
and pain, are the key drivers for reduced HRQoL in mRCC (measured by a 
cancer-specific questionnaire [EORTC QLQ-C30] and a generic questionnaire 
[EQ-5D-5L]). Since symptoms increase with progression of disease (as shown 
in chapter 4), targeted therapies that increase PFS can postpone reductions 
in HRQoL. 
Despite the reimbursement of the targeted therapies for mRCC, little is 
known about their cost-effectiveness in clinical practice. A cost-effectiveness 
analysis identifies the ratio between the costs of an intervention and its health 
benefits. In chapter 5 it is shown that current treatment practice, which is 
dominated by sunitinib, led to an increase of 0.230 quality-adjusted life years 
(QALYs) compared to a scenario in which none of the patients receives a tar-
geted therapy. The incremental costs are € 24,179, resulting in an incremen-
tal cost-effectiveness ratio (ICER) of € 105,011 per QALY gained. As discussed 
in chapter 5, health can be gained (in comparison with current treatment 
practice) if more treatment-eligible patients with mRCC receive targeted 
therapies (like sunitinib). However, the ICER is far beyond the upper limit 
of the cost-effectiveness threshold of € 80,000 per QALY, as proposed by the 
Dutch Council for Public Health. 
The PERCEPTION renal cell cancer registry provided information about 
uptake, use and outcomes of the new drugs for mRCC in clinical practice. It 
also provided evidence on the effect of CN prior to treatment with sunitinib. 
Chapter 5 and 6 provide recommendations for future research. Chapter 6 
provides practical guidance in setting up patient registries to facilitate re-
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The growing pressure on healthcare budgets creates great tension between 
financial sustainability of healthcare systems and accessibility to (new) treat-
ments. Healthcare authorities need to make choices between reimbursement 
of healthcare procedures, services and programs, but these choices have to 
be made under considerable uncertainty about (long-term) costs and effects. 
To ensure equal and undelayed access to promising but expensive inpatient 
drugs, conditional funding was introduced in the Netherlands in 2006. At 
that time, conditional funding implied the additional funding of innovative 
drugs (i.e. reimbursing hospitals [most of] the drug costs) for a period of 
three years on the condition that data regarding uptake, use and outcomes 
of these drugs in clinical practice were to be collected. These data were used 
to decide whether or not additional funding continued to exist. Two drugs for 
metastatic renal cell carcinoma (mRCC), that is, bevacizumab and temsiroli-
mus, were eligible for conditional funding. The collection and analysis of data 
about uptake, use, and outcomes of these new drugs in clinical practice form 
the focus of the present thesis. This thesis also illustrates the possibilities and 
impossibilities of evaluating these outcomes. Additionally, it reflects on the 
difficulties of making decisions about future funding (based on evidence 
from clinical practice).
To evaluate the uptake and use of the new drugs for mRCC in Dutch clin-
ical practice, as well as treatment outcomes (in terms of effectiveness and 
cost-effectiveness), a population-based registry was created (i.e. PERCEPTION, 
PharmacoEconomics in Renal CEll carcinoma: a PopulaTION-based regis-
try). Since the registry was disease-oriented (i.e. all patients diagnosed with 
[m]RCC were eligible for inclusion, regardless of the type of treatment they 
received), it not only provided data on patients treated with bevacizumab 
or temsirolimus, but also on patients treated with other so-called targeted 
therapies. 
Chapter 2 of this thesis shows that targeted therapies, sunitinib in par-
ticular, have largely replaced interferon-alfa (IFN-α) as first-line standard of 
care. Furthermore, the results from the PERCEPTION registry revealed that few 
patients were treated with bevacizumab (combined with IFN-α) or temsiroli-
mus, even though these therapies were added to European guidelines in 2009, 
and to Dutch guidelines in 2010. Chapter 2 also shows that approximately 
one-third of treatment-eligible patients did not receive targeted therapies 
despite their ability to improve survival. Patients aged 65+ years were less 
likely to receive targeted therapy; other factors like number of metastatic 
sites were of influence in some subgroups. 
160 161
Besides the challenges associated with the evaluation of a drug’s effectiveness 
and cost-effectiveness in clinical practice, it appeared to be difficult to decide 
about future funding based on these outcomes (after a period of conditional 
funding). Only in some cases outcomes research (i.e. the collection and anal-
ysis of data from clinical practice) influenced the decision-making process 
in the Netherlands. 
In line with the current policy on so-called specialist drugs (including ex-
pensive inpatient and outpatient drugs), the present thesis argues to limit the 
use of conditional funding and put more emphasis on initial reimbursement 
decisions. Results of cost-effectiveness analyses should be used to inform 
(initial) reimbursement decisions, in order to keep our healthcare system 
financially sustainable as the number of cancer patients increases and the 
number of innovative, expensive drugs grows. If cost-effectiveness ratios are 
above a given (equity weighted) threshold that reflects societal willingness 
to pay for health gains, price negotiations (or other measures) are essential to 
improve the relationship between costs and effects of a new drug, and allow 
reimbursement from the basic health insurance package. Only in specific 
cases (e.g. orphan drugs) is outcomes research able to provide a more robust 
estimate of cost-effectiveness. These cases should be selected carefully in order 
to minimize the costs of extensive data collection.
al-world data collection for health care decision-making. In this chapter it 
is argued that it is crucial to set up an efficient registry that serves its aims, 
by collecting the right data of the right patient in the right way. Chapter 7 
provides practical recommendations to conduct cost-effectiveness analyses 
of treatment strategies spanning multiple treatment lines, using data from 
clinical practice and a discrete event simulation model. As more treatments 
become available (within and beyond treatment lines), full disease models 
are expected to increase in importance.
Chapter 8 provides a discussion of the findings and explores the implica-
tions and limitations of this thesis. As illustrated with the PERCEPTION renal 
cell cancer registry, patient registries can provide important information 
about uptake and use of new therapies in clinical practice. However, data from 
registries are seldom able to assess the effectiveness and cost-effectiveness of a 
drug. First, it is often not only treatment that causes a difference in outcome, 
because physicians may have profound reasons to choose a particular treat-
ment over another, and these reasons will often relate to a patient’s prognosis. 
There are several ways to reduce confounding in observational studies, but 
all these methods assume no selection on unobserved confounders, while it 
is almost impossible to assume that all possible confounders are observed 
(and measured) and have been adjusted for. A second reason why patient 
registries are seldom able to assess the effectiveness and cost-effectiveness 
of a drug is the difficulty to include the minimum number of patients (in 
the intervention and the control group) needed to detect true and clinical-
ly important differences between treatments. The problem of insufficient 
patient numbers is expected to grow in the near future, since new therapies 
often target small patient subgroups. 
Continuous registries might be able to provide data from patients treated 
with the standard or usual treatment (control group), data that are usually 
unavailable when a registry starts when a new drug has been introduced. The 
existence of continuous patient registries might therefore overcome some of 
the limitations of time-restricted registries, such as the PERCEPTION registry. 
Nationwide patient registries could increase patient numbers (in comparison 
with registries restricted to certain regions or hospitals). However, expanding 
registries in both length (i.e. from a time-restricted registry to a continuous 
registry) and width (i.e. from a registry restricted to certain regions or hospi-
tals to a nationwide registry) will increase the time and costs of data collec-
tion. Collecting data on confounding variables (or instrumental variables) 
will further increase costs. It is therefore important to consider the overall 
costs of a registry in relation to its value. 
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handelingen worden aanbevolen in Europese richtlijnen sinds 2009, en in 
Nederlandse richtlijnen sinds 2010. Hoofdstuk 2 laat bovendien zien dat on-
geveer een derde van de patiënten die in aanmerking kwamen voor een doel-
gerichte therapie niet behandeld werd met één van deze therapieën, terwijl 
deze behandelingen overleving kunnen verbeteren. Patiënten ouder dan 65 
jaar kregen minder vaak een doelgerichte therapie; andere factoren, zoals het 
aantal locaties met metastasen, waren van invloed in sommige subgroepen. 
De nieuwe doelgerichte therapieën voor mRCC hebben aangetoond pro-
gressie-vrije en totale overleving te verlengen. Het is echter niet bekend of 
een cytoreductieve nefrectomie (CN) (i.e. een chirurgische ingreep met als 
doel de omvang van de tumor te verminderen) de levensduur van patiën-
ten met primair mRCC die behandeld worden met sunitinib (of een andere 
doelgerichte therapie) verder kan verlengen, vanwege het gebrek aan bewijs 
uit gerandomiseerde gecontroleerde trials (randomised controlled trials, 
RCTs). Dit heeft geleid tot grote behandelvariatie in de klinische praktijk. 
De gegevens uit het PERCEPTION register ondersteunen dit, en laten zien dat 
33% van de patiënten met primair mRCC een CN onderging voorafgaand aan 
behandeling met sunitinib. Hoofdstuk 3 toont aan dat CN mogelijk effectief is 
in deze patiëntengroep, gebaseerd op gegevens uit het PERCEPTION register en 
‘propensity score matching’. Het voordeel bleek echter bescheiden na correc-
tie voor de tijd tussen diagnose en de start van de behandeling met sunitinib.
Zoals eerder gesteld verbeteren de nieuwe doelgerichte therapieën voor 
mRCC progressie-vrije overleving. Er wordt verondersteld dat dit een gunstig 
effect heeft op gezondheidsgerelateerde kwaliteit van leven (health-related 
quality of life, HRQoL), maar er zijn weinig gegevens beschikbaar die deze 
relatie ondersteunen. Hoofdstuk 4 laat zien dat ziektesymptomen, zoals 
vermoeidheid en pijn, bepalende factoren zijn voor een achteruitgang in 
kwaliteit van leven van patiënten met mRCC (gemeten aan de hand van een 
kanker-specifieke vragenlijst [EORTC QLQ-C30] en een generieke vragenlijst 
[EQ-5D-5L]). Omdat symptomen toenemen bij progressie van ziekte (zoals 
aangetoond in hoofdstuk 4), kunnen doelgerichte therapieën die progres-
sie-vrije overleving verlengen, achteruitgang in kwaliteit van leven uitstellen. 
Ondanks de vergoeding van de doelgerichte therapieën voor mRCC, is 
er weinig bekend over de kosteneffectiviteit van deze behandelingen in de 
klinische praktijk. Een kosteneffectiviteitsanalyse laat zien hoe de kosten van 
een interventie zich verhouden tot de gezondheidsopbrengsten. Hoofdstuk 
5 toont aan dat de huidige inzet van behandelingen, die gedomineerd wordt 
door sunitinib, leidt tot een toename van voor kwaliteit-gecorrigeerde le-
vensjaren (quality-adjusted life years, QALYs) met 0,230 in vergelijking met 
een scenario waarin patiënten niet behandeld worden met doelgerichte 
Samenvatting
De toenemende druk op zorgbudgetten veroorzaakt een grote spanning tus-
sen de betaalbaarheid van het zorgsysteem enerzijds en de toegankelijkheid 
tot (nieuwe) behandelingen anderzijds. Zorgautoriteiten moeten keuzen ma-
ken tussen de vergoeding van zorgprocedures, diensten en programma’s, ter-
wijl er op dat moment vaak onzekerheid is over de (lange termijn) kosten en 
effecten van deze interventies. Om gelijke en tijdige toegang tot veelbeloven-
de maar kostbare intramurale medicijnen te garanderen, werd in Nederland 
in 2006 voorwaardelijke financiering geïntroduceerd. Voorwaardelijke finan-
ciering stond op dat moment voor de aanvullende financiering van innovatie-
ve medicijnen (i.e. de vergoeding van ziekenhuizen voor [het merendeel van] 
de kosten van deze medicijnen) voor een periode van drie jaar. Gedurende 
deze periode dienden gegevens met betrekking tot de opname, het gebruik 
en de uitkomsten van deze medicijnen in de klinische praktijk te worden 
verzameld. Deze gegevens werden gebruikt om te bepalen of de aanvullen-
de financiering werd gecontinueerd. Twee medicijnen voor gemetastaseerd 
niercelcarcinoom (metastatic renal cell carcinoma, mRCC), te weten beva-
cizumab en temsirolimus, kwamen in aanmerking voor deze voorwaarde-
lijke financiering. Het verzamelen en analyseren van gegevens omtrent de 
opname, het gebruik en de uitkomsten van deze nieuwe medicijnen in de 
klinische praktijk vormen de focus van dit proefschrift. Dit proefschrift gaat 
eveneens in op de mogelijkheden en onmogelijkheden van het evalueren van 
deze uitkomsten. Ook reflecteert dit proefschrift op de moeilijkheden bij het 
maken van beslissingen over toekomstige financiering (op basis van bewijs 
uit de klinische praktijk).
Om de opname, het gebruik en de uitkomsten (in termen van effectiviteit 
en kosteneffectiviteit) van de nieuwe medicijnen voor mRCC in de klinische 
praktijk te evalueren, werd een patiëntenregister opgezet (i.e. PERCEPTION, 
PharmacoEconomics in Renal CEll carcinoma: a PopulaTION-based regis-
try). Omdat dit register ziekte-georiënteerd was (i.e. alle patiënten met de 
diagnose [m]RCC kwamen in aanmerking voor inclusie, ongeacht het type 
behandeling dat zij kregen) leverde het niet alleen gegevens op over pati-
enten die behandeld werden met bevacizumab of temsirolimus, maar ook 
over patiënten die behandeld werden met andere zogenaamde doelgerichte 
(targeted) therapieën. 
Hoofdstuk 2 van dit proefschrift laat zien dat de traditionele behandeling 
met interferon-alfa (IFN-α) grotendeels vervangen is door behandeling met 
doelgerichte therapieën, voornamelijk sunitinib. Ook toonden de resultaten 
van het PERCEPTION register aan dat weinig patiënten werden behandeld met 
bevacizumab (gecombineerd met IFN-α) of temsirolimus, terwijl deze be-
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medicijn op basis van gegevens uit patiëntenregisters is de inclusie van het 
minimum benodigde aantal patiënten (in de interventie- en controlegroep) 
om ware en klinisch van belang zijnde verschillen tussen behandelingen 
aan te tonen. Dit probleem zal naar verwachting groter worden in de nabije 
toekomst, omdat nieuwe behandelingen zich steeds vaker richten op kleine 
subgroepen van patiënten. 
Continue registers zijn mogelijk in staat om informatie te bieden over 
patiënten die behandeld werden met de standaard of gebruikelijke behan-
delmethode (controlegroep). Deze gegevens zijn normaal gesproken niet 
beschikbaar als een register start op het moment dat een nieuw medicijn 
wordt geïntroduceerd. Continue patiëntenregisters kunnen daarom som-
mige beperkingen van tijdgebonden registers, zoals het PERCEPTION register, 
voorkomen. Landelijke patiëntenregisters kunnen patiëntenaantallen ver-
hogen (in vergelijking met registers die beperkt zijn tot bepaalde regio’s of 
ziekenhuizen). Echter, het uitbreiden van registers in zowel lengte (i.e. van 
tijdgebonden registers naar continue registers) als breedte (i.e. van een regis-
ter beperkt tot bepaalde regio’s of ziekenhuizen naar een landelijk register) 
verhoogt de tijd en kosten die gepaard gaan met de gegevensverzameling. 
Het verzamelen van gegevens over verstorende variabelen (of instrumentele 
variabelen) zal de kosten nog verder doen toenemen. Het is daarom belang-
rijk om de totale kosten van een register te bezien in relatie tot de waarde 
van het register. 
Naast de uitdagingen rond de evaluatie van de effectiviteit en kosteneffec-
tiviteit van medicijnen in de klinische praktijk, blijkt het ook lastig om beslis-
singen te maken over toekomstige financiering op basis van deze uitkomsten 
(na een periode van voorwaardelijke financiering). Slechts in sommige geval-
len beïnvloedde uitkomstenonderzoek (i.e. het verzamelen en analyseren van 
gegevens uit de klinische praktijk) het besluitvormingsproces in Nederland. 
In lijn met het huidige beleid voor zogenaamde specialistische medicij-
nen (inclusief kostbare intramurale en extramurale medicijnen), betoogt dit 
proefschrift om het gebruik van voorwaardelijke financiering te beperken en 
meer de nadruk te leggen op initiële vergoedingsbeslissingen. Resultaten van 
kosteneffectiviteitsanalyses moeten gebruikt worden ter ondersteuning van 
deze (initiële) beslissingen, voor het behoud van een financieel duurzaam 
zorgsysteem, nu het aantal kankerpatiënten toeneemt en het aantal innova-
tieve en kostbare medicijnen groeit. Als kosteneffectiviteitsratio’s boven een 
bepaalde (‘equity’-gewogen) drempel, die de maatschappelijke bereidheid 
om voor gezondheidswinsten te betalen reflecteert, uitkomen, dan zijn prijs-
onderhandelingen (of andere maatregelen) essentieel om de relatie tussen 
kosten en effecten van een nieuw medicijn te verbeteren, en vergoeding van-
therapieën. De additionele kosten zijn € 24.179, resulterend in een incremen-
tele kosteneffectiviteitsratio (incremental cost-effectiveness ratio, ICER) van 
€ 105.011 per gewonnen QALY. Zoals besproken in hoofdstuk 5 kan er meer 
gezondheid gewonnen worden (in vergelijking met de huidige inzet van be-
handelingen) wanneer meer patiënten met mRCC behandeld zouden worden 
met doelgerichte therapieën (zoals sunitinib). De ICER ligt echter ver boven 
de drempel voor kosteneffectiviteit van € 80.000 per QALY, zoals voorgesteld 
door de Nederlandse Raad voor de Volksgezondheid & Zorg.
Het PERCEPTION register bood inzicht in de opname, het gebruik en de 
uitkomsten van nieuwe medicijnen voor mRCC in de klinische praktijk. Het 
register bood ook bewijs over het effect van CN voorafgaand aan de behan-
deling met sunitinib. Hoofdstuk 5 en 6 bieden handvatten voor toekomstig 
onderzoek. Hoofdstuk 6 bevat praktische aanbevelingen voor het opzetten 
van patiëntenregisters voor het verzamelen van gegevens uit de klinische 
praktijk ter ondersteuning van besluitvorming in de gezondheidszorg. In 
dit hoofdstuk wordt betoogd dat het cruciaal is om een efficiënt register op 
te zetten dat de beoogde doelen dient, door de juiste gegevens te verzame-
len van de juiste patiënt op de juiste manier. Hoofdstuk 7 biedt praktische 
aanbevelingen voor het uitvoeren van kosteneffectiviteitsanalyses van be-
handelstrategieën bestaande uit één of meer behandellijnen, waarbij gebruik 
gemaakt wordt van gegevens uit de klinische praktijk en een zogenaamd ‘dis-
crete event simulation’ model. Nu er steeds meer behandelingen beschikbaar 
komen (in verschillende behandellijnen) zullen volledige ziektemodellen in 
belang toenemen.
Hoofdstuk 8 bevat een discussie over de bevindingen en verkent de 
implicaties en beperkingen van dit onderzoek. Zoals aangetoond met het 
PERCEPTION register, kunnen patiëntenregisters belangrijke informatie bie-
den ten aanzien van de opname en het gebruik van nieuwe behandelingen 
in de klinische praktijk. Het is echter zelden mogelijk om de effectiviteit en 
kosteneffectiviteit van een medicijn vast te stellen aan de hand van gegevens 
uit registers. Ten eerste wordt een verschil in uitkomsten vaak niet alleen door 
de behandeling veroorzaakt. Artsen hebben veelal gegronde redenen om de 
voorkeur te geven aan een bepaalde behandeling, en deze redenen zullen vaak 
gerelateerd zijn aan de prognose van de patiënt. Er zijn diverse manieren om 
deze verstoring (confounding) in observationele studies te reduceren, maar 
al deze methoden gaan er vanuit dat selectie enkel plaatsvindt op basis van 
geobserveerde variabelen. Het is echter bijna onmogelijk te veronderstellen 
dat alle mogelijke verstorende variabelen (confounders) geobserveerd (en 
gemeten) zijn en dat daarvoor voldoende gecorrigeerd is. Een tweede com-
plexiteit bij het vaststellen van de effectiviteit en kosteneffectiviteit van een 
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uit de basisverzekering mogelijk te maken. Alleen in specifieke gevallen (zoals 
bij medicijnen voor zeldzame ziekten) is uitkomstenonderzoek in staat om 
een meer robuuste schatting te geven van de kosteneffectiviteit. Deze gevallen 
dienen zorgvuldig te worden geselecteerd om de kosten van omvangrijke 
gegevensverzameling te beperken.
170
PhD portfolio
List of publications
About the author
172 173
Bachelor and master theses, bachelor programme Health Policy & 
Management and Master programme Health Economics Policy & Law, 
Erasmus University Rotterdam. Supervisor and co-evaluator. 2011–2014.
Statistics A, pre-master programme Health Policy & Management, Erasmus 
University Rotterdam. Tutor. 2013–2014.
Socio-medical sciences, bachelor programme Health Policy & Management 
and Pre-master programme Health Policy & Management, Erasmus 
University Rotterdam. Tutor. 2011–2014.
Podium presentations
Challenges and solutions to successfully determine real-world cost-effectiveness 
[Workshop]. ISPOR 18th annual European congress: Milan, Italy. 2015.
As real as it gets: challenges in setting up patient registries for the collection of real-
world data on behalf of policy making [Workshop]. ISPOR 17th annual European 
congress: Amsterdam, the Netherlands. 2014.
Potential health gains for patients with metastatic renal cell carcinoma in daily 
clinical practice: A cost-effectiveness analysis of sequential first- and second line 
treatments. EuroTARGET meeting: Cambridge, United Kingdom. 2014.
First results PERCEPTION registry [presentation in Dutch: Eerste resultaten 
PERCEPTION-studie]. Symposium Wat stroomt er door de nier?: Tilburg, the 
Netherlands. 2013.
When is lower level evidence of effectiveness acceptable in reimbursement 
decisions? [Discussed]. LolaHESG 2012: Almen, the Netherlands. 2012.
PERCEPTION, a patient registry to inform outcomes research [presentation in 
Dutch: PERCEPTION, een patiëntenregistratie ten behoeve van 
uitkomstenonderzoek]. Symposium Nieuwe ontwikkelingen in de 
behandeling van niercelcarcinoom: Amsterdam, the Netherlands. 2012.
Poster presentations
Patient and disease characteristics are important determinants of health-related 
quality of life of patients with metastatic renal cell carcinoma: results from a 
population-based registry. ISPOR 17th annual European congress: Amsterdam, 
the Netherlands. 2014.
The cost-effectiveness of sequential first- and second-line treatments in metastatic 
renal cell carcinoma using real-world data and a patient-level simulation model. 
ISPOR 16th annual European congress: Dublin, Ireland. 2013.
PhD Portfolio
PhD candidate:   Saskia de Groot
Institute:   institute of Health Policy & Management, Erasmus 
University Rotterdam, the Netherlands
PhD period:   2009–2016
Promotors:  Prof.dr. C.A. Uyl-de Groot
 Prof.dr. L.A.L.M. Kiemeney
Copromotor:   Dr. W.K. Redekop
PhD Training
Propensity Scores and Observational Studies of Treatment Effect.  
ISPOR short course: Berlin, Germany. 2012.
MSc in Health Sciences, specialisation Clinical Epidemiology. 
  Core Curriculum
 –  Study Design
 –  Classical Methods for Data-analysis
 –  Clinical Epidemiology
 –  Methodologic Topics in Epidemiological Research
 –  Modern Statistical Methods
Netherlands Institute for Health Sciences: Rotterdam, the Netherlands. 
2009–2011.
Patient registries. ISPOR short course. Prague, Czech Republic. 2010.
Advanced Modelling Methods for Health Economic Evaluation. University of 
York: York, United Kingdom. 2010.
Academic Writing in English. Language & Training Centre, Erasmus University 
Rotterdam: Rotterdam, the Netherlands. 2010.
Teaching
Health Technology Assessment, master programme Health Economics Policy 
& Law, Erasmus University Rotterdam. Instructor computer lab. 2014–2016. 
Health Economics, Erasmus Summer Programme, Erasmus MC - Netherlands 
Institute for Health Sciences. Instructor computer lab. 2014–2015.
Methods & Techniques 1, bachelor programme Health Policy & Management, 
Erasmus University Rotterdam. Tutor. 2014–2015.
174 175
List of scientific publications
Blommestein, H.M., de Groot, S., Aarts, M.J., Vemer, P., de Vries, R., van 
Abeelen, A.F.M., Posthuma, E.F., Uyl-de Groot, C.A. Cost-effectiveness of 
obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. 
Leukemia research 2016; In Press. [shared first authorship]
de Groot, S., van der Linden, N., Franken, M.G., Blommestein, H.M., 
Leeneman, B., van Rooijen, E., van der Hoeven, J.J.M., Wouters, M.W., 
Westgeest, H.M., Uyl-de Groot, C.A. Balancing the optimal and the 
feasible: A practical guide for setting up patient registries for the 
collection of real-world data for health care decision making based on 
Dutch experiences. Value in Health 2016; In Press. [shared first authorship]
de Groot, S., Sleijfer, S., Redekop, W.K., Oosterwijk, E., Haanen, J.B., 
Kiemeney, L.A.L.M., Uyl-de Groot, C.A. Variation in use of targeted 
therapies for metastatic renal cell carcinoma: Results from a Dutch 
population-based registry. BMC Cancer 2016;16:364.
de Groot, S., Redekop, W.K., Sleijfer, S., Oosterwijk, E., Bex, A., Kiemeney, 
L.A.L.M., Uyl-de Groot, C.A. Survival in patients with primary metastatic 
renal cell carcinoma treated with sunitinib with or without previous 
cytoreductive nephrectomy: Results from a population-based registry. 
Urology 2016;95:121-127.
Blommestein, H.M., Verelst, S.G., de Groot, S., Huijgens, P.C., Sonneveld, P., 
Uyl-de Groot, C.A. A cost-effectiveness analysis of real-world treatment 
for elderly patients with multiple myeloma using a full disease model. 
Eur J Haematol 2016;96(2):198-208.
de Groot, S., Rijnsburger, A.J., Versteegh, M.M., Heymans, J.M., Kleijnen, S., 
Redekop, W.K., Verstijnen, I.M. Which factors may determine the 
necessary and feasible type of effectiveness evidence? A mixed methods 
approach to develop an instrument to help coverage decision-makers. 
BMJ Open 2015;5(7).
van Gils, C.W., de Groot, S., Tan, S.S., Redekop, W.K., Koopman, M., Punt, C.J., 
Uyl-de Groot, C.A. Real-world resource use and costs of adjuvant 
treatment for stage III colon cancer. Eur J Cancer Care (Engl) 
2015;24(3):321-332.
van Gils, C.W., de Groot, S., Redekop, W.K., Koopman, M., Punt, C.J., Uyl-de 
Groot, C.A. Real-world cost-effectiveness of oxaliplatin in stage III colon 
cancer: a synthesis of clinical trial and daily practice evidence. 
Pharmacoeconomics 2013;31(8):703-718.
Uyl-de Groot, C.A., de Groot, S., Steenhoek, A. The economics of improved 
cancer survival rates: better outcomes, higher costs. Expert Rev 
Pharmacoecon Outcomes Res 2010;10(3):283-292.
The evaluation of the use and effectiveness of bevacizumab for patients with 
metastatic renal cell carcinoma in daily practice. ISPOR 15th annual European 
congress: Berlin, Germany. 2012.
Are population-based registries a suitable tool for outcomes research in cancer? 
Experiences from four registries. ISPOR 15th annual European congress: Berlin, 
Germany. 2012. (nominated)
A population-based registry for the evaluation of new treatment options for 
patients with metastatic renal cell carcinoma. ISPOR 14th annual European 
congress: Madrid, Spain. 2011.
When is lower level evidence of effectiveness acceptable in reimbursement 
decisions?: a decision algorithm to guide policy makers. ISPOR 14th annual 
European congress: Madrid, Spain. 2011.
176 177
About the author
Saskia de Groot was born in Gouda on December 6th 1985. In 2004 she start-
ed the bachelor programme Health Policy & Management at the Erasmus 
University Rotterdam (2004–2007). In 2009, she obtained her master’s degree 
in Health Economics, Policy & Law. She continued her studies by enrolling 
in a research master programme in Health Sciences with a specialisation 
in Clinical Epidemiology at the Netherlands Institute for Health Sciences 
(2009–2011). During her studies at the Erasmus University Rotterdam, she 
started working as a research assistant at the institute of Health Policy & 
Management. In 2009 she started a PhD project on the evaluation of clinical 
and economic outcomes of new therapies for metastatic renal cell carcino-
ma, which resulted in this dissertation. Besides this research, she worked on 
various advisory projects, including different projects for the Dutch National 
Health Care Institute.
List of policy-related publications
Fayter, D., Büyükkaramikli, N., Birnie, R., de Groot, S., Wolff, R., Armstrong, 
N., Worthy, G., Albuquerque de Almeida, F., Stirk, L., Al, M., Kleijnen, J. 
Pomalidomide with dexamethasone for treating relapsed and refractory 
multiple myeloma after at least two regimens including lenalidomide 
and bortezomib (review of TA338): a Single Technology Assessment. York: 
Kleijnen Systematic Reviews Ltd.
Advice to The National Institute for Health and Care Excellence, 2016.
de Groot, S., Aben, K., Sleijfer, S., Haanen, J.B.A.G., Bex, A., Kiemeney, 
L.A.L.M., Uyl-de Groot, C.A. Meaningful care: The use of expensive drugs 
in renal cell carcinoma [in Dutch: Zinnige zorg: Inzet van dure 
oncolytica bij niercelcarcinoom]
Advice to the Dutch National Health Care Institute, 2016.
Versteegh, M.M., Weistra, K., de Groot, S., Redekop, W.K., Davis, P., Rutten, 
F.F.H., Oortwijn, W. Literature-based approach to defining the concept of 
healthcare which requires “highly specialised and cost-intensive 
medical infrastructure or medical equipment”
Advice to the European Commission, 2014.
de Groot, S., Rijnsburger, A.J., Redekop, W.K., Versteegh, M.M., Heymans, 
J.M., Link, A., Verstijnen, I.M., Boksteijn, B., Kleijnen, S., Staal, P. Academia 
II: Methodology Development, Sub-project ‘Effectiveness and Evidence-
Based Medicine [in Dutch: Academia II: Methodiekontwikkeling, 
Deelproject ‘Effectiviteit en Evidence-Based Medicine’]
Advice to the Dutch health care insurance board, 2012.
van Gils, C.W.M., Redekop, W.K., Mol, L., de Groot, S., Tan, S.S., Koopman, M., 
Gaultney, J., Franken, M.G., Punt, C.J.A., Uyl-de Groot, C.A. Pilot outcomes 
research: Effects and costs of oxaliplatin in stage III colon and metastatic 
colorectal cancer
Advice to the Dutch health care insurance board, 2010.
178
Dankwoord
180 181
zoveel meer, zoals de congressen en de vele kilometers die we samen hebben 
hardgelopen. Bedankt voor de fijne samenwerking en al het plezier dat we 
samen hadden, en daarnaast bedankt voor jouw zorgzaamheid! Lieve Igna, 
toen we nog studeerden werkten we samen in verschillende commissies. Na 
ons afstuderen, werkten we tegelijk, weliswaar op uiteenlopende onderzoek-
sterreinen, aan onze promotieonderzoeken. Het is fijn om jou in de buurt te 
hebben. Ik wil je graag bedanken voor jouw oprechte interesse in de voort-
gang van mijn proefschrift, en mijn leven buiten de universiteit. Lieve Laura, 
je bent niet weg te denken uit de afgelopen jaren. Wat heb ik genoten van 
onze tripjes naar onder andere Praag, Madrid, Berlijn en Dublin, maar ook 
Lola! Bedankt voor alle afleiding gedurende de afgelopen jaren en onze fijne 
gesprekken! Matthijs, bedankt dat je er vaak voor me bent en naar me luistert. 
Daarnaast dank voor de kansen die je me biedt binnen iMTA. Tim, bedankt 
voor zoveel meer dan je hulp bij het opmaken van mijn tabellen. Bedankt 
voor al je adviezen en steun in de afgelopen jaren. Het delen van een kamer 
met jou is één groot geluksmomentje ;-). 
Lieve Jac, ook al zijn we al tijden geen kamergenoten meer, jij kan niet 
ontbreken in dit dankwoord. Jouw steun in de eerste jaren van mijn promo-
tietraject was voor mij van hele grote waarde. Bedankt voor al jouw goede raad 
en de gezelligheid! Lieve Annemieke, samen starten we de dag vaak met een 
theetje (hoe groter, hoe beter!), en bespreken we wat ons bezighoudt. Bedankt 
voor jouw fijne aanwezigheid! Lieve Margreet, regelmatig hielp je mij bij het 
beantwoorden van vragen over de data-verzameling voor het PERCEPTION 
register. Ik had dat alleen niet gekund. Ook met andere vragen kwam ik graag 
naar jou, en jij nam altijd de tijd. Bedankt daarvoor! 
Ook wil ik graag alle andere (oud-)collega’s van het iBMG bedanken voor 
de fijne werksfeer en de gezelligheid tijdens de jaarlijkse uitjes.
Lieve Eva en Melissa, de allereerste jaren bij het iBMG bracht ik met jullie 
door. Samen studeerden we voor tentamens, bezochten we feestjes en waren 
we actief voor de FBMG. Wat was het een fijne tijd! Deze activiteiten zijn in-
tussen vervangen door etentjes en borrels. En ook al zien we elkaar niet meer 
dagelijks, het blijft fijn om met jullie te praten, nu onder andere over onze 
ervaringen op de werkvloer. Dank jullie wel dat jullie er altijd voor me zijn, 
en ik mijn ervaringen met het geven van onderwijs en presentaties, en het 
schrijven van mijn proefschrift met jullie kon delen!
Lieve Eline, ook jij bent niet weg te denken uit mijn eerste jaren bij het 
iBMG. Wat maakte je me vaak aan het lachen met jouw rake opmerkingen. 
Tegelijkertijd was je zorgzaam en geïnteresseerd, en daarmee een hele fijne 
vriendin. Ook na ons afstuderen, toen we elkaar minder vaak zagen, toonde jij 
altijd veel interesse in mijn promotieonderzoek en alles daarbuiten. Ik mis je.
Dankwoord
Dit proefschrift zou niet tot stand zijn gekomen zonder de hulp van vele men-
sen. Een aantal van hen wil ik hier in het bijzonder noemen.
Allereerst wil ik graag mijn promotoren bedanken. Carin, jij motiveerde 
me tot het schrijven van dit proefschrift. Bedankt voor deze kans en het ver-
trouwen! Je was altijd enorm betrokken, ik wil je daarom ook bedanken voor 
de prettige en persoonlijke samenwerking. Jouw toewijding om de kwaliteit 
van zorg te verbeteren is onvoorstelbaar, en daarmee weet jij veel mensen te 
inspireren! Bart, het was fijn om jou als tweede promotor te hebben. Jouw 
bijdrage aan het opzetten en onderhouden van het PERCEPTION register, 
evenals jouw aandeel bij de publicaties die hieruit voortkwamen vormden 
een belangrijk onderdeel van het welslagen van mijn promotieonderzoek. 
Bedankt daarvoor! 
Ook wil ik graag mijn copromotor bedanken. Ken, jouw bijdrage aan mijn 
proefschrift is van onschatbare waarde. Onze gesprekken vormden veelal 
aanleiding tot aanvullende analyses, je wist me altijd te motiveren om nog 
net één stapje verder te gaan. Ik heb hier ontzettend veel van geleerd. Bedankt 
ook voor jouw geduld en alle kansen die je me de afgelopen jaren bood op 
het gebied van onderwijs en onderzoek. 
Beste Stefan en John, bedankt voor jullie steun bij het opzetten van het 
PERCEPTION register. Zonder jullie vertrouwen was het niet gelukt dit register 
te laten slagen. Stefan, ik wil jou ook graag hartelijk danken voor je hulp bij 
de interpretatie van de onderzoeksresultaten. Beste Egbert, ook jou wil ik 
graag bedanken voor je hulp bij het opzetten van het PERCEPTION register, en 
de waardevolle feedback op de hieruit voortgekomen publicaties.
Mijn dank gaat ook uit naar de registratiemedewerkers en datamana-
gers van het Integraal Kankercentrum Nederland, in het bijzonder Paulien, 
Kees, Aysun, Anita, Anita en Karin. Ook al was de data-verzameling voor het 
PERCEPTION register omvangrijk en niet altijd eenvoudig, jullie zorgden er-
voor dat de data tijdig beschikbaar was. Bedankt voor jullie doorzettingsver-
mogen en zorgvuldigheid. Daarnaast wil ik jullie graag bedanken voor het 
fijne contact. Ook wil ik de andere personen van het Integraal Kankercentrum 
Nederland bedanken die het tot stand komen en het onderhouden van het 
PERCEPTION register hebben ondersteund, in het bijzonder Marjorie, Katja, 
Sigrid, Wilma, Erica en Rob.
Apostolos, Hedwig, Igna, Laura, Matthijs, Pieter en Tim; zonder jullie 
aanwezigheid op de universiteit waren de afgelopen jaren lang zo leuk niet 
geweest. Lieve Hedwig, vanwege de vele raakvlakken van onze onderzoeken 
werkten we veel samen en dat was altijd een feestje. Samen ontwierpen we 
onze ziektemodellen, en ontwikkelden we onze vaardigheden. Maar er was 
182 183
Lieve Marije, samen studeerden we in onze zolderkamers aan de Aegidiusstraat. 
Daarna volgden er vele experimenten in de keuken. Tegenwoordig kiezen we 
vaak voor wat meer gemak en gaan we lekker uit eten (tenzij we erop uit trek-
ken op de racefiets ;-)) Bedankt voor al je interesse en alle gezelligheid in de 
afgelopen jaren. Ik weet zeker dat je een glansrijke carrière tegemoet gaat! 
Lieve Daphne, nauwgezet volgde je de voortgang van mijn proefschrift, 
en de status van mijn artikelen. Ook al zijn we al jaren geen collega’s meer 
en gaan we al jaren niet meer samen skaten, we voeren nog steeds eindelo-
ze gesprekken en ik hoop dat we dat blijven doen. Bedankt dat je zo’n lieve 
vriendin voor me bent!
Lieve Anne, Charlotte, Jannet, Leontien, Manouk, Marieke, Marrit en Tara, 
bedankt voor alle gezellige momenten in de afgelopen jaren, in wisselende 
samenstellingen, en soms opeens weer compleet! Lieve Lot, intussen hebben 
we zoveel mooie plekken met elkaar bezocht, toen we nog studeerden, maar 
ook daarna. Ook al worden de tripjes steeds korter, het is altijd fijn om met 
jou op pad te gaan! Lieve Manouk, samen werkten we de afgelopen jaren aan 
onze proefschriften. We deelden tegen- en meevallers. Ook was er de nodige 
ontspanning, van samen eten (bij voorkeur kort ;-)) en festivalletjes bezoeken 
tot mooie reizen. Dank je voor te veel om op te noemen, maar in het bijzonder 
je enorme steun en lieve gebaren! Lieve Taar, wat bof ik dat we al zoveel jaren 
vriendinnetjes zijn. Bedankt voor de vele fijne momenten in de afgelopen ja-
ren in de vorm van etentjes, festivalletjes en sauna-bezoeken. Daarnaast kan ik 
je niet genoeg bedanken voor je meeleven tijdens mijn promotieonderzoek. 
Lieve Lin, pap en mam, zoals jullie weten bezorgde het schrijven van dit 
proefschrift me soms best wel eens kopzorgen. Ik was daarom soms gehaast 
en niet altijd ontspannen. Bedankt voor alle liefde die ik desondanks van jullie 
kreeg. Lieve Lin, ik kan me geen betere zus wensen. Dank je dat je altijd voor 
me klaarstaat, en het me altijd gemakkelijk probeert te maken. Ook wil ik je 
bedanken voor je enorme hulp bij de laatste loodjes van dit proefschrift. Lieve 
pap en mam, jullie hebben me altijd alle ruimte en mogelijkheden gegeven 
om mijzelf te ontwikkelen. Ook staat de deur bij jullie altijd open, het is heel 
erg fijn om bij jullie weer even op te laden. Bedankt voor jullie grenzeloze 
steun en het vertrouwen.
185
Colofon
Author
Saskia de Groot
Design
Joost Dekker Grafisch ontwerper
Published & Printed by
Drukkerij Mostert en van Onderen!
ISBN/EAN 978 94 90858 48 3
The PERCEPTION registry was financially supported by the Netherlands 
Organisation for Health Research and Development (grant number: 
152001014). 
Additional funding for the registry was provided by Pfizer B.V. (formerly 
Wyeth Pharmaceuticals B.V.) and Roche Nederland B.V.
All rights reserved. No part of this thesis may be reproduced or transmitted 
in any form by any means without written permission from the author.
186
